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In spite of the vast amount of evidence on the benefits of blood pressure (BP) 
lowering that has accumulated to date, hypertension (HTN) remains the leading 
risk factor for disease and disability worldwide. Since the first BP-lowering agents 
became available in the 1950s, their effects have been tested thoroughly by means 
of the best evidence-providing approach, namely, large randomised controlled 
trials (RCTs). In the same way, the pharmacogenomics of HTN have the potential 
to identify genetic biomarkers that predict the response of BP-lowering agents 
through genome-wide association studies (GWAS), which analyse quantitative 
traits at millions of markers across the genome to identify genetic variations that 
could contribute to HTN. For the most part, computational approaches and 
software tools have played a significant role in translating RCTs and GWAS 
findings.  
 
This thesis aims first to systematically review the BP responses of main BP-
lowering agents, including angiotensin-converting enzyme inhibitors (ACEIs), 
angiotensin II receptor blockers (ARBs), calcium channel blockers (CCBs), diuretics 
(DIs) and beta-blockers (BBs) in RCTs, and second to identify the single nucleotide 
polymorphisms (SNPs) associated with the BP-lowering responses of CCBs and BBs 
on Nordic Diltiazem (NORDIL) subjects using GWAS.  
 
Description of the research results: Following the Population Intervention 
Comparison Outcome Study (PICOS) design framework, a literature search of 
multiple sources resulted in the identification of 10,577 publications, with 5,568 
unique records identified after duplicates were excluded. In total, 184 studies 
were identified as potentially eligible, of which 82 RCTs with a total of 197,684 
participants were selected for quantitative synthesis. With regard to BP-lowering 
strategies, 13 studies with 41,886 participants focused on lowering BP 
intentionally, while the remaining 69 studies (155,798 participants) were 
classified as unintentional BP-lowering studies. 
Risk of bias in included studies: Using the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) framework, all included studies 
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were described as RCTs; however, most studies did not address how treatment 
randomization occurred or how allocation of treatment was concealed. All 
included studies also stated that they were double-blind studies, but again, most 
did not describe how the double blinding was ensured throughout the studies. The 
risk of attrition bias was avoided as all randomized participants were included in 
the analysis. All of the studies had a low risk for reporting bias. BP-lowering agents 
were added to randomly allocated treatment to control high BP; consequently, 
one potentially unclear source of bias was present in 13 of the 82 studies. The 
overall quality was rated to be acceptable to high. In all, 48 studies were rated to 
be high-quality studies, and 34 studies were rated as acceptable quality. 
Effect of intervention: After a systematic search and selection process, 56 studies 
were included in the analysis of delta BP response, 37 studies were included in 
the analysis of single-measure BP response and 20 studies were included in the 
analysis of repeated measures. A number of BP-lowering agents showed a 
significantly (P<0.05) superior BP response in comparison with other agents 
included in the review; however, the level of BP response was still small. CCBs 
were superior to ACEIs in lowering both systolic BP (SBP) and diastolic BP (DBP). 
DIs were superior to ACEIs and CCBs in lowering SBP. ARBs were superior to BBs in 
lowering SBP. CCBs and DIs were significantly superior to placebos in lowering both 
SBP and DBP. 
 
Genome-wide study: Following NORDIL quality control standards, a final set of 
3,850 samples and 500,905 SNPs was available for analysis. In total, 51 SNPs 
showed a significant (P<1X10-5) association with BP response. The top discordant 
signals identified in NORDIL included five SNPs for SBP on BB arm, seven SNPs for 
DBP on BB arm, 12 SNPs for SBP on CCB arm and nine SNPs for DBP on CCB arm. 
Discordant SNPs from the NORDIL were replicated, based on the interests of five 
collaborative RCTs; including 11 SNPs for SBP on BB arm, 22 SNPs for DBP on BB 
arm, 23 SNPs for SBP on CCB arm and 18 SNPs for DBP on CCB arm. However, no 
SNP achieved a genome-wide significance of (P<5x10-8).  
Future recommendations: Further systematic reviews of RCTs comparing 
different BP-lowering agents are required to provide evidence of the options for 
BP-lowering medication. Specifically, there is a need to study BP response as an 
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outcome by itself, taking into account different BP-lowering agent combinations, 
including classes and sub-classes, along with co-morbidities such as type 2 
diabetes mellitus, coronary heart disease and chronic renal failure. 
Regarding the genome-wide study, further studies are needed to clarify the 
potential contribution of plausible SNPs in relation to CCB and BB response in HTN. 
These studies should include comprehensive sequencing of the candidate interval, 
genotyping of variants in many population samples, testing for association, 
functional studies and investigation of interactions with other genes or 
environmental factors. Furthermore, genome-wide studies need to identify 
directionally discordant signals between SNP and BP response for BB and CCB and 
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HR Heart rate  
HTN Hypertension  
HWE Hardy-Weinberg equilibrium 
HYVET Hypertension in the Very Elderly Trial 
HYVET- 
pilot 
Hypertension in the Very Elderly Trial- pilot study 
I/D Insertion/ deletion polymorphism 
I2 Inconsistency 
IBD Identity by descent 
IBS Identity by state 
IDEAL Identification of the Determinants of the Efficacy of Arterial Blood 
Pressure Lowering drugs 
IDNT Irbesartan Diabetic Nephropathy Trial 
IMT Intima media thickness 
INSIGHT International Nifedipine GITS Study Intervention as a Goal in 
Hypertension Treatment 
INTERSALT International Study of Salt and Blood Pressure 





International Verapamil SR-Trandolapril Study- genetic sub-study 
ISH Isolated systolic hypertension 
ITT Intention-to-treat 
IVRS Interactive Voice Response System 
JMIC-B Japan Multicenter Investigation for Cardiovascular Diseases-B 
JNC Joint national committee 
JPT Japanese in Tokyo 
JSH Japanese society of hypertension 
KCNMB1 Calcium-activated potassium channel subunit beta-1 
KHS KYOTO HEART Study 
KM Kaplan–Meier 
LAARS Losartan Vascular Regression Study 
LD Linkage disequilibrium 
Leu Leucine  
LIFE Losartan Intervention for Endpoint Reduction in Hypertension 
LIVE Left ventricular hypertrophy regression, Indapamide Versus 
Enalapril 
LOTHAR Amlodipino e Losartana no Tratamento da Hipertensão Arterial 
LVH   Left ventricular hypertrophy 
LVM  Left ventricular mass  
Lys Lysine  
MAF Minor allele frequency 
MAISH Manidipine versus Amlodipine in Elderly Subjects with Isolated 
Systolic Hypertention 
MAPAVEL Monitorización Ambulatoria Presión Arterial Aprovel 
MARVAL Microalbuminuria Reduction With valsartan 
mBB Beta blocker monotherapy 
mCC Calcium-channel blocker monotherapy 
mDI Diuretic monotherapy 
MDS Multidimensional scaling 
MEDLINE Medical literature analysis and retrieval system online 
Met Methionine 
MI Myocardial infarction 
MIDAS Multicenter Isradipine Diuretic Atherosclerosis Study 
MOSES  Morbidity and Mortality after Stroke, Eprosartan Compared with 
Nitrendipine for Secondary Prevention  
MRC Medical Research Council trial of treatment of mild hypertension 
MRCO Medical Research Council trial of treatment of mild hypertension in 
Older adults 
mRNA Messenger ribonucleic acid 
N Number  
Na+ Sodium ion  
NCI-NHGRI National Cancer Institute - National Human Genome Research 
Institute  
NEBIS Nebivolol, Bisoprolol Multicentre Study 
NEDD4L Neural precursor cell expressed a developmentally down-regulated 
4-like gene 
NICE National institute for clinical excellence 
NICE-Combi Nifedipine and Candesartan Combination 
NICE-EH National Intervention Cooperative Study in Elderly Hypertensives 
NICOLE  Nisoldipine in Coronary Artery Disease in Leuven 
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NOAAH Newer Versus Older Antihypertensive Agents in African Hypertensive 
Patients  
Non-DHP Non-Dihydropyridines 
NORDIL Nordic Diltiazem 
OD Once-daily 
ONTARGET Ongoing Telmisartan Alone and in Combination With Ramipril Global 
Endpoint Trial 
OR Odds ratio 
ORIENT Olmesartan Reducing Incidence of End stage renal disease in 
diabetic Nephropathy Trial 
PAMELA Pressioni Arteriose Monitorate e Loro Associazioni  
PATS Post-stroke Antihypertensive Treatment Study   
PCKD Polycystic kidney disease 
PD Pharmacodynamics 
PEACE Prevention of Events with Angiotensin Converting Enzyme Inhibition 
PEAR Pharmacogenomics Evaluation of Antihypertensive Responses 
PG Pharmacogenomics 
PICOS Population Intervention Comparison Outcome Study 
PICXEL Perindopril/Indapamide Combination more effective than Enalapril 
in Reducing Blood Pressure and Left Ventricular Mass 
PK Pharmacokinetics 
POS  Chromosomal position 
PP Per-protocol 
PRA Plasma-renin activity 
PRESERVE Prospective Randomized Enalapril Study Evaluating Regression of 
Ventricular Enlargement 
PRESMA Preferred reporting items for systematic reviews and meta-analyses 
PROBE Prospective, randomised, open trial with blinded endpoint 
PROGRESS Perindopril Protection Against Recurrent Stroke Study 
PTCD3 Pentatricopeptide repeat domain 3  
PVD Peripheral vascular disease  
PWV Pulse wave velocity 
RAAS Renin–angiotensin–aldosterone system  
RACE Ramipril Cardioprotective Evaluation 
RCT Randomised controlled trial 
RE Random effect model 
REF Reference 
REGAAL Losartan Left Ventricular Hypertrophy regression 
REIN-2 Renoprotection in Patients with Non-Diabetic Chronic Renal Disease 
RENAAL Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist 
Losartan 
RF Renal failure 
SAKURA Study of Assessment for Kidney Function by Urinary Microalbumin in 
Randomized Trial 
SBP Systolic blood pressure  
SCOPE Study on Cognition and Prognosis in the Elderly 
SD Standard deviation 
SE Standard error 
Ser Serine  
SELECT Systolic Evaluation of Lotrel Efficacy and Comparative Therapies 
SHELL Systolic Hypertension in the Elderly Long-term Lacidipine 
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SILVHIA Swedish Irbesartan Left Ventricular Hypertrophy Investigation 
versus Atenolol 
SNP Single nucleotide polymorphism 
SNTG1 Syntrophin gamma 1 
Syst-China Systolic Hypertension in China 
Syst-Eur Systolic Hypertension in Europe 
T Thymine  
T2DM Type 2 diabetes mellitus 
TEST Tenormin after Stroke and Transient Ischaemic Attack 
Thr Threonine 
TIA Transient ischaemic attack 
TOMHS Treatment of Mild Hypertension Study 
TRANSCEND Telmisartan Randomised Assessment Study in ACE Intolerant 
Subjects with Cardiovascular Disease 
Trp Tryptophan  
UKPDS United Kingdom Prospective Diabetes Study 
VA Veterans Administration 
Val Valine  
VALUE Valsartan Antihypertensive Long-term Use Evaluation 
VHAS Verapamil in Hypertension and Atherosclerosis Study 
WHO World health organization 
WMD Weighted mean difference 
YOR Yoruba in Nigeria 






1.1 Cardiovascular disease  
Cardiovascular disease (CVD) comprises of a group of disorders of the heart and 
blood vessels, including hypertension (HTN), coronary heart disease (CHD) and 
cerebrovascular disease, as well as renal disease. CVD has major public health 
importance with a high prevalence throughout the world. This was emphasized by 
the Global Burden of Disease Study (GBD1997)1, which analysed data from 47 
countries between 1950 and 1990 to estimate the leading causes of mortality and 
disability worldwide (1;2).  
According to the World Health Organisation (WHO), HTN currently kills nine million 
people every year and is responsible for at least 45% of the deaths due to CHD and 
51% of the deaths due to stroke (3).Therefore, HTN is one of the most important 
indications for drug therapy in CVD. It is estimated that the total number of adults 
with HTN will increase by more than 60% to 1.56 billion by 2025 (4).  
Decreasing blood pressure (BP) levels to recommended targets is crucial to 
improving the CV prognosis in the HTN population. The reduction of CHD mortality, 
observed in a number of countries, has, at least in part, been associated with 
improved medical treatment and control of risk factors, mainly with regards to 
systolic BP (SBP) and total cholesterol (5).For instance, the International 
Verapamil SR-Trandolapril Study (INVEST 2003) showed that hypertensive patients 
with CHD and a higher proportion of visits in which BP control was attained had a 
42% decrease in the risk of myocardial infarction (MI) and a 50% reduction in the 
risk of stroke (6). Accordingly, the identification and characterisation of 
mechanisms contributing to the pathogenesis of HTN is vital for the future 
treatment and prevention of CVD. 
                                         
1
 The numbers next to the study represent the study’s publication year. 
21 
 
1.2 Human HTN  
BP is a quantitative trait that is highly variable, both between and within 
individuals (7). It refers to the pressure exerted by circulating blood on the walls 
of blood vessels, and is mainly determined by cardiac output and peripheral 
vascular resistance. Cardiac output — the volume of blood pumped by the heart 
per minute (ml/min) — depends on the heart rate (HR) and stroke volume. The 
former is the number of heart beats per minute, while the latter is the volume of 
blood pumped out of the heart with each beat. Peripheral vascular resistance, the 
resistance to the flow of blood in peripheral arterial vessels, depends on 
functional and anatomic changes in the small arteries (lumen diameter 100–400 
μm) and arterioles.  
Guyton was the first person to suggest a primary role for the kidney in the 
development of HTN as noted in his seminal paper (8), persistently high BP or HTN 
is characterised by a disturbance of renal function that subsequently leads to an 
increase in sodium ion (Na+) reabsorption. Therefore, there is an accumulation of 
Na+ in the body, stimulating a marked expansion of extracellular volume and, 
consequently, cardiac output. When cardiac output rises, it increases blood flow 
to almost all body tissues. Consequently, an auto-regulatory mechanism for local 
control of blood flow causes an instant adjustment in the blood vessel diameter, 
re-establishing sufficient tissue perfusion. Insufficient autoregulation then 
increases peripheral vascular resistance and BP. The price of this biological 
adaptation is HTN. 
1.2.1 Causation and 
epidemiology  
BP is controlled by a complex network of physiological pathways, comprising 
vascular, neural, endocrine and renal mechanisms that act together to preserve 
continuous BP control. About 5% of patients with HTN have an underlying cause 
for their high BP, such as renal disease, constrictive vessel disease or monogenic 
disease. Although the other 95% have essential or primary HTN in which there is 
no underlying identifiable cause for the high BP, a genetic tendency caused by the 
cumulative effects of various lifestyle factors (e.g. high salt intake, low levels of 
physical activity and increasing obesity) over many years is a likely explanation.  
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Whilst the aetiology of HTN in unknown in the majority of individuals with HTN, 
studies have focused on the classifying the environmental and genetic (as 
mentioned below, Section 1.4.1) components in the causation of HTN to 
understand the molecular pathogenesis of the condition.  
Many environmental factors elevate BP, including obesity, high dietary sodium 
intake, excess alcohol consumption, smoking, lack of physical exercise, low 
potassium intake, low calcium intake and psychological stress (9). Two variables 
that have been studied a great detail are salt intake and obesity. For example, 
the Intenational Study of Salt and Blood Pressure (INTERSALT 1989) was a large, 
prospective epidemiological study involving 52 centres from 32 countries. The 
study identified a strong link between SBP and urinary Na+ excretion, which was 
independent of any other risk factors for HTN (10). Positive associations have also 
been documented between body mass index (BMI) and BP in both cross-sectional 
and prospective studies, with the odds of progression to HTN increase by 20–30% 
for every 5% gain in body weight (11). 
 
Environmental factors also have an important link with the genetic component. 
For example, alcohol intake is, clearly, mainly determined by consumption. 
However, individuals who inherit a variant of aldehyde dehydrogenase 2 (ALDH2), 
which is common among Japanese population, experience a more extreme 
negative response to alcohol and therefore consume less on average (12). The 
relationship between salt intake and BP is mediated by a person’s salt sensitivity, 
which is partly genetically determined, as the change in SBP from a high to low 
sodium diet was significantly greater in patients’ 460 tryptophan (Trp) variant of 
the alpha-adducin (ADD1) polymorphism (13). 
1.2.2 Measurements and 
diagnosis   
BP is measured in millimetres of mercury (mmHg) and is expressed in two terms: 
systolic, which represents the highest pressure in each cardiac cycle and is related 
to cardiac output; and diastolic, which represents the lowest pressure in each 
cardiac cycle and is related to systemic vascular resistance. According to the 
National Institute for Clinical Excellence (NICE), HTN is a chronic medical 
condition defined currently using the thresholds of SBP >=140 mm Hg and/or 
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diastolic BP (DBP)>=90 mm Hg; however, there is no definitive cut-off point above 
which a diagnosis of HTN is confirmed and below which it is excluded (14).As 
shown in Table 1.1, according to a number of guidelines, such as NICE in the 
United Kingdom (14), the European Society of Hypertension (ESH) / European 
Society of Cardiology (ESC) in Europe (15) and the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) in 
the United States(16), BP measurements can be taken: 
 At home (using home blood pressure monitoring (HBPM))  
 In the clinic/office (using a sphygmomanometer) 
 Over 24 hours (using ambulatory blood pressure monitoring (ABPM)) 
  
Table 1.1 Guidelines for definitions of HTN according to the measurement techniques. 
NICE-United Kingdom 
Clinic/Office  SBP ≥140 mmHg and/or DBP ≥90 mmHg 
ABPM (Day-time) SBP ≥135 mmHg and/or DBP ≥85 mmHg 
HBPM SBP ≥135 mmHg and/or DBP ≥85 mmHg 
ESH/ESC-Europe 
Clinic/office  SBP ≥140 mmHg and/or DBP ≥90 mmHg 
ABPM  
Day-time  SBP ≥135 mmHg and/or DBP ≥85 mmHg 
Night-time  SBP ≥120 mmHg and/or DBP ≥70 mmHg 
24-hour SBP ≥130 mmHg and/or DBP ≥80 mmHg 
HBPM SBP ≥135 mmHg and/or DBP ≥85 mmHg 
JNC-United States 
Clinic/Office  SBP ≥140 mmHg and/or DBP ≥90 mmHg 
ABPM  
Day-time  SBP ≥135 mmHg and/or DBP ≥85 mmHg 
Night-time  SBP ≥120 mmHg and/or DBP ≥75 mmHg 
 
Diagnoses of HTN are based on the measurement of BP, which is classically 
performed non-invasively in a clinic or office using a sphygmomanometer via a 
cuff around the upper arm, with the person relaxed and seated, and their arm 
outstretched and supported. The BP readings should be taken manually in a 
standardised way (most clinical studies use Korotkoff I and V, from the first sound 
heard to the complete disappearance of sounds). However, in a clinic or office, 
BP is usually higher compared to ABPM or HBPM; 15-20% of patients with stage I 
HTN may only have elevated BP levels in the presence of a healthcare worker, due 
to anxiety induced by the clinical setting; this phenomenon is referred to as ‘white 
coat HTN’ (17).  
The NICE guidelines recommend that all patients suspected of having HTN should 
undertake ABPM, ensuring that the device is validated and a suitable cuff size for 
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the person’s arm is used (14). However, ESH/ESC recommend that only those with 
grade I HTN and a low/moderate CV risk undertake ABPM or HBPM, in order to 
exclude white coat HTN (15). ABPM and HBPM may have greater prognostic value 
for the risk of CV events than clinic/office BP measurements; additionally, ABPM 
is associated with a doubling of BP control rates in comparison to clinic/office 
measurements (15;18;19).  
HBPM offers more extensive data than office BP measurement can provide, is less 
expensive, is widely available and convenient, and has been shown to improve 
patient compliance with treatment and BP control. Therefore, HBPM can be used 
as a substitute for ABPM when the latter is not accessible or is not acceptable to 
the patient. It can also be used for monitoring treated patients between office 
visits and subsequently improving long-term medication adherence (20). For 
example, home and office BP were compared in Pressioni Arteriose Monitorate e 
Loro Associazioni’s (PAMELA1997) study. It was found that SBP and DBP were 
significantly lower at home than in the office by 9.5 mmHg and 4.9 mmHg, 
respectively (P< 0.01) (21). 
1.2.3 Management approaches 
HTN management has improved significantly, due to increased awareness of the 
health risks associated with HTN, improved HTN management offered by primary 
care practitioners and the availability of effective treatment options. BP-lowering 
agents have been shown practically to be effective in decreasing mortality risk for 
stroke, MI and heart failure (HF) by 35-40%, 20-25% and >50% respectively (22). A 
meta-analysis of 1 million adults from 61 prospective studies showed that 
decreasing SBP by 20 mm Hg reduces CV risk by 50%, and, for every 2 mm Hg 
decrease in mean SBP, there is a lowering of mortality risk from CHD and stroke, 
by 7% and 10% respectively (23). HTN management can be accomplished by two 
main approaches: non-pharmacological (lifestyle interventions) and 
pharmacological. 
1.2.3.1 Non-pharmacological approach  
When a patient is suspected of having HTN, non-pharmacological measures are a 
crucial step that should be tried first (16). Lifestyle modifications are generally 
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useful in reducing a variety of CVD risk factors (including HTN) and promoting good 
health; therefore, they can be used either as a definitive treatment or as an 
adjunct to drug therapy. A practical, comprehensive approach for hypertensive 
patients includes weight loss for the overweight patient, regular physical activity, 
moderate alcohol consumption, dietary modification (such as reducing Na+ and fat 
and increasing calcium, potassium and fibres) and quitting smoking (16).In 
general, modifying one’s lifestyle effectively lowers BP and might be more 
worthwhile than the initial choice of BP-lowering agent in patients with stage 1 or 
2 HTN (24). 
In PREMIER2003, investigators compared the effect of three interventions: 
comprehensive lifestyle modifications, incorporating the JNC-7 recommendations, 
behavioural modification without Dietary Approaches to Stop Hypertension (DASH) 
2 (‘established’ group), ‘established plus DASH’ group and an ‘advice-only’ group. 
Results showed superior mean reductions in SBP/DBP in the established group by 
-10.5/-5.5 mmHg, compared with the advice-only group at -6.6/-3.8 mmHg, with 
the greatest reductions seen when DASH was also incorporated (-11.1/-6.4 
mmHg)(25). However, the anticipated BP target is not always achieved as BP can 
continue to increase; to address this, BP-lowering agents need to be introduced.  
1.2.3.2 Pharmacological approach: BP-lowering agents  
Patients are commonly treated with one or more of the following BP-lowering 
therapies: angiotensin converting enzyme inhibitors (ACEIs), angiotensin II 
receptor blockers (ARBs), calcium channel blockers (CCBs), diuretics (DIs) or beta-
blockers (BBs). In general, ACEI hampers the formation of angiotensin II and 
aldosterone, which leads to a reduction in vascular tone and extracellular fluid 
volume and, consequently, a lowering of BP. ARBs and CCBs act as vasodilators to 
widen resistance arteries, reducing peripheral resistance. DIs increase water and 
salt excretion, thereby reducing extracellular fluid and blood volume, as well as 
BP. BBs decrease cardiac output and, therefore, BP. Table 1.2, outlines the BP-
lowering treatments for patients with comorbid conditions. 
 
                                         
2
    DASH is a diet rich in fruits, vegetables, and lowfat dairy products with a reduced content of 
dietary cholesterol as well as saturated and total fat. It is rich in potassium and calcium content. 
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Table 1.2 BP-lowering therapy for patients with comorbid conditions (adapted from 
Carretero and Oparil, 2000) (26) . 
Condition BP-lowering agents  
Isolated systolic hypertention(ISH) DIs or CCBs 
Heart Failure ACEIs, DIs, or ΒBs 
Myocardial Infarction  BBs or ACEIs 
Angina BBs or CCBs 
Atrial tachycardia and fibrillation  BBs or CCBs 
Diabetes Mellitus  ACEIs or CCBs 
Hyperthyroidism BBs 
Osteoporosis Thiazide DIs 
Essential tremor BBs 
Migraine BBs or CCBs 
Renal insufficiency (except for renal HTN) ACEIs 
 
According to the recommendations of a number of guidelines produced by NICE, 
ESH/ESC and JNC (14-16), the main BP-lowering agents for the initial management 
of HTN are ACEIs, ARBs, CCBs, DIs and BBs, as shown in Table 1.3. 
Table 1.3 Guideline recommendations regarding monotherapy and combination HTN 
treatment. 
Guidelines Type of therapy HTN therapy 
NICE- 
United 
Kingdom   
Monotherapy 
 
CCBs are recommended for the initiation of 
treatment in Patients ≥55 years, blacks of African or 
Caribbean origin of any age.  
ACEI or ARB are recommended for the initiation of 
treatment in other patients aged <55 years  
Combination therapy 
Recommended combinations as second-line 





DIs, CCBs, ACEIs, ARBs, and BBs are recommended 
for the initiation and maintenance of treatment 
Combination therapy 
 
Recommended combinations in pateints at high risk 







Non-black patients: thiazide-DIs, CCBs, ACEI, or ARBs 
are recommended as initial treatment  
Black patients: thiazide-DI or CCBs are 
recommended as initial treatment 
Combination therapy 
 
Up titration or combination with another class of 
agents recommended.  
ACEIs and ARBs are recommended for patients with 
CKD 
 
  27 
 
Monotherapy has a solid place in the treatment algorithm of HTN, especially for 
grade 1 or mild HTN, as it allows for a determination of the drug’s efficacy and 
tolerability, whereas one of the agents may be ineffective with combination 
therapy. However, when monotherapy is insufficient or less tolerated, finding an 
alternative that is more effective and/or better tolerated can be challenging and 
might erode patients’ compliance and adherence. Escalating the dosage of a 
recommended monotherapy may be less effective for BP reduction than combining 
agents from different BP-lowering classes (27). However, the response to 
monotherapy with any of these agents is less than 50%, and despite the multiple 
initial therapies for HTN, less than half of hypertensive patients have their BP 
controlled to target and require additional BP-lowering agents (28). 
Combination therapy allows a more rapid BP response in comparison to 
monotherapy and has a greater probability of achieving the target BP, and also 
may enhance patients’ adherence (15). In addition, the combination of BP-
lowering agents reduces incidences of major CV events (stroke and CHD) and may 
have greater CV benefits than when starting on monotherapy (29). For example, 
the Anglo-Scandinavian Cardiac Outcomes Trial — Blood Pressure Lowering Arm 
(ASCOT-BPLA 2005) study showed that about nine out of ten patients required two 
or more BP-lowering agents to reduce BP to less than 140/90 mmHg (30). 
Consequently, most patients, and mainly those with high CV risk, will need 
combination therapy with two or more BP-lowering agents in order to achieve a 
controlled BP; recent guidelines also recommend that a two-drug combination 
therapy be considered a first-line alternative to monotherapy (15;16). 
In addition, the combination of certain classes of BP-lowering agents has an 
additive effect, which allows earlier, larger and more sustained reductions in BP 
than up titration of monotherapy and a sequential add-on regimen (29). For 
instance, the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies 
(SELECT 2005) showed that CCB-amlodipine/ACEI-benazepril combination therapy 
was significantly more effective in reducing SBP and pulse pressure in patients 
with severe systolic HTN than either type of monotherapy (p < 0.0001) (31).  
Similarly to the ACEI–CCB combination, ARB–CCB combinations have shown 
efficacy in reducing BP. The Nifedipine and Candesartan Combination (NICE-Combi 
2005) study showed that BP reduction was significantly greater in the CCB-
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nifedipine/ARB-candesartan combination therapy group (12.1/8.7) than in the up-
titrated candesartan monotherapy group (4.1/4.6, P< 0.0001). In addition, 
combination therapy was better for renal protection and also brought a significant 
decrease in urinary micro-albumin excretion levels, compared to either 
monotherapy (P< 0.05) (32). This evidence shows that combination therapy is more 
effective in reducing BP than high-dose monotherapy. 
1.2.3.3 Control and resistance  
Current control rates (SBP < 140 mm Hg and DBP < 90 mm Hg), though improved, 
are still far below the healthy population goal of 50% (33), which was originally 
set as the goal for the year 2000 and has since been extended. Despite the 
guidelines for the management of HTN, the attainment of ideal BP goals can be 
challenging for both physicians and patients. The former tend to base their HTN 
management plans on their own experiences with patients, as well as the 
recommendations of the HTN clinical guidelines. These are generally based on 
studies that were conducted on large populations with possibly unknown genetic 
variations, in which there was significant inter-individual variation in BP response 
to all classes of BP-lowering agents. Therefore, optimum BP control has been 
achieved only in a limited number of patients, despite the widespread availability 
of approved agents from several drug classes and with several mechanisms of 
action (34). 
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT 2000), which involved a large number of participants, including 47% 
female, 35% African American, 19% Hispanic, in addition to 36% with diabetes, 
about 34% of subjects managed to control their BP on an average of two BP-
lowering agents after nearly five years of follow-up. In addition, about 50% needed 
three or more drugs to achieve adequate BP reduction (35).  
According to NICE, resistant HTN is defined as BP that remains above 140/90 
mmHg, despite the use of three BP lowering medications of different classes at 
the best tolerated doses, one of which must be a DI(14). A considerable number 
of patients fail to reach target BP ranges, despite lifestyle advice and standard 
medical therapy. The cross-sectional analysis of the Framingham Heart Study 
(FHS) also revealed that only 48% of HTN-treated patients were controlled to < 
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140/90 mm Hg, while < 40% of elderly patients (> 75 years of age) were at target 
BP (36). 
For instance, less than 50% of hypertensive patients worldwide have their BP 
controlled, despite multiple BP-lowering agents, with the control rate at ∼10% in 
the Middle East, 13% in Northern Europe, 20% in Southern Europe, 24% in Asia, 28% 
in North America and 31% in Latin America(28). Additionally, a recent analysis of 
national surveys in 2013 revealed that England had lower levels of HTN treatment 
(51%; USA 74%; Canada 80%) and control at < 140/90 mm Hg (27%; USA 53%; Canada 
66%) than many other countries (37).
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1.3 Clinical studies in BP-lowering agents: An overview  
The clinical development of a new drug is usually associated with risk and 
uncertainty, with about 90% of human studies failing to achieve registration (38). 
A clinical study is any form of planned experimental study design that is designed 
to evaluate the effect of a new drug or intervention on clinical outcomes in 
humans. In general, clinical studies may be either pre-clinical studies (Phase 0), 
small clinical studies to investigate effect and safety (Phase I/II) or full–scale 
evaluation of the new treatment (Phase III), which includes randomised controlled 
trials (RCTs)(39). 
 
In the main, the strength of RCTs is their superior ability to measure change over 
time from a treatment. They are often considered to be the ‘gold standard’ of 
clinical and epidemiological studies. This is because, if they are well-conducted, 
it is often possible to be fairly sure that the results are correct, at least for the 
type of patients who enrolled in the study. Consequently, they have an important 
role in determining the efficacy and safety of interventions. Treatment 
differences identified from cross-sectional observational studies, rather than 
RCTs, have methodological weaknesses, include confounding and cohort effects in 
addition to selection bias(39;40). 
 
In addition, RCTs often share a number of principles, including: randomisation of 
subjects to receive one or other of the treatments under investigation, or to 
receive either treatment or placebo; blinding of all participants as to which group 
subjects are in; similarity of relevant demographics between group subjects (such 
as age and ethnic origin); dealing with dropouts and withdrawals (41).  
 
1.3.1 Historical perspective 
HTN therapy was, without a doubt, one of the main achievements of medicine in 
the second half of the twentieth century. This is not only because BP- lowering 
agents have been effectively developed, starting from the 1950s, but also 
because, in the same time window, the effects of drug-induced BP lowering have 
been tested thoroughly by means of the best evidence-providing approach, which 
is through large RCTs. 
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 In 1965, the first BP-lowering RCT was conducted by Wolff and Lindeman, 
involving patients with baseline DBP (93.3 mmHg); this was followed by a 
slightly larger one conducted by the Veterans Administration Cooperative 
Study Group on Antihypertensive Agents-I (VA-I 1967), including patients with 
baseline DBP (115 through 129 mm Hg). Both studies compared the BP-
lowering effects of hydralazine, hydrochlorothiazide and reserpine (42;43). 
Following this, RCTs comparing active BP-lowering drug treatments with 
placebo or, no drug treatment or less active treatment, were carried out 
in order to answer the question of whether drug-induced BP lowering is 
indeed beneficial. 
 From 1965 to 1985, most of the placebo-controlled studies on BP-lowering 
agents were conducted, such as the Veterans Administration Cooperative 
Study Group on Antihypertensive Agents-II (VA-II 1970)(44), Oslo 1980(45) and 
the European Working Party on High Blood Pressure in the Elderly (EWPHE 
1985)(46); the agents used in the active treatment arm were those agents 
commonly used at that time, such as thiazide-DI, BB, methyldopa, reserpine 
and hydralazine.  
 From 1980, new classes of BP-lowering agents (such as CCB, ACEI and ARB) 
became increasingly used and studied as they proved their effectiveness in 
reducing the risk of HTN, such as in the Verapamil in Hypertension and 
Atherosclerosis Study (VHAS 1998) (47), ALLHAT 2002 (48) and Diabetics 
Exposed to Telmisartan and Enalapril (DETAIL 2004) (49).  
1.3.2 Perspective challenge 
In general, RCTs have shown that large numbers of people have HTN that is 
inadequately treated and are not achieving the goals set by the main clinical 
guidelines. However, in the past 20 years, there have been no studies reporting 
primary outcome data on the scale of ALLHAT 2002 (N=33,357) (48), the African 
American Study of Kidney Disease and Hypertension (AASK 2002) (N=1,094) (50), 
ASCOT-BPLA 2005 (51) (N=19,257), Nordic Diltiazem (NORDIL 2000) (N=10,881) (52) 
and other key studies that have marked clinical trial activity and informed 
guideline committees during the past two to three decades. 
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Regardless of the large number of RCTs that have studied BP-lowering agents, the 
study of BP response involves many challenges: differences in study designs, small 
sample sizes, short duration of follow-up and different methods for assessing drug 
exposures, as well as the fact that the ideal BP control rates seen in these studies 
have almost never been replicated in a community-based setting. Recent clinical 
studies have been designed to show that a BP-lowering agent is as good as, if not 
better than, an existing agent. However, in spite of the large number of RCTs on 
BP-lowering agents, some issues of practical importance in the management of 
HTN have not been investigated, or examined according to diagnostic criteria or 
definitions that are scarcely applicable today. 
 
However, RCTs are typically time-consuming, and large sample sizes are often 
needed to ensure sufficient statistical heft. Evidence from RCTs has shown the 
benefit of BP-lowering agents in reducing adverse health outcomes in hypertensive 
patients. Consequently, clinical guidelines are at the intersection between 
research evidence and clinical actions that can improve patient outcomes. 
Pharmacogenomics (PG) of HTN aims to identify potential genetic biomarkers to 
predict anti-HTN agent responses and adverse drug outcomes, allowing physicians 
to identify patients who are expected to either benefit or suffer harm from the 
treatments, so that they can use alternative pharmacotherapy and avoid adverse 
drug reactions. By integrating PG with pharmacokinetics (PK) and 
pharmacodynamics (PD), superior predictive medical care and treatment can be 
assured and provided, leading to more effective BP control and improved 




1.4 Genetics and pharmacogenomics of HTN  
1.4.1 Genetic component of 
HTN 
The identification of genetic mechanisms in HTN is challenging, just like other 
complex diseases, due to the lack of identification of the specific genes involved 
and the extent to which specific genes contribute to the phenotypes, populations 
and environments. Despite this, the study of genetic variation implicates common 
and rare mutations that are involved in the genetic architecture of HTN.  
Epidemiology and family aggregation studies have shown that genes play a 
significant role in determining susceptibility to HTN. The heritability of clinic SBP 
is around 15–40% and 15–30% for clinic DBP; whereas for ambulatory night-time 
SBP and DBP the heritabilities are 69% and 51% (54;55).The genetic component of 
HTN has been confirmed. First, the BP distribution among the general population 
follows normal distribution, which reflects the presence of many environmental 
and genetic factors. Second, the rare monogenic syndromes of HTN, which directly 
alter renal tubular electrolyte transport, influence BP levels (56). Third, studies 
conducted on adoption, twins and families have shown that correlations in BP are 
more significant between biological parents and children than between parents 
and adopted children, revealing the presence of a heritable component in HTN 
and identifying the strong genetic factor that influences BP levels and leads to 
HTN diseases (57;58). 
Individuals who have one or two parents with HTN are about twice as likely to 
develop high BP phenotypes; in addition, BP is increasingly more correlated to 
identical twins (monozygotic) than non-identical twins (dizygotic) (59). The 
Montreal Adoption Study compared BP correlation between biological sibling pairs 
and adoptive sibling pairs (as well as parent-child correlations). SBP correlation 
coefficients were 0.38 and 0.16 for biological and adopted siblings respectively, 
and DBP coefficients 0.53 compared with 0.29 respectively(57). 
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1.4.2 The study of genetic 
architecture to identify 
genes of HTN 
Single nucleotide polymorphism (SNP) is the most common form of DNA sequence 
variation, where a single nucleotide adenine (A), cytosine (C), guanine (G), 
thymine (T) is replaced by another; this occurs more frequently in non-coding 
regions of the genome. Consequently, patterns of polymorphisms that differ 
systematically between individuals with different disease states can be identified 
and the effects of risk-enhancing or protective alleles can be represented. 
Strategies to identify variants involved in the complex traits of essential HTN can 
be divided into two broad categories: linkage and association studies. These can 
be further subdivided into candidate gene analysis and genome-wide scans. 
1.4.2.1 Linkage studies 
Linkage studies search for genetic loci or traits in related individuals (such as 
family cohorts) where affected and unaffected family members are phenotyped 
and genotyped. If two loci are transmitted together from parent to offspring more 
often than expected under independent inheritance, they are considered to be 
linked. The genetic relationships between family members are statistically 
analysed (using methods such as parametric or non-parametric analysis) to find 
the genetic markers in linkage disequilibrium (LD). Parametric analysis is so-called 
as it needs a specific assumption about the genetic model with defining multiple 
parameters; mode of inheritance, gene frequencies, and penetrance. Parametric 
analysis is frequently performed on Mendelian traits, in which the genetic model 
can be easily specified (60). 
For HTN, parametric linkage analysis is unlikely, since there is not a simple disease 
model and mode of inheritance. Instead, non-parametric, (that is, assumption-
free) linkage analysis is used. For example, the Medical Research Council British 
Genetics of Hypertension (BRIGHT 2003) study was successful in identifying 
potential loci that modestly increase the risk of HTN after rigorous quality control, 
and analysed the genotypic data using non-parametric linkage. This study initially 
enrolled affected sibling pairs from 1599 families with severe HTN. The work 
identified a locus on chromosome (CHR) 6 that achieved genome-wide significance 
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(P= 0.042) and three more loci with suggestive significance on CHRs 2, 5 and 9 (P= 
0.017) (61). 
1.4.2.2 Association studies  
Association studies are typically conducted in unrelated case-control samples 
(though it is poosible to conduct them on related individulas) through comparing 
the allele frequencies of a single marker or group of markers in candidate regions 
across the human genome. For qualitative traits, association analysis directly 
measures the statistical association between a disease (phenotype) and genetic 
marker (genotype) by comparing the allele frequencies of cases and controls. The 
goal is to find out whether a certain allele occurs in cases (compared with 
controls) more often than would be expected by chance. Quantitative traits, such 
as cholesterol and glucose, are measured for association using linear regression 
(62). 
The least frequent allele of a SNP needs to be above 1% in a population to be 
effectively assessed by association studies (63). Consequently, such studies 
potentially have far greater power than linkage analysis for detecting variants 
with a modest effect on disease risk, given that the genetic marker is close enough 
to show strong LD with the functional variant. There are two types of association: 
direct and indirect. In the former, studies focus on the causal polymorphism of a 
phenotype (association between an identified functional variant and disease). 
Indirect association studies are more commonly performed (such as most genome 
wide association studies (GWAS)), as they require prior knowledge of the known 
function of the candidate regions involving the SNP numbers, which could be the 
causal variants themselves, or of LD with the causal polymorphisms (association 
between the disease and a marker locus that lies close to the disease locus and is 
in LD with it) (60;64).  
1.4.2.3 Candidate gene studies  
Candidate gene studies rely on a group of markers based on an a priori hypothesis 
about the role of a selected gene, or a group of pathway-related genes, on a 
phenotype. These studies suggest that several polymorphisms act together (along 
with environmental variables) to produce a CV phenotype. 
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To date, no candidate gene study has yet demonstrated a reproducible association 
with HTN; there are a number of possible reasons for this, which highlights the 
limitations of such studies. First, the choice of candidate genes may be incorrect. 
Second, the causative genes may be upstream or downstream from the genes 
studied. Third, the SNPs selected may offer incomplete coverage of all variants in 
the genes under study. Fourth, most studies are underpowered and problematic 
due to population stratification or phenotypic or locus heterogeneity. Finally, 
candidate gene studies depend on prior hypotheses about disease mechanisms, 
which prelude the discovery of genetic variants in earlier unknown pathways (60) 
.However, candidate gene studies do have an advantage over GWAS in that 
markers can be typed more densely. Consequently, the probability of detecting 
any true causal effect is improved, besides the probability that negative findings 
are truly negative. 
1.4.3 GWAS  
In recent years, there has been a great increase in the number of GWAS, which 
have become a standard method for disease gene discovery as well as a 
comprehensive approach that can be attempted to exploit the strength of 
association studies, even in the absence of convincing evidence about the 
causative variant locations or functions within candidate genes(60).  
 
GWAS offers a large scale, hypothesis-free strategy based on SNP association 
mapping, which provides novel approaches for testing the hypothesis of ‘common 
disease common variant’ (CDCV) by using high-throughput genotyping technologies 
to assay hundreds of thousands of common SNPs and relate them to clinical 
conditions and measurable traits. This hypothesis states simply that common 
disorders are likely to be influenced by genetic variation that is also common in 
the population; in other words, one or a few predisposing alleles of relatively high 
frequency (60;63). However, there is insufficient empirical evidence to determine 
the validity of the CDCV hypothesis, and arguments for and against have been put 
forward. For GWAS it has been suggested that, as a rough guide, SNPs should meet 
a threshold of minor allele frequency (MAF) ≥ 1% or 2 % to be considered common 
(63). 
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However, the availability of SNP maps from haplotype map (HapMap) has led to a 
revolution in the examination of common diseases and traits, based on the CDCV 
hypothesis, using the GWAS approach. Those SNP maps provided a deeper 
understanding of the inter-individual genetic variations and population diversity, 
and reduced the cost of genotyping.For instance, the dense genotyping chips that 
are now offered cover hundreds of thousands of SNPs and offer ever greater 
coverage of the human genome (whether within or outside genes)(65).  
Unfortunately, only a small number of GWAS on HTN and/or BP have been 
published, including studies whose main objective was not BP genetics (66). 
Several ethnicities have been examined, although most investigations have 
studied European origin because samples of European origin are more accessible 
and because the genetic analysis of African American individuals is more 
challenging. Incomplete accounting for admixture and African genomes have 
undergone a higher number of recombinations than European genomes. Two 
published studies on BP traits by the Cohorts for Heart and Aging Research in 
Genomic Epidemiology-Blood Pressure (CHARGE-BP) and Global Blood Pressure 
Genetics Consortium (Global-BP Gen) have identified an association that 
withstands correction for multiple testing (“genome-wide significance”) within 
the study that can be replicated in an independent study. However, all of these 
variants have been found in individuals of European origin. Thus, comprehensive 
testing in other ethnic groups of the strongest associations is still needed (67;68). 
1.4.3.1 Replication studies  
The gold standard for validation of any genetic study is replication in further 
independent samples. The replication of GWAS findings is as important as that of 
candidate gene associations. Therefore, it should be conducted on an independent 
dataset drawn from the same population as the GWAS, in order to confirm the 
effect in the GWAS target population. When the latter is achieved, further 
populations may be sampled to determine if the SNP has an ethnic-specific effect 
(69). 
Replication of a significant result in an additional population is sometimes referred 
to as generalisation, meaning that the genetic effect is of general relevance to 
multiple human populations. It is essential for the study to be well-powered in 
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order to detect false associated SNPs, where the null hypothesis is most likely true 
(that is, to confidently call the initial GWAS result a false positive.The National 
Cancer Institute and the National Human Genome Research Institute in the United 
States (NCI-NHGRI 2007) produced a summary of their recommendations on the 
reporting of association studies, as well as criteria for replication, such as that 
replication studies should have adequate sample sizes in order to detect the effect 
of the possible allele (70). Often, the effects identified in an initial GWAS suffer 
from ‘winner’s curse,’ which is a bias whereby genetic effect size estimates are 
overestimated in initial discovery studies of disease-predisposing variants (71). 
Therefore, replication samples should, if possible, be larger to account for the 
over-estimation of effect size.  
1.4.3.2 Post GWAS functional studies and clinical utility 
Post-GWAS analyses are needed in order to identify the truly functional variants 
that are responsible for the observed risk-differences, and to unravel the 
mechanisms causing their effects. Post-GWAS analyses involve a detailed genetic 
epidemiological analysis of the associated locus, bio-informatic calculations of 
functionality, and in vitro and in vivo experimental confirmation of the molecular 
mechanisms for the causal variants and their target genes. Epidemiological studies 
need dense SNP genotyping in large sample sizes to analyse the effects of less 
common candidate variants and to separate adjacent genetic variants that are 
frequently correlated and that make it difficult to recognise the truly causal 
variants.  
Furthermore, to translate GWAS findings for clinical settings, a biomarker or a 
diagnostic test is important. A biomarker is a characteristic that is independently 
measured and assessed as an indicator of normal biologic processes, pathogenic 
processes, or pharmacological responses to a medical intervention (72). A PG 
biomarker is any molecular “barcode” detected via analysis of messenger 
ribonucleic acid (mRNA), deoxyribonucleic acid (DNA), protein or circulating cells 
that might be used to stratify patients for treatment advantage within clinical 
studies, to predict patient outcomes and/or observe responses to therapy (73). A 
PG biomarker can be used in a wide range of clinical studies; for patient selection, 
the result of a PG biomarker assay can decide whether a patient is suitable for 
treatment with a specific drug, or the most efficient dose for the patient, or the 
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patient’s susceptibility to side effects, or the course and efficiency end-point of 
a treatment (74) . 
1.4.4 PG of BP response to BP-
lowering agents: An 
overview  
In BP responses, BP-lowering agents were the first CV treatments for which there 
was a significant detection of clinical variation based on ethnicity. For instance, 
blacks generally respond well to DI or CCB, whereas whites respond well to all the 
drug classes. More specifically, the drug responses for DI and CCB were superior 
in blacks, while in whites, ACEI and BB were better (75). Given that different 
pathways influence HTN in divergent ethnic groups, there is a role for PG and 
personalised therapy that is targeted to certain pathways, based on ethnicity. 
Identification of patient characteristics (such as age, sex and BMI) that are 
associated with BP response to each BP-lowering class could increase the control 
rate, improve the ‘trial-and-error’ approach and reduce the CV risks of HTN (76). 
In the main, data on predictors of BP response were generated from four clinical 
studies: the Genetic Epidemiology of Responses to Antihypertensives (GERA and 
GERA2 2002) studies (77); the Genetics of Drug Responsiveness in Essential 
Hypertension Study (GENRES 2007) (78); and the Pharmacogenomics Evaluation of 
Antihypertensive Responses (PEAR 2009) study (79). For the most part, PG studies 
of BP-lowering agents have used the candidate gene approach, which focuses on 
genetic variations that can impact BP-lowering agent PK or PD mechanisms. In line 
with this, the first GWAS of a BP-lowering drug to be published was based on an 
analysis of BP response to hydrochlorothiazide in the GERA2002 study. 
As shown in the Figure 1.1 below, BB suppress renin secretion and are effective 
only in individuals who have either a predominantly sympathetic cause for their 
BP or if their RAAS is activated. While CCBs tend to increase renin secretion and 
their effect is more prominent when the RAAS is suppressed. Thus opposite 
direction of effect shown by a SNP for BB and CCB may indicate that that SNP has 
a specific role for either BB or CCB. 
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Figure 1.1 Drugs acting on the RAAS.  
Drugs which suppress the system are shown in red, those which activate the system 
are in green. 
 
 
1.4.4.1 ACEIs and ARBs 
ACEIs and ARBs are inhibitors of the renin–angiotensin–aldosterone system (RAAS). 
While the former inhibit the conversion of angiotensin to angiotensin II and 
prevent the breakdown of bradykinin, the latter block the angiotensin II 
receptors(80). The candidate genes identified for PG associations in BP response 
to ACEI and ARBs are those in the RAAS, which plays an essential role in regulating 
BP and sodium homoeostasis. Genes encoding the components of RAAS include 
angiotensin-converting enzyme (ACE), angiotensinogen (AGT) and angiotensinogen 
II type-1 receptor (AGTR1), in addition to renin.  
The ACE gene encodes ACE, and has been comprehensively studied for its effects 
on ACEI response. There is evidence of an association between the ACE insertion 
(I) and (D) deletion polymorphism and plasma ACE activity, with an increased level 
of activity in those possessing the D allele (81). According to its association with 
ACE concentrations, different studies have tested the contribution of I/D 
polymorphism to the inter-patient variability in ACEI response. 
For example, the reduction in SBP was significantly greater in patients carrying 
the DD compared to II or ID genotypes (5.6 +/- 3.1 vs. 3.1 +/- 1.1 or 3.6 +/- 2.2, 
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respectively (P < 0.05)). In addition, the reduction in DBP was also significantly 
greater in DD hypertensives compared with II or ID (8.9 +/- 6 vs. 5.5 +/- 3.4 or 5.8 
+/- 4, respectively (P < 0.05)) (82). The reduction of both SBP and DBP in the DD 
genotype was significantly greater than in the II genotype (10.13 +/- 4.91 vs 5.37 
+/- 2.79, P <.01; 7.47 +/- 3.50 vs 4.71 +/- 2.40, P <.05, respectively) and no 
significant association of I/D polymorphism with essential HTN was found (83). 
Similarly, a sub-study of ALLHAT 2002, called Genetics of Hypertension-Associated 
Treatments (GenHAT 2002), tested the association of various outcomes in ALLHAT 
2002 with the I/D polymorphism in 37,939 patients. However, no association was 
found between this polymorphism and BP-lowering agents in the study (including 
lisinopril, amlodipine and chlorthalidone), nor with any of the study outcomes, 
either when considered in combination or stratified by drug therapy (84). 
AGT encodes pre-angiotensinogen, which is expressed in the liver and is cleaved 
by the enzyme renin in response to lowered BP. The substitution of a threonine 
(Thr) for a methionine (Met) (SNP: rs6990) has been shown to be functional, with 
higher plasma AGT levels identified in individuals with the Thr/Thr genotype 
compared to those with the Met/Met genotype (85). For example, the reductions 
in both SBP and DBP after six weeks of treatment of the patients carrying the 
Thr/Thr genotype (SBP = 26 mm Hg, DBP = 14.83 mm Hg) were greater than in the 
groups carrying Met/ Thr (SBP = 3.0 mm Hg, DBP = 6.2 mm Hg) and Met/Met 
genotypes (SBP = 1.2 mm Hg, DBP = 0.10 mm Hg), suggesting that the Thr allele 
may be a possible genetic marker for HTN (86). 
AGTR1 encodes the type I angiotensin II receptor, which is thought to mediate the 
CV effects of angiotensin II. A number of clinical studies have suggested that AT1R 
is involved in BP regulation and modulation of the effect of angiotensin II in 
relation to HTN. The main polymorphism studied was A1166C most studies showed 
no association with BP response to the RAAS blockade. For instance, the INVEST 
genetic sub-study (INVEST-GENES 2007) showed that although race was associated 
with diastolic BP response, as DBP decrease was significantly smaller in Hispanics 
and blacks than whites (P= 0.0032 and P= 0.0069, respectively), the difference is 
likely not to be clinically significant and AGTR1 genotype was not associated with 
BP response (87). Similarly, Ohasama’s 2004 study on hypertensive Japanese 
patients showed no difference among AT1R genotypes, although the AC and CC 
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genotypes were more common in hypertensives than in normotensives. This study 
proposed that the A1166C polymorphism is not a major genetic predisposing factor 
for HTN in the Japanese (88). 
1.4.4.2 CCBs 
CCBs inhibit the function of the calcium channel, preventing the calcium influx 
within the peripheral vascular smooth muscle cells and causing peripheral 
vasodilatation. Similarly, they act on cardiac myocytes, producing negative 
inotropic and chronotrophic effects. The PG of many CCBs has been studied in a 
range of clinical researches in relation to common genetic polymorphisms within 
calcium voltage-dependent channels subunit alpha1 C and subunit beta 2 
(CACNA1C and CACNB2) and the calcium-activated potassium channel subunit 
beta-1 (KCNMB1). However, the PG studies of CCBs were mainly based on an 
analysis of INVEST-GENES 2007(89-91). 
INVEST-GENES 2007 showed that there is no evidence of the association of CACNA1C, 
CACNB2 SNPs and BP responses to after-verapamil monotherapy, although there 
were significant differences in long-term CV outcome by genotype between them 
(89;90). KCNMB1 has two common non-synonymous polymorphisms: the 
substitution of a glutamate (Glu) for a lysine (Lys) and of a valine (Val) for a 
leucine (Leu), Glu65Lys (rs11739136) and Val110Leu (rs2301149), respectively. For 
instance, INVEST-GENES 2007 tested the association of these two nonsynonymous 
SNPs with BP response in hypertensive patients with CHD after verapamil 
monotherapy. The study stated that the SBP response did not differ with the 
KCNMB1 genotype, although, Lys65 variant carriers achieved BP control earlier 
than in Glu65Glu individuals (1.47 versus 2.83 months, P= 0.01) (91).  
1.4.4.3 Thiazide-DIs 
The PG of many thiazide-DI has been studied in many clinical studies in relation 
to common genetic polymorphisms within ADD1; the neural precursor cell 
expressed a developmentally down-regulated 4-like gene (NEDD4L). 
The ADD1 gene encodes for a cytoskeletal protein called alpha-adducin, which 
plays a significant role in signal transduction and renal Na+ transport. Therefore, 
it also has an important role in regulating sodium reabsorption. The glycine (Gly) 
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460Trp polymorphism in the ADD1 gene has been tested in many candidate gene 
studies. Patients who were carriers of the 460Trp allele had a lower base plasma-
renin activity (PRA) as well as a greater BP-lowering response to 
Hydrochlorothiazide treatment, compared to Gly/Gly homozygotes (mean arterial 
BP decrease of 15.9 versus 7.4 mm Hg (p = 0.001) (92).  
A population-based case-control study showed a lower risk of the combined 
outcome of MI and stroke with thiazide-DI, based on the Gly460Trp genotype (93); 
however, INVEST-GENES 2007 did not replicate this finding, instead showing that 
the effect of thiazide-DI on the risk of CV outcomes did not vary by Gly460Trp 
genotype (94). The ADD1 gene remains an interesting candidate and, together 
with NEDD4L, reveals a significant association with BP response to thiazide-DI, 
whereas neither gene alone shows such an association (95).  
NEDD4L is an important determinant of sodium reabsorption in the distal nephron. 
It encodes an ubiquitin ligase that regulates the cell surface expression of the 
epithelial sodium channel (ENaC). For example, in the NORDIL 2000 study, where 
patients were randomised to diltiazem, versus conventional BP-lowering agents, 
mainly DI and/or BB, rs4149601 G allele carriers were shown to have a superior BP 
response (SBP/SBP: −19.5/−15.4 mm Hg) than patients with the AA genotype when 
treated with a thiazide DI/BB. However, no differences in response to CCB-
diltiazem by genotype were identified (96). 
 
The association of the G allele of rs4149601 with the BP response to thiazide-DI 
was also tested in the PEAR 2009 study. The study showed that with 
hydrochlorothiazide, there was a superior BP reduction for GG over GA and AA 
(SBP: −12.4 mm Hg, −10.2 mm Hg and −7.4 mm Hg; DBP: −5.5 mm Hg, −5.0 mm 
Hg and −2.2 mm Hg, respectively). Despite this, there was no evidence of such an 
association in the atenolol-treated patients (97). 
 
1.4.4.4 BBs 
The most convincing PG association for BP response to BB is that of adrenoceptor 
beta 1 (ADRB1), which was shown to be associated with BP response and long-term 
CV outcomes. ADRB1 genes encode the beta 1-adrenergic receptors (β1-ARs), 
which are the main myocardial targets for many BB medications and competitively 
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inhibit the agonist binding to β1-ARs and stop catecholamine-stimulated receptor 
signalling. They include two non-synonymous polymorphisms, arginine (Arg) 
389Gly and serine (Ser) 49Gly. 
There is some evidence suggested that the Ser49Gly polymorphism alone does not 
significantly influence BP response, although when considered in combination with 
the Arg389Gly polymorphism, it can be more informative than Arg389Gly alone 
(98;99). Therefore, the most commonly studied is the Arg389Gly polymorphism, 
on which the majority of studies show a significant association with BP-lowering 
response to BBs. Two independent studies have shown an association between 
treatment-related hypertensive outcomes (such as MI and stroke) and ADRB1 
polymorphisms (100;101).  
With regard to BB, Arg389Gly and Ser49Gly are important determinants of BP-
lowering response to metoprolol, as they can be used to predict the DBP response 
to Metoprolol in patients with HTN (98). Administration of BB-bisoprolol to healthy 
Arg 389-homozygous participants was associated with greater response in basal 
PRA, DBP and HR compared to homozygous Gly389 participants (102). On the other 
hand, Gly389 has been associated with decreased SBP and DBP in a large genetic 
study evaluating 30 regions that code for known BP-lowering agent targets (103).
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1.5 Aims and Objectives 
The previous chapter has outlined the pharmacological and pharmacogenetic 
approaches for HTN management and control, highlighting gaps in the current 
understanding of the effects of BP-lowering agents. These gaps raise a number of 
research questions to be answered through the specific aims of this thesis: 
 
To systematically review the main BP-lowering agents, including ACEIs, ARB, CCBs, 
DIs and BBs in RCTs. This review has main objective; to identify the drug specific 
effect of BP-lowering agents on BP responses. 
 
To identify SNPs associated with the BP-lowering responses of CCBs and BBs on 
NORDIL2000 subjects using GWAS.
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2 Materials and Methods  
2.1 Systematic review  
This section summarises the strategies applied in systematically reviewing the 
main BP-lowering agents in RCTs (eligibility and exclusion criteria, search methods 
for identification of studies, data collection, software and meta-analysis) to 
identify the drug-specific effect of BP-lowering agents on BP responses. 
The criteria for considering and excluding studies for this review have been 
determined according to the Population Intervention Comparison Outcome Study 
(PICOS) design framework (104), which grouped search terms into thematic groups 
in order to identify medical literature for systematic reviewing. The standard 
search strategy of the BP-lowering agents review, with supplementary terms, was 
used to identify the relevant works. 
2.1.1 Eligibility criteria  
2.1.1.1 Population  
The population was evaluated according to three criteria: [1] Definition of disease 
of interest: persistently high BP or HTN, (as defined earlier, Section 1.2.2). As 
well, according to NICE, ISH defined as baseline SBP of 140 mm Hg or higher and 
DBP of less than 90 mm Hg)(14). [2] Participant characteristics: men and women 
(non-pregnant women), aged 18 years and over, who had a baseline resting SBP of 
140 mm Hg or higher and/or DBP of at least 90 mm Hg, measured in a standard 
procedure for the duration of the study. Participants could be either previously 
treated with BP-lowering agents or untreated. [3] Healthcare setting3:  
participants with HTN, or who had (with HTN) any of following risk factors that 
require primary or secondary care setting. Primary care setting: smoking and 
obesity with body BMI of ≥ 30 kg/m2) (105). Secondary care setting: type 2 
diabetes mellitus (T2DM), mild to moderate chronic kidney diseases (CKD): 
glomerular filtration rate (GFR), 30-89 mL/min per 173m2 (106), or history of CHD, 
                                         
3
 Thresholds in health care setting were defined according NICE guidelines. 
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left ventricular hypertrophy (LVH) secondary to HTN, peripheral vascular diseases 
(PVD) or cerebrovascular events (CVE). 
2.1.1.2 Interventions and comparators  
Interventions and comparators were evaluated using three criteria: [1] 
Interventions: the BP-lowering agents ACEI, ARB, CCB, DI and BB were included in 
different doses and sub-classes as monotherapy or combination therapy in a 
stepped-care approach. [2] Comparators: a placebo or another BP-lowering agent 
(ACEI, ARB, CCB, DI or BB) was included in different doses and sub-classes as 
monotherapy or combination therapy in a stepped-care approach. In addition, 
drug doses should have been mentioned in both the intervention and the 
comparator treatment arms or, at least, in the intervention treatment arm. [3] 
Co-interventions: protocol for the continuation or discontinuation of background 
BP-lowering therapies before randomisation had to be the same in both arms. In 
addition, supplemental drugs from other classes were allowed as part of the 
stepped therapy. However, the addition of supplemental drugs after 
randomisation had to be pre-specified and follow the same protocol in both arms. 
2.1.1.3 Outcome measures  
Outcome measures were evaluated by five criteria: [1] Definition of outcome: 
clinic/office mean BP response, including delta, single or repeated BP measures. 
[2] Measurement protocol: mean BP response measured using a standard 
technique at least twice, with the patient resting for at least one minute. [3] 
Measurement duration: BP response measured for at least three months of active 
treatment, with all subsequent BP measurements recorded. [4] Primary outcomes: 
change from baseline of trough SBP and DBP for at least three months of active 
treatment was measured, if available at more than one time within the accepted 
window of three months or more. [5] Secondary outcomes: standard deviation (SD) 
of the change in BP compared with a placebo or other BP-lowering agents.  
2.1.1.4 Study design   
Study design was evaluated using three criteria: [1] Study design: single- or multi-
centre RCTs. [2] Study sample size: RCTs that randomised at least 100 
participants. However, in studies that were not limited to participants with HTN, 
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> 70% of participants should have had a resting SBP of at least 140 mm Hg or a DBP 
of at least 90 mm Hg or both, as defined above. [3] Study duration: RCTs that 
followed the participants for at least 12 months of active treatment. 
2.1.2 Exclusion criteria  
The population was excluded following the criteria mentioned earlier: [1] 
Participant characteristics: men and women (non-pregnant women) aged less than 
18 years. Participants with resistant HTN, (as defined earlier ‘Control and 
resistance, Section 1.2.3.3). Participants with HTN; however, baseline BP was 
not specified. [2] Healthcare setting: participants who had (with HTN) any of 
following risk factors that require tertiary care setting :kidney diseases including 
polycystic kidney disease (PCKD), glomerulonephritis, severe CKD: GFR, 15-29 
mL/min per 173m2 , renal failure (RF): GFR, < 15mL/min per 173m2 or on dialysis 
and kidney transplant (106). Heart diseases including cardiac arrhythmia, HF: 
preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF, < 40 %) 
and heart transplant (107). Hospitalised participants, due to high risk 
(accelerated/malignant) of HTN. 
Interventions and comparators were excluded following the criteria mentioned 
earlier: [1] Interventions: BP-lowering drugs other than ACEI, ARB, CCB, DI or BB. 
In addition, the same drug within the same class of BP-lowering was compared to 
itself, using a different drug combination or different doses. [2] Comparators: BP-
lowering agents were compared to non-pharmacological lifestyle changes or 
approaches, or compared according to different BP treatment goals. [3] Co-
interventions: non-pre-specified protocol for dis/or continuation of background 
BP-lowering drugs before randomisation, as well as non-pre-specified protocol for 
supplemental drugs after randomisation.  
Outcome measures were excluded following the criteria mentioned earlier: [1] 
Definition of outcome: Home or self-measurement mean BP response, as well as 
when clinic/office mean BP response was not specified. [2] Measurement protocol: 
mean BP response using non-auscultatory or oscillometric method, including pulse 
wave velocity (PWV) or ABPM, as well as when BP measurement protocol was not 
specified. [3] Measurement duration: mean BP response measured for less than 
three months of active treatment, as well as when duration of mean BP response 
  49 
 
was not specified. [4] Outcomes: change from baseline of trough SBP and DBP for 
less than three months of active treatment was measured. 
Study designs were excluded following the criteria mentioned earlier: [1] Study 
design: all studies where the unit of randomization is not at the individual level, 
including observational studies (case control, cross-sectional and cohort studies) 
and interventional studies (controlled clinical trials (CCTs)). Subgroup or ancillary 
studies. Crossover studies without a washout period. [2] Study sample size: RCTs 
that randomised less than 100 participants. Studies that included non 
hypertensives, either where there was < 70% hypertensives or the % of 
hypertensives was not specified. [3] Study duration: RCTs that followed 
participants for less than 12 months of active treatment. 
2.1.3 Search methods for 
identification of studies 
2.1.3.1 Electronic searches  
The search was applied to four databases, including the Medical Literature 
Analysis and Retrieval System Online (MEDLINE (OVID), 1995-2015), the Erpta 
Medica Database (EMBASE (OVID), 1995-2015), the Cochrane Central Register of 
Controlled Trials (CENTRAL, 1995-2015) and the Web of Science (1995-2015). The 
Cochrane Database of Systematic Reviews (CDSR) and the Database of Abstracts 
of Reviews of Effects (DARE) in the Cochrane Library were searched for previous 
reviews and meta-analyses until 15 October 2015. The last search was run on 26 
November 2015. No language restriction was used .The detailed search strategy 
for each of these databases is shown in appendix Table 6.1, Table 6.2, Table 6.3 
and Table 6.4 respectively. 
The literature search in the current review spanned the last 20 years as  
internationally recognised major medical journals, such as the Journal of the 
American Medical Association (AMA) (108) and the British Medical 
Journal (BMJ)(109), have been increasingly interested in publishing studies that 
report on the results of RCTs in parallel with the drug regulatory bodies like the 
Food and Drug Administration (FDA) (110) requiring RCT evidence for efficacy and 
safety before approval in the last two decades. 
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2.1.3.2 Searching other resources 
The reference lists of papers (both primary studies and reviews) were screened 
for any additional potentially eligible studies. 
Overall, 48 relevant reviews were screened (ordered by review ID): 
Abuissa 2005 (111) Doulton 2005 (112) Li 2014 (113) Tsuchiya 2015 (114) 
Andraws 2007 (115) Ghamami 2014 (116) Lindholm 2005 (117) Turnbull 2008 (118) 
Angeli 2004 (119) Gillespie 2005 (120) Ma 2010 (121) Van Vark 2012 (122) 
Baguet 2007 (123) Goeres 2014 (124) Mukete 2015 (125) Vejakama 2012 (126) 
Bakris 2014 (127) Grossman 2000 (128) Nakao 2012 (129) Wang 2006 (130) 
Bangalore 2011 (131) Heran 2010 (132) Neal 2000 (133) Wiysonge 2012 (134) 
Bell 2010 (135) Hsu 2001 (136) Pahor 2000 (137) Wright 2009 (138) 
Briasoulis 2014 (139) Kang 2004 (140) Pasty 2003 (141) Wu 2013 (142) 
Chen 2010 (143) Khan 2006 (144) Peters 2014 (145) Xu 2012 (146) 
Chen 2013 (147) Kronish 2011 (148) Sipahi 2012 (149) Zanchetti 2015 (150) 
de Leeuw 2002 (151) Kuyper 2014 (152) Staessen 2001 (153) Zhang 2014 (154) 
Diao 2012 (155) Li 2014 (156) Takagi 2014 (157) Zou 2011 (158) 
 
2.1.4 Data collection  
2.1.4.1 Selection of studies  
The author (Safaa Mohemmed Alsanosi) conducted the Initial screening           
(including titles and abstracts) of potentially eligible article. Two independent 
reviewers (Mohammed Abdulbasit Alsieni and Aishah Binti Che Roos) were given a 
random sample of 150 studies and asked to independently evaluate whether the 
studies would be included or excluded after they had been given the pre-specified 
PICOS framework. The reviewers disagreed on about five studies, which was due 
to the misunderstanding of certain criteria, on which they required further details. 
A meeting was arranged to clarify the problematic criteria and thoroughly explain 
each stage of the following process. As a result, reviewers agreed to exclude the 
five problematic studies.   
2.1.4.2 Assessment of risk of bias 
Mohammed and Aishah independently assessed the risk of bias for all included 
studies, using the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) framework (including methodology checklist and flow-diagram) 
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(41). Any disagreements were resolved by discussion (between Safaa, Mohammed 
and Aishah) or by involving a third reviewer (Sandosh Padmanabhan). 
The risk of bias was measured for each study through assessing seven specific 
domains: [1] Random sequence generation, [2] Allocation concealment, [3] 
Blinding of participants and personnel, [4] Blinding of outcome assessment, [5] 
Incomplete outcome data, [6] Selective outcome reporting and [7] Other issues.  
 To check for publication bias, a funnel plot was used to estimate the 
intervention effect from the included studies against some measure of each 
study’s size. Intervention (BP-lowering agents) was measured as mean 
differences. A funnel plot was used only when there were at least ten 
studies included in the meta-analysis; with fewer studies, the test’s power 
is low in distinguishing chance from real asymmetry.The effect estimates 
were plotted on the horizontal scale, and the measures of the study size 
were put on the vertical axis. The effect estimates from the small studies 
would scatter more widely at the bottom of the graph, with the spread 
narrowing among the larger studies. In the absence of bias, the plot should 
approximately resemble a symmetrical (inverted) funnel(159). 
 
Each potential source of bias was graded as high, low or unclear, and provide a 
quote from the study report together with a justification for our judgement in the 
‘Risk of bias’ tables (as mentioned below, Section 4.2.1). The ‘Risk of bias’ 
judgements were summarised across different studies for each of the domains 
listed. 
2.1.5 Data extraction  
The data collection form was designed after taking into consideration how much 
information should be collected. All data from each eligible study was entered 
independently by reviewers (Mohammed and Aishah) into a standardised 
spreadsheet (Microsoft Excel 2010) and collected according to the PICOS 
framework: [1] population, [2] intervention and comparators, [3] outcome 
measures and [4] study design. 
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The extracted data from each study was assigned according to PICOs, as intended 
for the population: [1] Overall number (N), [2] Baseline: mean SBP and mean DBP, 
[3] N of randomised patients in each treatment arm, [4] % of participants with 
HTN and [5] Type of participants with HTN: previously treated with BP-lowering 
agents or untreated.  
For the intervention and comparators: [1] Placebo run in period, [2] Washout 
period, [3] Class of BP-lowering agent, [4] Type of BP-lowering agent, [5] Doses of 
BP-lowering agent, [6] Duration of treatment and [7] Supplemental agents.  
For the outcome measures: [1] BP measurement protocol: position, machine and 
process, [2] Mean SBP response, [3] SD of mean SBP response, [4] Mean DBP 
response, [5] SD of mean DBP response, [6] Duration of mean BP response and [7] 
Type of outcomes analysis: intention-to-treat (ITT) or per-protocol (PP) analysis. 
ITT analysis included all patients as originally allocated after randomisation, 
including those who deviated from the protocol (due to noncompliance, 
withdrawal or anything that occurred after randomisation). PP analysis included 
only those patients who completed the treatment originally allocated, excluding 
patients who deviated from the protocol. 
For study types: [1] Study acronym, [2] Study full name, [3] Publication year, [4] 
Study overall duration, [5] Study design and [6] Primary and secondary outcome 
measures.  
BP-lowering RCTs have been defined as all those in which [1] Any BP–lowering 
agents were compared with the placebo or another BP–lowering agent with the 
intention of investigating the BP differences between studies, defined as 
intentional BP-lowering RCTs. To expand the body of evidence, [2] Non-intentional 
BP-lowering RCTs were also included: that is, those studies in which BP-lowering 
agents were compared with the placebo or other BP–lowering agents, although the 
studies were not designed to investigate the effects of BP differences. 
For studies with more than two intervention groups (multi-arm studies), only the 
directly relevant arms were included. When studies with various relevant arms 
were identified, the groups were combined into a single pairwise comparison and 
included the disaggregated data in the corresponding subgroup category. If the 
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study was comparing different BP-lowering agents and a number of them had many 
doses (e.g., the study had four treatment arms, nebivolol 5mg vs nebivolol 10 mg 
vs nebivolol 20mg vs amlodipine 10mg), the highest dose was considered (e.g., 
nebivolol 20mg vs amlodipine 10mg). 
If the study was comparing different BP-lowering agents and a number of them 
belong to the same class with different doses (e.g., the study had four treatment 
arms, losartan: 100 mg vs olmesartan: 40 mg vs valsartan 320 mg vs amlodipine 
10mg), the highest dose was considered (e.g., valsartan 320 mg vs amlodipine 
10mg). In addition, if the study was a crossover study, BP-lowering agents should 
be randomized to one of the four sequences: two active treatment periods, 
separated by placebo wash-out periods.  
2.1.5.1 Dealing with missing data  
The position of the patient during BP measurement may alter the BP-lowering 
effect. However, in order not to lose valuable data, if only one position was 
reported, data from that position was extracted. When BP measurement data was 
available for more than one position, data was imputed in accordance with the 
following order of preference: [1] sitting and [2] supine. 
SD of BP change at the end of the study was used if available. If this value was not 
reported at the end of the study: [1] SD of the change at other time points during 
treatment was imputed. [2] If SD of the change was not available at all, then the 
value imputed was SD of baseline SBP and DBP. [3] In cases where these values 
were also missing, SD of the change from other studies with the closest sample 
size was imputed. 
If data was presented numerically (in tables or text) and graphically (in figures), 
the numeric data was imputed because of possible measurement error when 
estimating from graphs. However, if the data was only presented graphically, 
measurements were imputed and calculated approximately from graphs. All 
numeric calculations and extractions from graphs or figures were confirmed by 
reviewers (Mohammed and Aishah) .If relevant data were missing; authors were 
contacted. Though, not all of them responded. 
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2.1.5.2 Measures of treatment effect  
BP response was documented in three ways, based on the type of data presented: 
[1] BP-delta, where the difference between mean BP readings was presented (such 
as -2.3 mmHg). [2] BP-single measure, where only one mean BP reading was 
presented (such as 120 mmHg). [3] BP-repeated measures, where a number of 
mean BP readings was presented (such as 120, 160 and 140 mmHg). 
2.1.6 Software  
2.1.6.1 Cochrane Review Manager 5.3 
Cochrane Review Manager 5.3 (RevMan) software (160) is an open-source software 
for formulating and maintaining Cochrane reviews, including protocols and full 
reviews. It can be installed on computers without the need for system 
administrator privileges. RevMan is most useful when the review question is 
already formulated, as it allows the researchers to prepare the text, form tables 
showing the characteristics of studies and the comparisons in the review and add 
study data. 
A number of features implemented by RevMan include standard statistical models 
(such as risk ratio, odds ratio (OR) and so on), meta-analysis (such as calculating 
weighted mean difference (WMD), testing for fixed (FE) and random (RE) effects 
model and so on), heterogeneity and sensitivity analysis. It can present the data 
entered graphically (such as in a forest plot, funnel plot and so on) and allows the 
visualisation of publication-quality plots. In addition, standard analytical 
software, such as IBM SPSS Statistics 19 and Microsoft EXCEL 2010, was used for 
data sorting, visualisation and basic statistical runs. 
2.1.7 Meta-analysis  
Data was processed in accordance with the Cochrane Handbook for Systematic 
Reviews of Interventions (159); data synthesis and analyses were performed using 
the RevMan software. 
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2.1.7.1 Data synthesis 
Study participants were analysed in the groups to which they were randomised, 
regardless of which or how much treatment they actually received. Data for BP 
reduction was combined using the WMD method, which measures the total 
difference between the mean values in two groups in a clinical study. It evaluates 
the amount by which the studied treatments change the outcome from the usual, 
compared with the control. A P-value of < 0.05 was considered statistically 
significant for all comparisons. 
 
For delta and single measure, BP response was calculated by subtracting the 
baseline value at randomisation from the value reported at the end of the trial or 
at the last time point during treatment. For repeated measures, the area under 
the curve (AUC) was used to plot BP readings against time after drug 
randomisation. The area was usefully determined by the trapezoidal rule, where 
the data points are connected by straight line segments, perpendiculars are drawn 
of each data point from the X axis and the sum of the areas of the triangles and 





1 − 0 
 Y0 = first BP reading  
 Y1 = second BP reading  
 X1 = time of first BP reading  
 X0 = time of second BP reading  
 
2.1.7.2 Assessment of heterogeneity 
Heterogeneity, which signifies variability among studies in a systematic review, 
was explored qualitatively (by comparing the characteristics of included studies) 
and quantitatively (using the chi-squared test of heterogeneity and inconsistency 
(I2) statistic) (162). This review considered P <0.05 from the Chi 2 test as 
statistically significant for heterogeneity.  
In the absence of significant statistically heterogeneity between studies (P > 0.05), 
meta-analysis was performed using an FE model, which offered a result that could 
be viewed as a typical intervention effect from the included studies in the 
analysis. An assumption was made that the true effect of intervention had the 
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same value in every study, in order to calculate a confidence interval for an FE 
meta-analysis. This assumption suggested that the observed differences between 
study results were due to chance and that there was no statistical heterogeneity. 
I2 describes the % of total variation across studies that is due to heterogeneity 
rather than chance .To quantify I2, 60% of the variability, which represented 
moderate heterogeneity, was considered in effect estimates. Thresholds for the 
interpretation of I2 were as follows: 
 0-40%: might not be important. 
 30-60%: represents moderate heterogeneity. 
 50-90%: represents substantial heterogeneity. 
 75-100%: considerable heterogeneity. 
 
However, when there was significant heterogeneity between study results, the RE 
model was used. This model offered an assumption that the estimated effects in 
the included studies were not equal, but did follow a certain distribution. The 
model showed the lack of knowledge of the reasons for different intervention 
effects, through considering the differences as if they were random. The types of 
heterogeneity were explored in stages: 
 
 Step 1: methodological heterogeneity (such as variability in study design 
and risk of bias considered).  
 Step 2: clinical heterogeneity (such as variability in the participants, 
interventions and outcomes studied).  
 Step 3: statistical heterogeneity (such as variability in the intervention 
effects being evaluated in the different studies; this is a consequence of 
clinical or methodological differences, or both, among the studies).  
 
When there was significant statistical heterogeneity between study results, 
sensitivity analysis was conducted through repeating the analysis, substituting 
alternate decisions if any were arbitrary or unclear, and the cause of 
heterogeneity was investigated with reference to the characteristics of the studies 
included in the meta-analysis.
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2.2 Genome-wide Study  
This section summarises the strategies applied to GWAS the NORDIL 2000 subjects 
(including, study population, genotyping, software, quality control, survival 
analysis, and standardised regression coefficient and replication studies) in order 
to identify SNPs associated with the BP-lowering responses of CCBs and BBs. 
2.2.1 Study population  
NORDIL2000 was a prospective, randomised, open blinded endpoint (PROBE), 
multicentre study (163;164). It was conducted in both Norway and Sweden to 
compare the effects of diltiazem, a non-dihydropyridine CCB, versus conventional 
BP-lowering agents, mainly DI and/or BB. If the BP goal was not achieved, other 
BP-lowering agents were added. Recruitment started in September 1992 in 1032 
health centres in Norway and Sweden. The primary endpoints considered were CV 
mortality, defined as MI, stroke, sudden death and other fatal CVDs, as well as CV 
morbidity, defined as MI and stroke. Secondary endpoints were total mortality and 
development or deterioration of CHD, congestive heart failure (CHF), atrial 
fibrillation (AF), transient ischemic attack (TIA), T2DM and RF. 
The participants were hypertensive patients aged between 50 and 69 years, with 
an untreated DBP of at least 100 mmHg during the one-week washout period 
without BP-lowering agents. Individuals were both previously treated and 
untreated. The researchers enrolled 10,881 patients who had DBP of 100 mmHg 
or higher. Participants were randomly allocated to receive diltiazem (N= 5,410), 
DI or BB, or both (N = 5,471). Between the two groups, just over 51% of individuals 
were female and the mean age was 60. At baseline, mean SBP was 173.4 mmHg 
and mean DBP was 105.7 mmHg. During the mean follow-up period of 53 months, 
this decreased to 154.9/88.6 mmHg in the diltiazem group and 151.7/88.7 mmHg 
in the DI/BB group. The study showed that diltiazem was as effective as treatment 
based on BB-DI in preventing the combined primary endpoint of all stroke, MI, and 
other CV death. For the current study, Padmanabhan, S., and Dominiczak, A., 
have a collaboration to analyse NORDIL2000 pateints and data was available for 
5,280 Swedish patients. 
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2.2.2 Ethical considerations 
All studies were approved by institutional ethics review committees at the 
relevant organizations. All participants provided informed written consent. 
2.2.3 Genotyping  
The NORDIL2000-GWAS samples were genotyped using Illumina 550K Single and 
Illumina 610 Quad V1 BeadChip (165). DNA samples were available for 4,039 
Swedish NORDIL2000 patients and successfully genotyped. In total, 500,915 SNPs 
common to both the Single and Quad chips, were included in the analysis. 
Genotyping was performed by Lee, W.K., Di Blasio, A.M., Laing, S., and Gentilini, 
D., as described in Padmanabhan et al. paper (166). Independent SNPs from 
replication cohorts; ASCOT-BPLA 2005, GenHat2002, GENRES 2007, INVEST 2003 and 
PEAR 2009 were genotyped using Illumina Golden Gate Genotyping Assay and 
undertaken by investigators from each cohort (165).  
2.2.4 Software  
For computational efficiency, GWAS analyses were performed on a remote server 
via the open-source Telnet/SSH client PuTTY (http://www.chiark. 
greenend.org.uk/~sgtatham/putty/) and files were managed remotely using 
WinSCP (http://winscp.net/eng/index.php), an open-source SFTP, FTP and SCP 
client for Windows. Standard analytical software, such as IBM SPSS Statistics 19 
and Microsoft EXCEL 2010, was used for data sorting, visualisation and basic 
statistical runs. 
2.2.4.1 Quanto 
Quanto (167) is a program computes sample sizes or powers for association studies 
of genes, gene-environment interactions and gene-gene interactions. To calculate 
sample size, alpha value (level of significance) needs to be determined. Alpha is 
incorrectly rejecting the null hypothesis (H0) (false positive). The graphical user 
interface makes it possible for users to simply change the model and inspect the 
results without having to change input files and rerun the program for every 
model. The results of each session are stored to a log file, which can be printed 
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or saved to a file for review at a later date. In addition, users can create a text 
file of the log that can be imported into other documents. 
2.2.4.2 PLINK  
PLINK (168;169) is an open-source and command-line-based tool set for whole 
genome association analysis. It can manage large genome-wide datasets in a 
computationally effective manner and run several analyses on parallel processors 
to reduce computational time. Among its features are basic data management 
(including data reading, merging, extracting and so on), standard summary 
statistics (such as rate of missingness, MAF, Hardy-Weinberg Equilibrium (HWE) 
and so on) and meta-analysis. 
PLINK output results are stored as plain text files, of which there are several 
options for extensions, depending on the content of the results. Results files are 
often large; the genome-wide outputs may be uploaded to other applications (such 
as R) as a consequence. 
2.2.4.3 R 
R (170;171) is a well-developed, simple and effective programming language that 
includes user-defined functions and input-output facilities. It is an open-source 
software for flexible statistical analysis toolkits, such as data manipulation 
(transforming, merging and so on), standard statistical models (regression, 
analysis of variance (ANOVA) and so on), time-series analysis and clustering. 
Graphics/data visualisation and publication-quality plots can be formed through R 
(including mathematical codes and formulae).  
Data analysis is performed by writing functions and scripts, rather than by pointing 
and clicking. Writing scripts makes it easy to programme a sequence of tasks that 
can be integrated into other processes. R has open interfaces that integrate easily 
with other applications and systems, and more than 2000 add-on ‘packages’ 
extending the R language in several domains are available for free download.  
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2.2.4.4 NORDIL Navigator 
NORDIL Navigator is a closed-source software for genome association analysis. It 
is used to identify BP response associations between SNPs/genes and three BP-
lowering agents: CCB, DI and BB, through implying SNP ID and selecting plot type 
(such as regional and chromosomal). 
The Navigator provides, for each implication of SNP, an output results table 
including: [1] BP phenotype (such as SBP or DBP). [2] CHR number. [3] SNP 
chromosomal position (POS). [4] Major allele (A1) such as A, T, C or G. [5] Effect 
allele frequency, which represents the fraction of all CHRs in the GWAS population 
that carries that allele (0.1 to 0.99). [6] Standardised regression coefficient or 
beta, (see ‘Association analysis of BP response using linear regression’, Section 
3.2.5.1). [7] Standard error (SE), which provides an estimate of the precision of 
a parameter (such as a mean, proportion and OR) to make inferences about data 
from a sample to some relevant population. [8] Statistical level of significance P-
value, which measures probability of rejecting H0 when it is true; that is, no 
difference exists between BP-lowering agents .The GWAS Navigator allows plotting 
data (such as in a scattered plot) and visualise and download graphs. Output 
results are stored as EXCEL files and subsequently uploaded to other applications 
(such as SPSS). 
2.2.5 Quality control 
The NORDIL2000-GWAS dataset that are analysed had already been subject to 
quality control. Nevertheless the following basic quality control steps were 
applied: checking for excessive missingness in both subjects and SNPs, exclusion 
of SNPs with excessively low MAF, exclusion of SNPs very deviated from HWE and 
cryptic relatedness. The quality control was performed using PLINK. The 
thresholds used for these quality control steps were as reported in Wellcome Trust 
Case Control Consortium (63;172): 
 Rate of missingness, representing the number of called genotypes divided 
by the total number of genotypes scanned, was examined. PLINK reports 
missingness rate per individual and per marker in two output files; IMISS 
and LMISS respectively. Samples and SNPs with missingness rate of (>0.05) 
were removed.  
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 SNPs with MAF (<0.01) were removed.  
 
 Each SNP was tested to see whether its genotypes were in HWE. Those with 
a P-value <5×1-6 were removed. 
The subsequent quality control works best under an assumption of no LD among 
SNPs. So SNPs were pruned according to LD to produce dataset for a pruned SNP 
.Cryptic relatedness between individuals was estimated from GWAS data. Pairwise 
Identity by State (IBS) was calculated, from this identity by descent (IBD). Pairs of 
individuals whose estimated IBD indicated they were 3nd degree relatives or closer 
(plink output file PI_HAT>0.125) were identified.  
2.2.5.1 Analysis to detect population outliers  
Population structure was investigated using the NORDIL2000data merged with a 
HapMap dataset (release 23, 270 individuals, 3.96 million SNPs) consisting of  Utah 
residents with Northern and Western European ancestry (CEU), Chinese in Beijing 
(CHB) and Japanese in Tokyo (JPT) and Yoruba in Nigeria (YOR) samples. The SNP 
set for the merged dataset were restricted to the Nordil2000 LD pruned SNP set. 
Subsequently, multidimensional scaling (MDS) was plotted to provide a visual 
representation of any substructure, rather than clustering participants into 
groups. The first two components were plotted against each other to check 
similarities and differences between samples. 
2.2.6 Statistical analysis 
2.2.6.1 Association analysis of BP response using linear regression 
Using PLINK software, standardised regression coefficient or beta, is the estimate 
resulting from a regression analysis that have been standardized (the variances of 
dependent and independent variables are the same). It was used in order to signify 
how the BP reacted to changes from BP-lowering agents (CCBs or BBs) for each 
copy of the effect allele, after adjusting for all other covariates.  
Using Beta, SNPs were divided into the concordant and discordant and compared 
to their BP response/change under CCBs or BBs.The reason for studying 
discordance in the directionality of effect to CCB and BB is because this would 
prioritise a discordant SNP to be more specific for either BB or CCB. 
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For each copy of the effect allele (as mentioned above, Figure 1.1), SNPs that 
showed a positive BP change indicated that BP lowering agents and BP response 
were directly related (that is, as the value of one variable went up, the value of 
the other also tended to do so) and were considered to be concordant SNPs, 
labelled as 0. Conversely, SNPs that showed a negative BP change indicated that 
BP-lowering agents and BP response were inversely related (that is, as the value 
of one variable went up, the value of the other tended to go down) and were 
considered to be discordant SNPs, labelled as 1. 
2.2.6.2 Survival analysis 
Using R software, survival analysis refers to analysing the time to occurrence of 
death. In the context of this thesis survival analysis was used to model time-to-
event data through assessing the effects of BP-lowering agents (CCBs or BBs) by 
measuring the number of NORDIL2000 subjects who survived or were saved after 
that treatment, over a period of time.  
This implicited techniques that were required to compare the risks for death or 
an event associated with different therapy groups. Survival analysis included a 
sequence of statistical analytical methods that represented the time spent 
between a given exposure and the outcome of a certain event. Kaplan–Meier (KM), 
log-rank and cox-proportional hazards model were used to carry out the survival 
analysis.  
2.2.6.3 KM survival analysis 
KM test involves computing of probabilities of occurrence of event at a certain 
point of time and multiplying these successive probabilities by any earlier 
computed probabilities to get the final estimate. It measures the fraction of 
NORDIL2000 subjects living for a particular amount of time after receiving BP-
lowering agents (CCBs or BBs).  
KM survival curves measure the probability of surviving in a given length of time 
while considering time in many small intervals.They were used to estimate the 
curve from the observed survival times without assuming an underlying probability 
distribution and to determine whether the different categories of baseline 
predictor variable are statistically equivalent.  
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The log-rank test is a large- sample chi-square test where the test statistic 
provides an overall comparison of the KM survival curves being compared. It takes 
the whole follow-up period into account in the analysis and test the hypothesis 
that there is no difference between populations being studied in the survival 
probability at any given time point in follow up. It is recommended to present the 
survival plots as cumulative incidence (CV mortality) data displaying the 
proportion of patients with events increasing over time (173). This approach was 
followed for presentation of KM survival curves: 
 Cumulative incidence, which measures the disease frequency or rate during 
a period of time, was used as the vertical axis. It measures the probability 
that a certain event (such as CV mortality) has happened before a given 
time. 
 Survival time, which measures the follow-up time from a defined starting 
point to the occurrence of a given event, was on the horizontal axis. Start 
and endpoints had to be clearly defined, along with censored observations 
to measure survival time.  
2.2.6.4 Cox-proportional hazards model 
Since the KM method and the log-rank test can only study the effect of one factor 
at a time , Cox-proportional hazards model was set to predict the probability that 
CV mortality occurred at a given time for given values of the predictor variables 
(covariates) (174). The hazard was the probability of experiencing CV mortality, 
assuming that patients had survived up to a given point in time, or the risk of 
death at that moment. Cox model does not assume knowledge of absolute risk and 
only estimates relative risk. An additional advantage of Cox model over the KM-
method is that it can accommodate both discrete and continuous measures of 
event times. 
The Cox’s method is a ‘semi-parametric’ approach and no specific type of 
distribution is assumed for survival. Although, there are some strong basic 
assumptions made on the effect of exposure variable on survival. The main 
assumptions are (174;175): [1] The hazard rate of an individual at time is 
proportional to the hazard rate at any other given time point in the follow-up 
period and [2] The exposure variable of interests and other covariates contribute 
linearly to the natural log of the hazard ratio . 
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 A number of parameters were used: [1] The drug interventions, including 
BP-lowering agents (CCBs or BBs). [2] The phenotype was delta BP changes 
after drug randomisation. [3] Covariates, other than the main exposure of 
interest (CV mortality), which were possibly predictive of the outcome 
under study, were adjusted. Adjusted covariates were age, sex, BMI, 
smoking, cholesterol, fasting glucose, T2DM, DBP at randomisation (DBP-1) 
and SNP. 
2.2.6.5 Power calculations 
In the NORDIL2000 cohort, the SD of BP response was 16 and 18 mmHg for SBP and 
DBP, respectively. At alpha of 0.001, we would have >80% power to detect effect 
sizes of delta (∆) 2% change in SBP (~3mmHg) and ∆1%  change in DBP (~1.8mmHg) 
with 6000 subjects for different MAFs, as shown in Figure 2.1. For the long-term 
adverse outcome phenotype with 5,000 samples (assuming 300 incident adverse 
events), at alpha of 0.05, we will have > 80% power to detect interaction ORs of 
2.3, 1.9, 1.8 or 1.7 or greater for SNPs with MAF of 5%, 10%, 15% or 25%, 
respectively.  
 
Figure 2.1 Sample size calculation for different MAFs. 
 
2.2.7 Replication studies  
To provide convincing statistical evidence for association, increase effect 
estimation and rule out associations due to biases, 286 independent SNPs from the 
NORDIL 2000 study were replicated, based on the interests of five collaborative 
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RCTs; ASCOT-BPLA 2005, GenHat2002, GENRES 2007, INVEST 2003 and PEAR 
2009,(characteristics of excluded studies are described in Section 3.2.6.1). 
 
Subsequently, all replicated SNPs were checked through NORDIL Navigator in order 
to carry out a GWAS review for interesting signals of any significant associations 
with CCB and BB agents in relation to SBP or DBP changes. To determine the 
significant associations, the level of statistical significance (P<1x10-5)4 was used 


























                                         
4
 Level of statistical significance of (P<1x10-5) was considered after discussion with supervisor.  







2.2.7.1 Characteristics of replication studies (ordered by study ID) 
ASCOT-BPLA 2005 (51) 
Study design :multicentre, randomised controlled, double-blind study  
Study duration : 72 months 
Participants N: 19,257 
Participants type : hypertensives ( baseline BP: 164/95 mmHg) 
BP –lowering agents : CCB - amlodipine: 5 to 10 mg OD or BB - atenolol: 50 to 100 mg OD 
SNP replicated :253 SNPs 
 
GenHat2002(176)  
Study design : ancillary to ALLHAT 
Study duration : 57 months 
Participants N: 33,357 
Participants type : hypertensives ( baseline BP: 146/84 mmHg) 
BP –lowering agents : ACEI - lisinopril: 10 to 40 mg OD, CCB - amlodipine: 2.5 to 10 mg OD, or DI 
- chlorthalidone: 12.5 to 25 mg OD 
SNP replicated : only 38 SNPs , for monotherapy (CCB amlodipine) 
 
GENRES 2007 (78) 
Study design : single-centre, randomised controlled, crossover, double-blind trial 
Study duration : 8 months  
Participants N: 208 
Participants type : hypertensives ( baseline BP: 153/100 mmHg) 
BP –lowering agents : ARB – losartan: 50 mg OD, CCB - amlodipine: 5  mg OD, DI - 
hydrochlorothiazide: 25 mg OD or BB - bisoprolol: 50 mg OD 
SNP replicated :248 SNPS 
 
INVEST 2003 (177) 
Study design : multicentre, randomised controlled, open blinded endpoint study  
Study duration :31 months 
Participants N: 22,576 
Participants type : hypertensives ( baseline BP: 149.5/86.3 mmHg) 
BP –lowering agents :CCB - verapamil: 240 mg OD or BB - atenolol: 50 mg OD 
SNP replicated :245 SNPs 
 
PEAR 2009 (79) 
Study design : multicentre, randomised controlled, double-blind study  
Study duration : 9 weeks  
Participants N: 800 
Participants type : hypertensives ( baseline BP: 138.5/87mmHg) 
BP –lowering agents : DI - hydrochlorothiazide: 12.5 mg OD , BB - atenolol: 50 mg OD or their 
combination 




3  Systematic review  
This chapter summarises the results of systematically reviewing the main BP-
lowering agents in RCTs (literature searching, risk of bias in included studies and 
studies and effect of intervention) to identify the drug-specific effect of BP-
lowering agents on BP responses. 
3.1 Results of the search  
Literature searching resulted in identification of 10,577 publications through 
multiple sources. After excluding duplicates, there were 5,568 records identified. 
The results of the search strategy and the review of the publications is summarised 
in the PRISMA flow diagram (Figure 3.1). 
As shown in Figure 3.1, 184 were identified as potentially eligible studies, from 
which 102 RCTs were excluded after screening the full texts, (see ‘Description of 
excluded studies’, Section 3.1.1). 


















3.1.1 Description of excluded 
studies 
Overall, 102 RCTs were excluded after screening the full texts, (see 
‘Characteristics of excluded studies’, Section 4.1.1.1). In nine studies (Bagatin 
1998; Chan 1995; Elliott 2001; Giordano 1996; Kumar 2014; Ostergren 1996; STUMPE 1998; 
Thulin 1999; Townsend 1995) participants had HTN; however, baseline BP was not 
specified.  
 
Protocol for dis/or continuation of background BP-lowering drugs before 
randomisation was not pre-specified in ten studies (Cushman 2002; Koylan 2005; 
KHS2009; Lee 2008; Leonetti 2005; NOAAH 2014; Ohma 2000; ORIENT 2011; RENAAL 2001; 
SAKURA 2013), whereas protocol for supplemental drugs after randomisation was 
not pre-specified in 14 studies (ANBP 2003; CAPPP 1999; COLM 2009; Conlin 1998; DIME 
2014; E-COST 2005; Gerritsen 1998; GLANT 1995; Khan 2013; NEBIS 2003; Ono 2008; Ren 2006; 
SCOPE 2003; Syst-China 1998). 
 
Mean BP response was not specified in only TRANSCEND 2008, whereas measurement 
protocol was not specified in 26 studies (AAA 2009; Agabiti Rosei 2005; Barnett 2004; 
Bittar 1997; Bulpitt 1999; Chung 2009; Crepaldi 1995; CVIP 2004; Flack 2001; Fodor 1997; 
Fonarow 2009; Franke 1997; Gavras 1999; Grimm 2002; Hansson 1996; Himmelmann1996; 
Hu1999; Karch 1997; Marazzi 1996; Metelitsa 1996; Neldam 2001; PICXEL 2005; Poisson 1996; 
Schoenberger 1995; Testa 1998; Weiss 2005). Both mean and duration of BP response 
were not specified in three studies (Dahlöf 2005; HANE 1997; TEST 1995), while 
duration of mean BP response was not specified in four studies (Alici 2009; Aurell 
1997; Elliott 1999; Pessina 2001). 
 
In four crossover studies (Cifková 2000; De Rosa 2000; Konoshita 2010; Puig 2007) there 
was no washout period. In total, 31 studies included non hypertensives; 16 studies 
(ACTION 2005; ADVANCE 2007; APSIS 2006; BENDECT 2004; CAMELOT 2004; DEMAND 2011; 
DIABHYCAR 2004; DIRECT-2 2008  ;DREAM 2008; HOPE 2000; MARVAL 2002; NICOLE 2003; 
ONTARGET 2008; PEACE 2004; PROGRESS2001; REIN-2 2005 ) had < 70% hypertensives, 
and 15 studies (Bouhanick1996 ; Cağlar 2011; CARTER 2007; Derosa 2011; Fogari 2012 ;  
Fogari 2008; GEMINI 2004; Hayoz 2012; Kim 2014; Lin 2005; Liu 2005; LIVE 2000; Millar-Craig 
2003; Toto 2008; Wald 2008) not specified the % of hypertensives . 
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3.1.1.1 Characteristics of excluded studies (ordered by study ID) 
Study 5 Reason for exclusion 
AAA 2009 (178) Measurement protocol of BP response not specified 
ACTION 2005  (179) Study included < 70% hypertensives (52%)  
ADVANCE 2007 (180) Study included < 70% hypertensives (59%)  
Agabiti Rosei 2005 (181) Measurement protocol of BP response not specified 
Alici 2009 (182) Duration of BP response not specified 
ANBP 2003 (183) No pre-specified protocol for interventional or supplemental drugs after 
randomisation. Patients randomly assigned to Enalapril or 
Hydrochlorothiazide as initial therapy (agent and dose); choice was made 
by the family physician. 
APSIS 2006 (184) Study included < 70% hypertensives (27%)  
Aurell 1997 (185) Duration of BP response not specified 
Bagatin 1998 (186) Participants with HTN; however, baseline BP not specified 
Barnett 2004 (49) Measurement protocol of BP response not specified 
BENDECT 2004  (187) Study included < 70% hypertensives (57%)  
Bittar 1997 (188) Measurement protocol of BP response not specified 
Bouhanick1996(189) Study included hypertensives; however, % of hypertensives not specified 
Bulpitt 1999 (190) Measurement protocol of BP response not specified 
Cağlar 2011  (191) Study included hypertensives; however, % of hypertensives not specified 
CAMELOT 2004  (192) Study included < 70% hypertensives (60%)  
CAPPP 1999 (193) No pre-specified protocol for interventional or supplemental drugs after 
randomisation. Patients randomly assigned to Captopril or conventional 
BP-lowering agents BB and DI. 
CARTER 2007  (194) Study included hypertensives; however, % of hypertensives not specified 
Chan 1995  (195) Participants with HTN; however, baseline BP not specified 
Chung 2009 (196) Measurement protocol of BP response not specified 
Cifková 2000 (197) Crossover studies without a wash-out period 
COLM 2009 (198) No pre-specified protocol for interventional or supplemental drugs after 
randomisation. Patients randomly assigned to CCB (Azelnidipine and 
Amlodipine) and thiazides. 
Conlin 1998 (199) No pre-specified protocol for interventional or supplemental drugs after 
randomisation. Patients randomly assigned to Losartan +/- HCTZ or 
Nifedipine. 
Crepaldi 1995 (200) Measurement protocol of BP response not specified 
Cushman 2002 (201) No pre-specified protocol for dis/or continuation of background BP-
lowering drugs before randomisation. Patients previously treated with 
BP-lowering agents (discontinued if necessary). 
CVIP 2004 (202) Measurement protocol of BP response not specified 
Dahlöf 2005 (203) Mean and duration of BP response not specified 
De Rosa 2000 (204) Crossover studies without a wash-out period 
DEMAND 2011  (205) Study included < 70% hypertensives (44.2%)  
Derosa 2011  (206) Study included hypertensives; however, % of hypertensives not specified 
DIABHYCAR 2004 (207)  Study included < 70% hypertensives (56%)  
DIME 2014 (208) No pre-specified protocol for interventional or supplemental drugs after 
randomisation. Patients randomly assigned to receive DI or any other BP-
lowering agents. 
DIRECT-2 2008 (209) Study included < 70% hypertensives (62%)  
DREAM 2008  (210) Study included < 70% hypertensives (43.5%)  
E-COST 2005 (211) No pre-specified protocol for interventional or supplemental drugs after 
randomisation. Patients randomly assigned to ARB candesartan or 
conventional BP-lowering agents other than ACEI or ARBs. 
Elliott 1999 (212) Duration of BP response not specified 
Elliott 2001 (213) Participants with HTN; however, baseline BP not specified 
Flack 2001 (214) Measurement protocol of BP response not specified 
Fodor 1997 (215) Measurement protocol of BP response not specified 
                                         
5
 For studies acronyms (see ‘list of abbreviations’, Acronyms and symbols) 
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Fogari 2012  (216) Study included hypertensives; however, % of hypertensives not specified 
Fogari 2008  (217) Study included hypertensives; however, % of hypertensives not specified 
Fonarow 2009 (218) Measurement protocol of BP response not specified 
Franke 1997 (219) Measurement protocol of BP response not specified 
Gavras 1999 (220) Measurement protocol of BP response not specified 
GEMINI 2004  (221) Study included hypertensives; however, % of hypertensives not specified 
Gerritsen 1998 (222) No pre-specified protocol for interventional or supplemental drugs after 
randomisation. Patient received active drugs as ‘escape medication’ in 
addition to the study medication if necessary. 
Giordano 1996 (223) Participants with HTN; however, baseline BP not specified 
GLANT 1995 (224) No pre-specified protocol for interventional or supplemental drugs after 
randomisation. Patients randomly assigned to an ACEI or any kind of 
commercially available CCB could be used in this study. 
Grimm 2002 (225) Measurement protocol of BP response not specified 
HANE 1997 (226) Mean and duration of BP response not specified 
Hansson 1996 (227) Measurement protocol of BP response not specified 
Hayoz 2012 (228) Study included hypertensives; however, % of hypertensives not specified 
Himmelmann1996 (229) Measurement protocol of BP response not specified 
HOPE 2000 (230) Study included < 70% hypertensives (46.9%)  
Hu1999 (231) Measurement protocol of BP response not specified 
Karch 1997 (232) Measurement protocol of BP response not specified 
Khan 2013 (233) No pre-specified protocol for interventional or supplemental drugs after 
randomisation. Patients randomly assigned to CCB and non-selective BB. 
Kim 2014 (234) Study included hypertensives; however, % of hypertensives not specified 
Konoshita 2010 (235) Crossover studies without a wash-out period 
Koylan 2005 (236) No pre-specified protocol for dis/or continuation of background BP-
lowering drugs before randomisation. Patients previously treated with 
BP-lowering agents. 
Kumar 2014  (237) Participants with HTN; however, baseline BP not specified 
KHS2009 (238)  No pre-specified protocol for dis/or continuation of background BP-
lowering drugs before randomisation. Patients previously treated with 
BP-lowering agents other than ARB. 
Lee 2008 (239) No pre-specified protocol for dis/or continuation of background BP-
lowering drugs before randomisation. Patients previously treated with 
ARB (Valsartan). 
Leonetti 2005 (240) No pre-specified protocol for dis/or continuation of background BP-
lowering drugs before randomisation. Patients previously treated with 
BP-lowering agents (down titrated when applicable). 
Lin 2005 (241) Study included hypertensives; however, % of hypertensives not specified 
Liu 2005  (242) Study included hypertensives; however, % of hypertensives not specified 
LIVE 2000 (243) Study included hypertensives; however, % of hypertensives not specified 
Marazzi 1996 (244) Measurement protocol of BP response not specified 
MARVAL 2002 (245) Study included < 70% hypertensives (65%)  
Metelitsa 1996 (246) Measurement protocol of BP response not specified 
Millar-Craig 2003 (247)  Study included hypertensives; however, % of hypertensives not specified 
NEBIS 2003 (248) No pre-specified protocol for interventional or supplemental drugs after 
randomisation. Concomitant therapy was permitted at any time, apart 
from DI, ACEI, and CCB. 
Neldam 2001 (249) Measurement protocol of BP response not specified 
NICOLE 2003  (250) Study included < 70% hypertensives (40%)  
NOAAH 2014 (251) No pre-specified protocol for dis/or continuation of background BP-
lowering drugs before randomisation. Patients previously treated with 
BP-lowering agents. 
Ohma 2000 (252) No pre-specified protocol for dis/or continuation of background BP-
lowering drugs before randomisation. Patients previously treated with 
BP-lowering agents. 
Ono 2008 (253) No pre-specified protocol for interventional or supplemental drugs after 
randomisation. Patients randomly assigned to ARB (Candesartan) group 
or a non-ARB group. 
ONTARGET 2008  (254) Study included < 70% hypertensives (68.7%)  
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ORIENT 2011 (255) No pre-specified protocol for dis/or continuation of background BP-
lowering drugs before randomisation. Patients previously treated with 
ACEI. 
Ostergren 1996 (256) Participants with HTN; however, baseline BP not specified 
PEACE 2004 (257) Study included < 70% hypertensives (45.5%)  
Pessina 2001 (258) Duration of BP response not specified 
PICXEL 2005 (259) Measurement protocol of BP response not specified 
Poisson 1996 (260) Measurement protocol of BP response not specified 
PROGRESS 2001  (261) Study included < 70% hypertensives (48%)  
Puig 2007 (262) Crossover studies without a wash-out period 
REIN-2 2005  (263) Study included < 70% hypertensives (60%)  
Ren 2006 (264) No pre-specified protocol for interventional or supplemental drugs after 
randomisation. Patients randomly assigned to (Enalapril +/- Spirolactone) 
and BP-lowering agents not affecting RAAS (CCB and BB). 
RENAAL 2001 (265) No pre-specified protocol for dis/or continuation of background BP-
lowering drugs before randomisation. Patients previously treated with 
BP-lowering agents (continued to receive). 
SAKURA 2013 (266) No pre-specified protocol for dis/or continuation of background BP-
lowering drugs before randomisation. Patients previously treated with 
ACEI and ARB. 
Schoenberger 1995 
(267) 
Measurement protocol of BP response not specified 
SCOPE 2003 (268) No pre-specified protocol for interventional or supplemental drugs after 
randomisation. Concomitant therapy was permitted, apart from (ACEI 
and ARB); however, concomitant therapy was extensively used in the 
Placebo group. 
STUMPE 1998 (269) Participants with HTN; however, baseline BP not specified 
Syst-China 1998 (270) No pre-specified protocol for interventional or supplemental drugs after 
randomisation. Patients randomly assigned to Nitrendipine, with the 
addition of Captopril or Hydrochlorothiazide, or both. 
TEST 1995 (271) Mean and duration of BP response not specified 
Testa 1998 (272) Measurement protocol of BP response not specified 
Thulin 1999  (273) Participants with HTN; however, baseline BP not specified 
Toto 2008  (274) Study included hypertensives; however, % of hypertensives not specified 
Townsend 1995 (275) Participants with HTN; however, baseline BP not specified 
TRANSCEND 2008 (276) Mean BP response not specified 
Wald 2008 (277) Study included hypertensives; however, % of hypertensives not specified 
Weiss 2005 (278) Measurement protocol of BP response not specified 
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3.1.2 Description of included 
studies 
The literature search, which followed PRISMA statement recommendations, led to 
the identification of 82 studies (see ‘Characteristics of included studies, Section 
4.1.2.1) with a total of 197,684 participants, who were followed up for a median 
of 6 months.  
 
BP-lowering strategies: 13 studies (ALPINE 2003; Bremner 1997; CROSS 2003; FACET 
1998; Farsang 2007; Holsgreve 2003; HYVET 2008; INVEST 2003; Narkiewicz 2007; PATS 1995; 
SYST-EUR 1997; UKPDS 1998; VHAS 1998) with 41,886 participants were on intentional 
BP-lowering, while the remaining 69 (155,798 participants) studies were classified 
as non-intentional BP-lowering studies. 
 
Study design related characteristics: participants in the majority of studies had a 
placebo run-in period of at least one week before receiving BP-lowering agents. 
Additionally, in 19 studies (BLACK 2001; Cushman 1998; ELLE 2003; ELVERA 2004; FACET 
1998; Fogari 2008; Grassi 2003; Hoegholm 1995; HYVET–P 2003; IDNT 2001; LAARS 2002; 
LOTHAR 2006; Mallion 2007; Mounier-Vehier 1998; NICS-EH 1999; NORDIL 2000; RACE 1995; 
SHELL 2003; Wu 2004), participants had a washout period of at least one week before 
being administered the agents. In contrast, in 16 studies, participants did not have 
any placebo run-in or washout period (AASK 2002; ACCOMPLISH 2008; ALLHAT 2002; 
CASE-J 2008; CONVINCE 2003; Derosa 2014; DETAIL 2004; Freytag 2001; INVEST 2003; JMIC-
B 2004; McInnes 2000; Narkiewicz 2007; Nilsson 2007; UKPDS 1998; VALUE 2004; Yang 2015).   
Definition of HTN: Patients in 66 studies had a baseline resting BP of 140/90 mm 
Hg or higher. However, 16 studies (ACCOMPLISH 2008; ALLHAT 2002; Benetos 2000; 
BLACK 2001; CONVINCE 2003; DETAIL 2004; IDNT 2001; INVEST 2003; JMIC-B 2004; MAISH 
2007; Mallion 2007; Ruilope 2001; SHELL 2003; SYST-EUR 1997; VALUE 2004; Volpe 2003) 
included patients with ISH. In addition, while almost all studies were conducted 
entirely on hypertensives, only five included more than 70% hypertensives 
(CONVINCE 2003 (80%); DETAIL 2004 (81%); IDNT 2001 (76%); NICS-EH 1999 (> 70 %); PATS 
1995 (84%)).  
  
BP measurement: all studies followed well-defined protocols and standardised 
techniques of BP measurement for the duration of the study (at least twice, with 
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the patient resting for at least one minute). A number of studies mentioned the 
guidelines that were followed to measure BP: American Society of Hypertension 
(ASH) (Alcocer 1995; Freytag 2001), American Heart Association (AHA) 
(Papademetriou 1997; Volpe 2003), British Hypertension Society (BHS) (Holsgreve 2003; 
SYST-EUR 1997), JNC (ALLHAT 2002; BLACK 2001; INVEST 2003), Japanese Society of 
Hypertension (JSH) (CASE-J 2008) and WHO (Black 1997; Bremner 1997; Hegner 1997; 
Radauceanu 2004). 
In 75 studies BP was measured in a sitting position; seven teams measured it in a 
supine position (Alcocer 1995; Benetos 2000; Chanudet 2008; Freytag 2001; James 2002; 
Mallion 2000; NORDIL 2000), and in one study (JMIC-B 2004) both sitting and supine BP 
measurements were taken.  
Presence of co-morbidity: 56 included studies enrolled hypertensive patients 
without other comorbid conditions. However, in 26 studies participants had at 
least one comorbidity (AASK 2002; ACCOMPLISH 2008; ALLHAT 2002; ASCOT-BPLA 2005; 
CASE-J 2008; CONVINCE 2003; CROSS 2003; DETAIL 2004; ELSA 2002; FACET 1998; 
Holsgreve2003; IDNT 2001; INSIGHT 2000; INVEST 2003; JMIC-B 2004; LAARS 2002; LIFE 2002; 
Luque 2005; Mancia 2000; MIDAS 1996; Papademetriou 1997; PATS 1995; RACE 1995; REGAAL 
2002; UKPDS 1998; VALUE 2004). 
T2DM was the most common comorbidity in 12 studies (ACCOMPLISH 2008; ASCOT-
BPLA 2005; CASE-J 2008; CONVINCE 2003; DETAIL 2004; ELSA 2002; FACET 1998; 
Holsgreve2003; IDNT 2001; Luque 2005; Mancia2000; VALUE 2004), while CHD was the 
main comorbidity in nine studies (ACCOMPLISH 2008; ALLHAT 2002; ASCOT-BPLA 2005; 
CASE-J 2008; CONVINCE 2003; ELSA 2002; INSIGHT 2000; INVEST 2003; JMIC-B 2004) . CKD 
was the main comorbidity in six studies (AASK 2002; ACCOMPLISH 2008; ASCOT-BPLA 
2005; CASE-J 2008; INSIGHT 2000; VALUE 2004). 
Treatment status: 15 studies included previously treated hypertensives 
(ACCOMPLISH 2008; ALLHAT 2002; Bremner 1997; Cushman 1998; DETAIL 2004; ELSA 2002; 
FACET 1998; HYVET 2008; INSIGHT 2000; JMIC-B 2004; MIDAS 1996; PATS 1995; SHELL 2003; 
SYST-EUR 1997; VHAS 1998). However, only five studies included previously untreated 
hypertensives (Derosa 2014; ELVERA 2004; Freytag 2001; Holsgreve2003; Mallion 2007), 
whereas the remaining 62 included both previously treated and untreated 
patients. 
  75 
 
Treatment strategy:  monotherapy was used as the first line of approach in the 
majority of studies, whereas combination therapy was used in one of the 
treatment arms in seven studies (ACCOMPLISH 2008; ASCOT-BPLA 2005; Cremonesi 
2002; Holsgreve2003; McInnes 2000; Pareek 2010; Stimpel 1997) and in both treatment 
arms in eight studies (Benetos 2000; Chanudet 2001; CONVINCE 2003; INSIGHT 2000; 
Mallion 2000; NORDIL 2000; Os 1997; Waeber 1999). 
 
BP–lowering agents: In total 36,410 participants were randomised to ACEI, 20,705 
to ARB, 73,987 to CCB, 56,727 to DI and 43,617 to BB, as shown in Table 4.1.  
ACEI was used in 37 studies (AASK 2002; ACCOMPLISH 2008; Alcocer 1995; ALLHAT 2002; 
ASCOT-BPLA 2005; Black 1997; Bremner 1997; Chanudet 2001; Cremonesi 2002; Cushman 
1998; Derosa 2014; DETAIL 2004; ELVERA 2004; FACET 1998; Farsang 2007; Holsgreve 2003; 
HYVET–P 2003; JMIC-B 2004; Luque 2005; Mallion 2000; Mallion 2011; Mancia 2000; MAPAVEL 
2002; McInnes 2000; Mimran 1998; Mroczek 1996; Narkiewicz 2007; Nilsson 2007; Os 1997; 
PRESERVE 2001; RACE 1995; Ruilope 2001; Stimpel 1997; UKPDS 1998; Waeber 1999; Wu 
2004; Yang 2015). 
As regards ACEI sub-classes, seven dicarboxylate-containing agents (benazepril, 
delapril, enalapril, lisinopril, moexipril, perindopril and ramipril), two sulfhydryl-
containing agents (captopril and zofenopril) and one phosphonate-containing 
agent (fosinopril) were used in the studies. Of these, enalapril (31.1%) was the 
most commonly used as it has been compared to other BP-lowering agents in 12 
studies (Alcocer 1995; Cushman 1998; Derosa 2014; DETAIL 2004; JMIC-B 2004; Luque 2005; 
Mancia2000; MAPAVEL 2002; Mimran 1998; Os 1997; PRESERVE 2001; Ruilope 2001), and to 
Placebo in Cushman 1998. 
ARB was used in 34 studies (ALPINE 2003; Black 1997; Bremner 1997; CASE-J 2008; 
Chanudet 2001; CROSS 2003; Derosa 2013; DETAIL 2004; Fogari 2008; Freytag 2001; Giles 
2007; Guthrie 1998; Hanefeld 2001; Hegner 1997; IDNT 2001; James 2002; LAARS 2002; LIFE 
2002; LOTHAR 2006; Mallion 2007; Mallion 2011; MAPAVEL 2002; McInnes 2000; Mimran 1998; 
Narkiewicz 2007; Oparil 1998; Pareek 2010; Radauceanu 2004; REGAAL 2002; REZALT 2009; 
Ruilope 2001; VALUE 2004; Volpe 2003; Wu 2004). In total, seven ARB agents 
(candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan and 
valsartan) were used, with losartan (30.8%) the most commonly used as it has been 
compared to other BP-lowering agents in 12 studies (Chanudet 2001; Giles 2007; 
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James 2002; LAARS 2002; LIFE 2002; LOTHAR 2006; Narkiewicz 2007; Oparil1998; Pareek 
2010; REGAAL2002; Volpe 2003  ; Wu 2004) 
 
CCB was used in 46 studies (AASK 2002 ; ACCOMPLISH 2008; ALLHAT 2002; ASCOT-BPLA 
2005; Benetos 2000; BLACK 2001; CASE-J 2008; CONVINCE 2003; Cushman 1998; Derosa 2013; 
Derosa 2014; ELLE 2003; ELSA 2002; ELVERA 2004; FACET 1998; Farsang 2007; Hoegholm 
1995; Holsgreve 2003; IDNT 2001; INSIGHT 2000; INVEST 2003; James 2002; JMIC-B 2004; 
LOTHAR 2006; Luque 2005; MAISH 2007; Mallion 2007; Mancia 2000; MIDAS 1996 ; Mounier-
Vehier 1998; NICS-EH 1999; NORDIL 2000; Papademetriou 1997; Pareek 2010; PRESERVE 
2001; Radauceanu 2004; REZALT 2009; SHELL 2003; SYST-EUR 1997; VALUE 2004; VHAS 1998; 
Volpe 2003 ; Waeber 1999; Wu 2004; Yang 2015; Zanchetti 2001).  
 
As regards CCB sub-classes, ten dihydropyridines (DHP) agents (amlodipine, 
azelnidipine, felodipine, isradipine, lacidipine, lercanidipine, manidipine, 
nicardipine, nifedipine and nitrendipine) and two non-dihydropyridines (non-DHP) 
agents (verapamil and diltiazem) were used. Of them all, amlodipine (38.5%) was 
the most commonly used as it has been compared to other BP-lowering agents in 
21 studies (AASK 2002 ; ACCOMPLISH 2008; ALLHAT 2002; ASCOT-BPLA 2005; Benetos 2000; 
CASE-J 2008; Derosa 2013; ELVERA 2004; FACET 1998; Farsang 2007; Hoegholm 1995; IDNT 
2001; LOTHAR 2006; MAISH 2007; Mounier-Vehier 1998; Pareek 2010; Radauceanu 2004; 
VALUE 2004; Volpe 2003  ; Wu 2004; Zanchetti 2001) and to Placebo in IDNT 2001. 
 
DI was used in 26 studies (ACCOMPLISH 2008; ALLHAT 2002; ALPINE 2003; Benetos 2000; 
Chanudet 2001; CONVINCE 2003; Cremonesi 2002; CROSS 2003; Fogari 2008; Hegner 1997; 
Holsgreve 2003; HYVET 2008; HYVET–P 2003; INSIGHT 2000; Mallion 2000; McInnes 2000; 
MIDAS 1996; Mroczek 1996; NICS-EH 1999; NORDIL 2000; Os 1997; Papademetriou 1997; PATS 
1995; SHELL 2003; Stimpel 1997; VHAS 1998).  
 
For DI sub-classes, three thiazide DIs (bendroflumethiazide, hydrochlorothiazide 
and trichlormethiazide), two thiazide-like DIs (chlorthalidone and indapamide) 
and one potassium-sparing DI (amiloride) were used. Chlorthalidone (30%) was the 
most commonly used DI as it has been compared to other BP-lowering agents in 
four studies (ALLHAT 2002; Holsgreve2003; SHELL 2003; VHAS 1998). 
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BB was used in 22 studies (AASK 2002; ASCOT-BPLA 2005; Benetos 2000; CONVINCE 2003; 
ELSA 2002; Freytag 2001; Grassi 2003; Greathouse 2010; Holsgreve2003; INVEST 2003; LAARS 
2002; LIFE 2002; Mallion 2000; Nilsson 2007; NORDIL 2000; Os 1997; Pareek 2010; RACE 1995; 
REGAAL 2002; Stimpel 1997; UKPDS 1998; Waeber 1999).Looking at BB sub-classes, four 
beta-1 selective agents (atenolol, bisoprolol, metoprolol and nebivolol) were 
used; Atenolol (64%) was the most commonly used as it has been compared to 
other BP-lowering agents in 15 studies (ASCOT-BPLA 2005; CONVINCE 2003; ELSA 2002; 
Freytag 2001; Grassi 2003; Holsgreve2003; INVEST 2003; LAARS 2002; LIFE 2002; Mallion 2000; 
Nilsson 2007; Os 1997; RACE1995; REGAAL2002; UKPDS 1998). 
 
In addition, 8,728 participants were randomised to a placebo (6.6%), which was 
used in one of the treatment arms of 13 studies (Black 1997; BLACK 2001; Cushman 
1998; Giles 2007; Grethouse 2010; Guthrie 1998; Hanefeld 2001; HYVET 2008; IDNT 2001; 
Mroczek 1996; PATS 1995; SYST-EUR 1997; Waeber 1999).
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Table 3.1 Summary of BP-lowering agents used in the review.  
The table shows that CCBs are the choice for first-line mono-therapy or second-line combination therapy recommended by most of the existing BP 
guidelines as well as the current review (as mentioned above, Table 1.3). DIs and BBs are still prescribed; thiazide DIs are the most commonly 
prescribed DIs, whereas BBs are no longer commonly prescribed as first-line BP-lowering agents. [Red highlights] indicate the highest N or %. 




1st line monotherapy 
2nd line combination + CCB 
1st line monotherapy 
2nd line combination + CCB 
1st line monotherapy 




1st line monotherapy 
2nd line combination + CCB 
1st line monotherapy 
2nd line combination + CCB 
1st line monotherapy 
2nd line combination + ACEI ,ARB or DI 
1st line monotherapy 
2nd line combination Thiazide + CCB 1
st line Monotherapy 
JNC-  
United States 
1st line monotherapy 
2nd line combination + CCB 
1st line monotherapy 
2nd line combination + CCB 
1st line Monotherapy 
2nd line combination + ACEI ,ARB or DI 
1st line monotherapyThiazide 
2nd line combination Thiazide + CCB 
 
Current systematic review 
N of RCTs 37 34 46 26 22 
N of patients  36410 20705 73987 56727 43617 
% of patients 23.20% 21.20% 27.30% 8.10% 13.60% 
BP–lowering sub-class  Dicarboxylate-containing AT1receptor antagonists DHP  Thiazide  Beta-1 selective 
 Benazepril 8.90% Candesartan  7.70% Amlodipine 38.50% Bendroflumethiazide 10.00% Atenolol 64.00% 
 Delapril 4.40% Eprosartan  2.60% Azelnidipine 2.00% Hydrochlorothiazide 20.00% Bisoprolol 8.00% 
 Enalapril 31.10% Irbesartan 12.80% Felodipine 7.70% Trichlormethiazide 10.00% Metoprolol 20.00% 
 Lisinopril 15.60% Losartan 30.80% Isradipine 3.80% Thiazide-like Nebivolol 8.00% 
 Moexipril 6.70% Olmesartan 17.90% Lacidipine 3.80% Chlorthalidone 30.00%   
 Perindopril 13.30% Telmisartan 10.30% Lercanidipine 7.70% Indapamide 20.00%   
 Ramipril 4.40% Valsartan 17.90% Manidipine 7.70% Potassium-sparing   
 Sulfhydryl-containing   Nicardipine 2.00% Amiloride 10.00%   
 Captopril 2.20%   Nifedipine 9.60%     
 Zofenopril 6.70%   Nitrendipine 3.80%     
 Phosphonate-containing   Non-DHP     
 Fosinopril 6.70%   Verapamil 9.60%     
     Diltiazem 3.80%     
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SD of BP change at the end of the study was used in 46 studies (Alcocer 1995; 
ALLHAT 2002; ALPINE 2003; ASCOT-BPLA 2005; Benetos 2000; BLACK 2001; Chanudet 2001; 
Derosa 2013; Derosa 2014; ELLE 2003; ELVERA 2004; FACET 1998; Farsang 2007; Freytag 
2001; Fogari 2008; Grassi 2003; Grethouse 2010; Hanefeld 2001; Hegner 1997; Hoegholm 
1995; Holsgreve 2003; HYVET 2008; INSIGHT 2000; James 2002; LIFE 2002; Luque 2005; MAISH 
2007; Mallion 2000; MAPAVEL 2002; Mcinnes 2000; Mallion 2007; MIDAS 1996 ; Mounier-
Vehier 1998; Narkiewicz 2007; Nilsson 2007; Os 1997; Pareek 2010; PRESERVE 2001; 
Papademetriou 1997; Radauceanu 2004; UKPDS 1998; VHAS 1998; VALUE 2004; Volpe 2003; 
Wu 2004; Yang 2015).  
 
Subsequently, SD of the change at each time point during treatment was used in 
8 studies (AASK 2002; CASE-J 2008; LOTHAR 2006; NICS-EH 1999; NORDIL 2000; PATS 1995; 
REGAAL2002; SYST-EUR 1997). Thereafter, SD of baseline SBP and DBP was imputed 
in 26 studies (ACCOMPLISH 2008; Black 1997; Bremner 1997; CONVINCE 2003; Cremonesi 
2002; CROSS 2003; DETAIL 2004; ELSA 2002; Giles 2007; Guthrie 1998; HYVET–P 2003; IDNT 
2001; INVEST 2003; JMIC-B 2004; LAARS 2002; Mallion 2011; Mancia 2000; Mimran 1998; 
Mroczek 1996; Oparil 1998; RACE 1995; REZALT 2009; Ruilope 2001; SHELL 2003; Waeber 
1999; Zanchetti 2001). Finally, SD of the change from other studies with the closest 
sample size was implicated in two studies (Cushman 1998, imputed from MIDAS 1996 





3.1.2.1 Characteristics of included studies (ordered by study ID) 
AASK 2002(279-281) 
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 49 months 
Participants N: 1,094 
Mean baseline BP: seated 150/96 mmHg 
Method for BP measurement: 3 consecutive BP readings were measured using a Hawksley random 
zero sphygmomanometer after at least 5 minutes of rest with the mean of the last 2 readings 
recorded 
Hypertensive patients (%): 100%  
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: mild to moderate CKD 
Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: ACEI - ramipril: 2.5 to 10 mg once daily (OD) or CCB - amlodipine: 5 to 10 mg OD, or 
BB - metoprolol: 50 to 200 mg OD 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added consecutively 
(furosemide, doxazosin, clonidine, and hydralazine or minoxidil) 
Primary outcomes: GFR and other renal outcomes; all CV events, including CV deaths and 
hospitalisations for MI, strokes, HF, and revascularisation procedures; other hospitalised CV events 
 
ACCOMPLISH 2004(282;283)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 36 months 
Participants N: 11,506 
Mean baseline BP: seated 145.3/80 mmHg 
Method for BP measurement: BP measurements were recorded as the average of 3 readings taken 
at 2-minute intervals after the patient had remained in a seated position for 5 minutes 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: history of CHD, CVE, mild to moderate CKD, PVD, LVH, or T2DM 
Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: ACEI + CCB - benazepril + amlodipine: 20 mg OD + 5 mg OD or ACEI + DI - benazepril 
+ hydrochlorothiazide: 20 mg OD + 12.5 mg OD 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (excluding 
any CCBs, ACEIs, ARBs, and thiazide DI but including BBs, alpha-blockers, clonidine, and 
spironolactone) 
Primary outcomes: composite of death from CV causes, non-fatal MI, non-fatal stroke, 
hospitalisation for angina, resuscitation after sudden cardiac arrest, and coronary 
revascularisation 
 
Alcocer 1995(284)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 161 
Mean baseline BP: supine 163/100.5 mmHg 
Method for BP measurement: according to ASH recommendations 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: no 
Intervention: ACEI - enalapril: 10 to 20 mg OD or ACEI - perindopril: 4 to 8 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added 
(hydrochlorothiazide) 
Primary outcomes: drug efficacy and safety 
 
ALLHAT 2002(48;285) 
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 57 months 
Participants N: 33,357 
Mean baseline BP: seated 146/84 mmHg 
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Method for BP measurement: according to JNC V guidelines for HTN 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: at least 1 additional risk factor for CHD events 
Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: ACEI - lisinopril: 10 to 40 mg OD, CCB - amlodipine: 2.5 to 10 mg OD, or DI - 
Chlorthalidone: 12.5 to 25 mg OD 
Co-intervention: if BP goal was not achieved, other open-labelled BP-lowering agents were added 
consecutively (atenolol, reserpine, clonidine, or hydralazine) 
Primary outcomes: fatal CHD or non-fatal MI combined 
Secondary outcomes: all-cause mortality, stroke, combined CHD, and combined CVD 
 
ALPINE 2003(286); Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy 
evaluation  
Single-centre, randomised controlled, double-blind study 
Mean duration of follow-up: 12 months 
Participants N: 393 
Mean baseline BP: seated 154.8/96.9 mmHg 
Method for BP measurement: mean of 2 measurements in a standard way at least 2 times with 
the patient resting for at least 1 minute. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: no 
Intervention: ARB - candesartan: 16 mg OD or DI - hydrochlorothiazide: 25 mg OD 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (felodipine 
was added to the candesartan group and Atenolol was added to the hydrochlorothiazide group) 
Primary outcomes: glucose and lipoprotein metabolism, electrolytes, BP, and subjective 
symptoms 
 
ASCOT-BPLA 2005(51;287)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 72 months 
Participants N: 19,257 
Mean baseline BP: seated 164/95 mmHg 
Method for BP measurement: BP was measured in a standard way on at least 2 occasions. BP was 
measured 3 times, after 5 minutes of rest in the sitting position. A semi-automated device was 
used, and the mean of the last 2 readings was used. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: at least 3 other CV risk factors (male sex; age 55 years or older; 
smoking; history of CHD, CVE, mild to moderate CKD, PVD, LVH; hyperlipidaemia, or T2DM) 
Pre-intervention: placebo run-in period: 2 to 8 weeks; wash-out period: no 
Intervention: CCB + ACEI – amlodipine + perindopril: 5 to 10 mg OD + 4-8 mg OD or BB + DI – 
atenolol + bendroflumethiazide : 50 to 100 mg OD + 1.25-2.5Mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: non-fatal MI + fatal CHD 
Secondary outcomes: all-cause mortality, total stroke, primary end point minus silent MI, all 
coronary events, total CV events and procedures, CV mortality, and non-fatal and fatal HF 
Tertiary outcomes: silent MI, unstable angina, chronic stable angina, PVD, life-threatening 
arrhythmias, development of T2DM , development of RF 
 
Benetos 2000(288) 
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 164 
Mean baseline BP: supine 171.6/95.6 mmHg 
Method for BP measurement: 3 measurements were obtained with a manual mercury 
sphygmomanometer at 1-minute intervals after a 5-minute rest. The mean of the last 2 values 
was used. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
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Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 2 to 4 weeks; wash-out period: no 
Intervention: CCB - amlodipine: 5 mg OD or BB + DI - bisoprolol + hydrochlorothiazide: 2.5 mg OD 
+ 6.25 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety, and quality of life 
 
Black 1997(289) 
Multicentre, randomised controlled, double-blind study  
Mean duration of follow-up: 3 months 
Participants N: 734 
Mean baseline BP: seated 154/101.1 mmHg 
Method for BP measurement: according to WHO guidelines 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 2 to 4 weeks; wash-out period: no 
Intervention: ACEI - lisinopril: 10 to 20 mg OD, ARB - valsartan: 80 to 160 mg OD, or P - placebo 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy, tolerability, and safety 
 
Black 2001(290) 
Multicentre, randomised controlled, double-blind study  
Mean duration of follow-up: 13 months 
Participants N: 171 
Mean baseline BP: seated 149/83 mmHg 
Method for BP measurement: according to JNC guidelines for HTN  
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: ≤ 8 weeks 
Intervention: CCB - felodipine: 2.5 to 5 mg OD or P - placebo 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety, LVM, and quality of life 
 
Bremner 1997(291) 
Multicentre, randomised controlled, double-blind study  
Mean duration of follow-up: 13 months 
Participants N: 501 
Mean baseline BP: seated 172/102 mmHg 
Method for BP measurement: according to WHO guidelines 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 2 weeks; wash-out period: no 
Intervention: ACEI - lisinopril: 2.5 to 20 mg OD or ARB - valsartan: 40 to 80 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added 
(hydrochlorothiazide) 
Primary outcomes: total mortality (death due to all causes) and BP 
 
CASE-J 2008(292;293); Candesartan Antihypertensive Survival Evaluation in Japan  
Multicentre, randomised controlled, open-label study 
Mean duration of follow-up: 48 months 
Participants N: 4,728 
Mean baseline BP: seated 162.8/91.7 mmHg 
Method for BP measurement: according to JSH guidelines 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: at least 1 CV risk factor (history of CHD, CVE, mild to moderate 
CKD, PVD, LVH, or T2DM ) 
Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: ARB - candesartan: 4 to 12 mg OD or CBB - amlodipine: 2.5 to 10 mg OD 
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Co-intervention: no other BP-lowering agents were added 
Primary outcomes: (composite of the following events): sudden death. CVEs: stroke or TIA. 
Cardiac events: HF, angina pectoris, or acute MI. Renal events: serum creatinine concentration or 
end-stage renal disease. Vascular events: dissecting aortic aneurysm or arteriosclerotic occlusion 
of a peripheral artery.  
Secondary outcomes: all-cause deaths, new-onset T2DM, discontinuance of treatment because of 
adverse events 
 
Chanudet 2001(294)  
Multicentre, randomised controlled, double-blind study  
Mean duration of follow-up: 3 months 
Participants N: 277 
Mean baseline BP: supine 165.5/98.2 mmHg 
Method for BP measurement: 3 consecutive measurements were taken and the third was 
considered. The SBP value corresponded to phase I and the DBP value to phase V of the Korotkoff 
sounds. The BP value recorded for the study was measured after 5 minutes of rest. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 2 weeks; wash-out period: no 
Intervention: ACEI + DI - perindopril + indapamide: 2 mg OD + 0.625 to 1.25 mg OD or ARB - 
losartan: 50 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and tolerability 
 
CONVINCE 2003(295;296); Controlled Onset Verapamil Investigation of Cardiovascular End Points  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 36 months 
Participants N: 16,602  
Mean baseline BP: seated 150.1/86.8 mmHg 
Method for BP measurement: BP was measured in a standard way on at least 2 occasions with 
the patient resting for at least 1 minute. 
Hypertensive patients (%): 80% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: at least 1 CV risk factor (smoking; obesity; hyperlipidaemia; or 
history of CHD, CVE, PVD, LVH, or T2DM) 
Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: CBB - verapamil: 180 mg OD or BB/DI - atenolol or hydrochlorothiazide: 50 mg OD 
or 12.5 mg OD 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added as step 2 
(hydrochlorothiazide and atenolol). Any additional open-labelled BP-lowering agents (except a 
non-DHP CCB, thiazide DI, or BB) could be added as a step 3 if needed. 
Primary outcomes: first occurrence of stroke, MI, or CV disease-related death 
 
Cremonesi 2002(297) 
Multicentre, randomised controlled, open-label study 
Mean duration of follow-up: 3 months 
Participants N: 171 
Mean baseline BP: seated 160.3/101.3 mmHg 
Method for BP measurement: 3 measurements, with standard mercury sphygmomanometry, were 
taken at 3-minute intervals after 5 minutes of sitting 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 2 weeks; wash-out period: no 
Intervention: ACEI + DI - delapril + indapamide: 30 mg OD + 2.5 mg OD or ACEI + DI - fosinopril + 
hydrochlorothiazide: 20 mg OD + 12.5 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
 
CROSS 2003(298); Candesartan Role on Obesity and on Sympathetic System  
Multicentre, randomised controlled, double-blind study 
  84 
 
Mean duration of follow-up: 3 months 
Participants N: 176 
Mean baseline BP: seated 146.1/98.6 mmHg 
Method for BP measurement: measurements were made by taking the I and the V Korotkoff 
sounds as indicative of SBP and DBP values, respectively. The mean of 3 consecutive 
measurements was taken with the patient resting for at least 1 minute. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: obesity 
Pre-intervention: placebo run-in period: 2 weeks; wash-out period: no 
Intervention: ARB - candesartan: 8 to 16 mg OD or DI - hydrochlorothiazide: 25 to 50 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy on BP, insulin sensitivity, and sympathetic drive 
 
Cushman 1998(299)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 891 
Mean baseline BP: seated 154.2/101.7 mmHg 
Method for BP measurement: BP measurements were obtained in triplicate with a standard 
mercury sphygmomanometer and patient resting for at least 1 minute. Korotkoff phases I and V 
were used for SBP and DBP, respectively. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: 1 week 
Intervention: ACEI - enalapril: 5 mg OD, CCB - diltiazem: 120 or 180 mg OD, or P - placebo 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
 
Derosa 2013(300) 
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 12 months 
Participants N: 276 
Mean baseline BP: seated 148.8/98.6 mmHg 
Method for BP measurement: BP measurements were obtained using a standard mercury 
sphygmomanometer (Korotkoff I and V). 3 successive BP readings were obtained at 1-minute 
intervals, and the mean of the 3 readings was calculated. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 2 weeks; wash-out period: no 
Intervention: ARB – olmesartan: 20 mg OD or CCB – amlodipine: 10 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy 
 
Derosa 2014(301) 
Single-centre, randomised controlled, double-blind study 
Mean duration of follow-up: 24 months 
Participants N: 345 
Mean baseline BP: seated 153.8/97.3 mmHg 
Method for BP measurement: BP measurements were obtained using a standard mercury 
sphygmomanometer (Korotkoff I and V). 3 successive BP readings were obtained at 1-minute 
intervals, and the mean of the 3 readings was calculated. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: ACEI – Enalapril: 20 mg OD or CCB – Lercanidipine: 10 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: Biomarkers in CV risk stratification 
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DETAIL 2004(302) 
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 60 months 
Participants N: 250 
Mean baseline BP: seated 158/87 mmHg 
Method for BP measurement: BP response measured using a standard technique at least 3 times 
with the patient resting for at least 1 minute. 
Hypertensive patients (%): 81% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: T2DM 
Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: ACEI – enalapril: 10 to 20 mg OD or ARB – telmisartan: 40 to 80 mg OD 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added consecutively 
(excluding ACEI and ARB) 
Primary outcomes: Total mortality: death from all causes. CV events: MI, HF, CVE 
 
ELLE 2003(303); Elderly and Lercanidipine  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 6 months 
Participants N: 324 
Mean baseline BP: seated 167.2/97.5 mmHg 
Method for BP measurement: BP was measured twice at 3-minute intervals using the 
auscultatory method. Korotkoff phases I and V were used to identify SBP and DBP, respectively. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 2 weeks; wash-out period: 1 week 
Intervention: CCB – lacidipine: 2 to 4 mg OD, CCB – lercanidipine: 5 to 10 mg OD, or 
CCB – nifedipine: 30 to 60 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
 
ELSA 2002(304-306); European Lacidipine Study on Atherosclerosis  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 48 months 
Participants N: 2,334 
Mean baseline BP: seated 163.5/101.3 mmHg 
Method for BP measurement: 3 measurements of BP were taken by a mercury manometer after 
the patients had been seated for at least 5 minutes. The average of these 3 measurements was 
used. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: smoking, CHD, hyperlipidaemia, or T2DM 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: no 
Intervention: CCB – lacidipine: 4 to 6 mg OD or BB – atenolol: 50 to 100 mg OD 
Co-intervention: if BP goal was not achieved, another open-labelled BP-lowering agent was 
added (hydrochlorothiazide) 
Primary outcomes: change in mean maximum Intima media thickness (IMT), plaque number, fatal 
and non-fatal CV events, total mortality 
 
ELVERA 2004(307;308); Effects of Amlodipine and Lisinopril on Left Ventricular Mass and 
Diastolic Function (E/A Ratio)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 24 months 
Participants N: 166 
Mean baseline BP: seated 175/92.5 mmHg 
Method for BP measurement: 4 BP measurements were derived from several measurements 
made on 3 occasions. SBP and DBP were recorded at Korotkoff phase I and V to the nearest 2 
mmHg. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously untreated 
Other co-morbid conditions: no 
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Pre-intervention: placebo run-in period: 2 weeks; wash-out period: 8 weeks 
Intervention: ACEI – lisinopril: 10 to 20 mg OD or CCB – amlodipine: 5 to 10 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: the change from baseline of the combined mean maximum far wall IMT of 
carotid and femoral arteries 
 
FACET 1998 (309); Fosinopril Versus Amlodipine Cardiovascular Events Randomized  
Single-centre, randomised controlled, open-label study 
Mean duration of follow-up: 41 months 
Participants N: 380 
Mean baseline BP: seated 170/95 mmHg 
Method for BP measurement: BP was measured in a standard way on at least 2 consecutive visits 
with the patient resting for at least 1 minute. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: T2DM 
Pre-intervention: placebo run-in period: no; wash-out period: 2 weeks 
Intervention: ACEI – fosinopril: 20 mg OD or CCB – amlodipine: 10 mg OD 
Co-intervention: if BP goal was not achieved, the other study drug was added at full dose 




Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 303 
Mean baseline BP: seated 160/101.1 mmHg 
Method for BP measurement: BP readings were taken by a standard mercury sphygmomanometer 
after 10 minutes of rest. Korotkoff I and V were taken as the SBP and DBP readings, respectively. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 2 weeks; wash-out period: no 
Intervention: ACEI - zofenopril: 30 to 60 mg OD or CCB - amlodipine: 5 to 10 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: BP control and response rate 
 
Fogari 2008(311)  
Multicentre, randomised controlled, open blinded endpoint study 
Mean duration of follow-up: 4 months 
Participants N: 126 
Mean baseline BP: seated 170.3/103.9 mmHg 
Method for BP measurement: 3 measurements were taken using a standard mercury 
sphygmomanometer at 2-minute intervals after the patient had been seated for 10 minutes 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: no; wash-out period: 2 weeks 
Intervention: ARB + DI – olmesartan + hydrochlorothiazide: 20 mg OD + 12.5 mg OD or ARB + DI - 
telmisartan + hydrochlorothiazide: 80 mg OD + 12.5 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy 
 
Freytag 2001(312)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 7 months 
Participants N: 533 
Mean baseline BP: supine 165.8/101.8 mmHg 
Method for BP measurement: according to ASH recommendations 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously untreated 
Other co-morbid conditions: no 
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Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: ARB - telmisartan: 40 to 80 mg OD or BB - atenolol: 50 to 100 mg OD  
Co-intervention: if BP goal was not achieved, another open-labelled BP-lowering agent was 
added (hydrochlorothiazide) 
Primary outcomes: drug efficacy and tolerability 
 
Giles 2007(313)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 723 
Mean baseline BP: seated 154.6/103.4 mmHg 
Method for BP measurement: BP was determined in triplicate taken at 1-minute intervals after 
the patients had been sitting in the examination room for 5 minutes 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: no 
Intervention: ARB – losartan: 50 to 100 mg OD, ARB – olmesartan: 20 to 40 mg OD, ARB – 
valsartan: 80 to 320 mg OD, or P - placebo 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and tolerability 
 
Grassi 2003(314)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 205 
Mean baseline BP: seated 156.2/100.4 mmHg 
Method for BP measurement: BP was measured by a standard mercury sphygmomanometer using 
I and V Korotkoff phases to identify SBP and DBP values, respectively. 3 measurements (spaced by 
1 to 3-minute intervals) were taken after 5 minutes in the sitting position. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: 10 days 
Intervention: CCB – nebivolol: 5 mg OD or BB – atenolol: 100 mg OD 
Co-intervention: if BP goal was not achieved, another open-labelled BP-lowering agent was 
added (hydrochlorothiazide) 
Primary outcomes: drug efficacy and tolerability 
 
Greathouse 2010(315)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 811 
Mean baseline BP: seated 151.3/99 mmHg 
Method for BP measurement: BP was measured in a standard way. All measurements were taken 
in triplicate at 2-minute intervals, and the mean value was calculated. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 to 6 weeks; wash-out period: no 
Intervention: BB – nebivolol: 5 or 10 or 20 mg OD or P - placebo 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
 
Guthrie 1998(316)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 319 
Mean baseline BP: seated 148.2/100 mmHg 
Method for BP measurement: BP was measured with a standard mercury sphygmomanometer. 
Measurements were made in the seated position (after remaining at rest for 5 to 10 minutes) and 
in the standing position (after standing for 2 minutes). The mean of 3 readings was taken. 
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Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 to 5 weeks; wash-out period: no 
Intervention: ARB – irbesartan: 75 to 150 or 150 to 300 mg OD or P - placebo 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and tolerability 
 
Hanefeld 2001(317)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 123 
Mean baseline BP: seated 165.5/97.9 mmHg 
Method for BP measurement: BP was measured after the patient had rested in a sitting position 
for at least 3 minutes. The mean of 3 measurements was calculated. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 3 weeks; wash-out period: no 
Intervention: ARB – valsartan: 80 mg OD or P - placebo 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
 
Hegner 1997(318)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 167 
Mean baseline BP: seated 165.7/103.4 mmHg 
Method for BP measurement: according to WHO guidelines 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 2 weeks; wash-out period: no 
Intervention: ARB – valsartan: 80 mg OD or DI – hydrochlorothiazide: 25 mg OD 
Co-intervention: if BP goal was not achieved, another open-labelled BP-lowering agent was 
added (Atenolol) 
Primary outcomes: drug efficacy and safety 
 
Hoegholm 1995(319)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 4 months 
Participants N: 118 
Mean baseline BP: seated 170.3/105 mmHg 
Method for BP measurement: BP was measured after 3 and 5 minutes of rest with a standard 
sphygmomanometer, and the mean of the 2 measurements was used 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: 4 weeks 
Intervention: CCB – amlodipine: 5 to 10 mg OD or CCB – felodipine: 5 to 20 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
 
Holzgreve 2003(320)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 5 months 
Participants N: 463 
Mean baseline BP: seated 168.1/95.5 mmHg 
Method for BP measurement: according to the BHS recommendations 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously untreated 
Other co-morbid conditions: T2DM 
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Pre-intervention: placebo run-in period: 2 weeks; wash-out period: no 
Intervention: BB + DI - atenolol + chlorthalidone: 50 to 100 mg OD + 12.5 to 25 mg OD or CCB + 
ACEI - verapamil + trandolapril: 180 mg OD + 1 to 2 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcome: HbA1c after 20 weeks of active treatment 
Secondary outcome: measures were the change in sitting SBP and DBP, the proportions of 
patients achieving normal BP or responding to BP-lowering agents 
 
HYVET 2008(321;322); Hypertension in the Very Elderly Trial 
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 25 months 
Participants N: 3,845 
Mean baseline BP: seated 173.0/90.8 mmHg 
Method for BP measurement: 2 BP measurements were taken during each of 2 visits, 1 month 
apart, after the patient had been seated for 5 minutes .The BP measurements were recorded with 
the use of either a mercury sphygmomanometer or a validated automated device, but by the end 
of the trial, a validated automated device was used. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: ≥8 weeks; wash-out period: no 
Intervention: DI – indapamide: 1.5 mg OD or P - placebo 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added (perindopril) 
Primary outcomes: total stroke, total CHD, total mortality, total CV events 
 
HYVET pilot 2003(323); Hypertension in the Very Elderly Trial- pilot  
Multicentre, randomised controlled, open-label study 
Mean duration of follow-up: 13 months 
Participants N: 1,283 
Mean baseline BP: seated 181.5/99.6 mmHg 
Method for BP measurement: 2 readings of sitting BP were taken after the patient had rested for 
5 minutes. The measurements were repeated 1 month later. The DBP value corresponded to 
Korotkoff phase V. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: no; wash-out period: ≥ 4 weeks 
Intervention: ACEI – lisinopril: 2.5 mg OD or DI – bendroflumethiazide: 2.5 to 5 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added (diltiazem) 
Primary outcomes: total stroke, total mortality, CV mortality, cardiac mortality, SBP and DBP 
 
IDNT 2001(324-326); Irbesartan Diabetic Nephropathy Trial 
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 30 months 
Participants N: 1,715 
Mean baseline BP: seated 159/87 mmHg 
Method for BP measurement: BP was measured in a standard way on at least 2 occasions with 
the patient resting for at least 1 minute. 
Hypertensive patients (%): 76% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: T2DM 
Pre-intervention: placebo run-in period: no; wash-out period: 10 days 
Intervention: ARB – irbesartan: 300 mg OD or CCB – amlodipine: 10 mg OD or P - placebo 
Co-intervention: if BP goal was not achieved, other open BP-lowering agents were added 
(excluding ACEI, ARB, and CCB) 
Primary outcomes: renal outcomes 
Secondary outcomes: the composite of fatal or non-fatal CVS events, adverse events  
 
INSIGHT 2000(327); International Nifedipine GITS Study Intervention as a Goal in Hypertension 
Treatment  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 48 months 
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Participants N: 6,575 
Mean baseline BP: seated 173.0/99 mmHg 
Method for BP measurement: BP was measured in a standard way on at least 2 occasions, 3 times 
after the patient had rested for 5 minutes 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: history of at least 1 CV risk factor (smoking, hyperlipidaemia, 
history of CHD, LVH, mild to moderate CKD, or PVD) 
Pre-intervention: placebo run-in period: 2 to 4 weeks; wash-out period: no 
Intervention: CCB – nifedipine: 30 mg OD or DI - amiloride + hydrochlorothiazide: 2.5 mg OD + 25 
g OD 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (including 
atenolol and enalapril, excluding CCBs and DIs) 
Primary outcomes: CV death, MI, HF, or stroke 
 
INVEST 2003(177;328)  
Multicentre, randomised controlled, open blinded endpoint study 
Mean duration of follow-up: 31 months 
Participants N: 22,576 
Mean baseline BP: seated 149.5/86.3 mmHg 
Method for BP measurement: according to JNC guidelines for HTN  
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: clinical evidence of CHD 
Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: CCB - verapamil: 240 mg OD or BB - atenolol: 50 mg OD 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (including 
trandolapril and hydrochlorothiazide) 
Primary outcomes: the first occurrence of death from any cause, non-fatal MI, or non-fatal 
stroke 
Secondary outcomes: all-cause death, non-fatal MI, non-fatal stroke, CV death, angina, CV 
hospitalisations, BP control, cancer, Alzheimer’s disease, Parkinson’s disease, gastro-intestinal 
bleeding 
 
James 2002(329)  
Single-centre, randomised controlled, double-blind study 
Mean duration of follow-up: 4 months 
Participants N: 465 
Mean baseline BP: supine 165.3/102.3 mmHg 
Method for BP measurement: BP was measured using a standard mercury sphygmomanometer at 
least 2 times after the patient had been in a supine position for at least 5 minutes. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: no 
Intervention: ARB – losartan: 50 to 100 mg OD or CCB – lercanidipine: 10 to 20 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and tolerability 
 
JMIC-B 2004(330); Japan Multicenter Investigation for Cardiovascular Diseases-B  
Multicentre, randomised controlled, open blinded endpoint study 
Mean duration of follow-up: 36 months 
Participants N: 1,836 
Mean baseline BP: seated/supine 146/82 mmHg 
Method for BP measurement: BP was measured 3 times, and the average of the last 2 readings 
was calculated. Measurement was done with the patient in the sitting or supine position 
(whichever had been decided upon initially). 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: clinical evidence or history of CHD 
Pre-intervention: placebo run-in period: no; wash-out period: no 
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Intervention: ACEI - enalapril, imidapril, or lisinopril: 5 to 10 mg OD, 5 to 10 mg OD, or 10 to 20 
mg OD, or CCB – nifedipine: 10 to 20 mg Twice-daily (BID) 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (alpha 
blockers, doxazosin, bunazosin, or prazosin) 
Primary outcomes: Cardiac death, acute MI, hospitalisations for angina pectoris or HF, and 
coronary revascularisation 
 
LAARS 2002(331); Losartan Vascular Regression Study 
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 24 months 
Participants N: 280 
Mean baseline BP: seated 159.5/100.9 mmHg 
Method for BP measurement: several measurements were taken after 5 minutes of rest, and the 
mean of the last 3 sitting DBP measurements was calculated until each of the final 3 individual 
measurements did not deviate by > 5 mmHg from the calculated mean of the 3 measurements 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: ultrasonographically proven thickening of the IMT of the common 
carotid artery 
Pre-intervention: placebo run-in period: 2 weeks; wash-out period: 1 week 
Intervention: ARB – losartan: 50 to 100 mg OD or BB – atenolol: 50 to 100 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added (including 
hydrochlorothiazide and open-labelled CCBs) 
Primary outcomes: IMT of CCA 
 
LIFE 2002(332;333); Losartan Interventionfor Endpoint Reduction in Hypertension  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 56 months 
Participants N: 9,193 
Mean baseline BP: seated 174.4/97.8 mmHg 
Method for BP measurement: BP was measured according to standardised procedures at least 2 
times after subjects had been seated for 5 minutes 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: history of LVH 
Pre-intervention: placebo run-in period: 1 to 2 weeks; wash-out period: no 
Intervention: ARB – losartan: 50 to 100 mg OD; BB – atenolol: 50 to 100 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added (including 
hydrochlorothiazide and excluding ACEIs, ARBs, and BB) 
Primary Outcomes: CVD mortality and mortality (composite endpoint of CV death, MI and stroke) 
Secondary Outcomes: total mortality, angina pectoris or CHF requiring hospital admission 
 
LOTHAR 2006(334); Amlodipino e Losartana no Tratamento da Hipertensão Arterial  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 198 
Mean baseline BP: seated 156.3/99.7 mmHg 
Method for BP measurement: BP recorded represents the mean of 3 consecutive measurements 
obtained with a mercury sphygmomanometer following a 5-minute rest in the sitting position 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: no; wash-out period: 3 weeks 
Intervention: ARB - losartan: 50 to 100 mg OD or CCB - amlodipine: 5 to 10 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and tolerability, metabolic effects 
 
Luque 2005(335)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 6 months 
Participants N: 111 
Mean baseline BP: seated 163.5/97.5 mmHg 
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Method for BP measurement: Measurements were taken after the patient had rested for 10 
minutes. SBP and DBP were measured with a mercury sphygmomanometer at the time of phase I 
and phase V Korotkoff sounds, respectively. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: T2DM 
Pre-intervention: placebo run-in period: 3 weeks; wash-out period: no 
Intervention: ACEI – enalapril: 10 to 20 mg OD or CCB – manidipine: 10 to 20 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and tolerability, and effect on metabolic risk factors 
 
MAISH 2007 (336); Manidipine versus Amlodipine in Elderly Subjects with Isolated Systolic 
Hypertention 
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 195 
Mean baseline BP: seated 159.1/81.9 mmHg 
Method for BP measurement: 3 measurements, using a standard sphygmomanometer, were taken 
at 5-minute intervals after 10 minutes of rest in the sitting position. SBP and DBP values were 
taken at the time of phase I and phase V Korotkoff sounds, respectively. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 2 weeks; wash-out period: no 
Intervention: CCB - amlodipine: 5 to 10 mg OD or CCB - manidipine: 10 to 20 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added 
(chlortalidone) 
Primary outcomes: drug efficacy and safety 
 
Mallion 2000(337)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 446 
Mean baseline BP: supine 163.3/100.7 mmHg 
Method for BP measurement: BP was measured with a standard mercury sphygmomanometer 
(DBP = Korotkoff phase V) with 3 readings after 10 minutes of rest 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: no 
Intervention: ACEI + DI - perindopril + indapamide: 2 mg OD + 0.625 mg OD or BB - atenolol: 50 
mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
 
Mallion 2007(338)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 6 months 
Participants N: 382 
Mean baseline BP: seated 107.7/82.5 mmHg 
Method for BP measurement: 3 measurements were taken using a standard sphygmomanometer 
at 5-minute intervals after 10 minutes of rest. SBP and DBP values were taken at the time of 
phase I and phase V Korotkoff sounds, respectively. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 2 weeks; wash-out period: 1 to 2 weeks 
Intervention: ARB – olmesartan: 20 to 40 mg OD or CCB – nitrendipine: 10 to 20 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added 
(hydrochlorothiazide) 
Primary outcomes: drug efficacy and safety 
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Mallion 2011(339) 
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 351 
Mean baseline BP: seated 160.5/94.5 mmHg 
Method for BP measurement: 3 measurements were taken using a standard sphygmomanometer 
at 2-minute intervals after 5 minutes of rest. SBP and DBP values were taken at the time of the 
phase I and phase V Korotkoff sounds, respectively. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 2 weeks; wash-out period: no 
Intervention: ARB - olmesartan: 10 to 40 mg OD or ACEI - ramipril: 2.5 to 10 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
 
Mancia 2000(340) 
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 6 months 
Participants N: 101 
Mean baseline BP: seated 160/99.5 mmHg 
Method for BP measurement: BP was measured twice at 3-minute intervals after 5 minutes of 
rest using a mercury sphygmomanometer. SBP and DBP values were taken at the time of phase I 
and phase V Korotkoff sounds, respectively. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: T2DM 
Pre-intervention: placebo run-in period: 3 weeks; wash-out period: no 
Intervention: ACEI – Enalapril: 10 to 20 mg OD or CCB – Manidipine: 10 to 20 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy 
 
MAPAVEL 2002(341);  Monitorización Ambulatoria Presión Arterial aproVEL 
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 238 
Mean baseline BP: seated 159.3/101.8 mmHg 
Method for BP measurement: BP measurements, using mercury sphygmomanometer, were taken 
after patient had rested for 10 minutes. Three successive readings were obtained at 3-minute 
intervals. DBP was recorded at the disappearance of the Korotkoff sounds (phase V). The mean of 
the 3 values was recorded. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 3 weeks; wash-out period: no 
Intervention: ACEI – enalapril: 20 mg OD or ARB – irbesartan: 300 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
 
McInnes 2000(342)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 6.2 months 
Participants N: 355 
Mean baseline BP: seated 165.3/102.4 mmHg 
Method for BP measurement: measurements were taken using a fully automated device. Sitting 
BP was recorded 3 times at least 2 minutes apart after the patient had rested for at least 5 
minutes. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: ACEI + DI - lisinopril + hydrochlorothiazide: 10 mg OD + 12.5 mg OD or  
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ARB + DI - candesartan + hydrochlorothiazide: 8 mg OD + 12.5 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and tolerability 
 
MIDAS 1996(343); Multicenter Isradipine Diuretic Atherosclerosis Study  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 36 months 
Participants N: 883 
Mean baseline BP: seated 149.7/96.4 mmHg 
Method for BP measurement: BP was measured in a standard way on at least 2 occasions with 
the patient resting for at least 1 minute. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: hyperlipidaemia, ultrasonographically proven thickening of IMT of 
common carotid artery 
Pre-intervention: placebo run-in period: 3 to 8 weeks; wash-out period: no 
Intervention: CCB – isradipine: 2.5 to 5.0 mg BID or DI – hydrochlorothiazide: 12.5 to 25 mg BID 
Co-intervention: if BP goal was not achieved, another open-labelled BP-lowering agent was 
added (enalapril) 
Primary outcomes: mean maximum IMT and some other findings of carotid artery, and vascular 
events/procedures 
 
Mimran 1998(344)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 200 
Mean baseline BP: seated 164.4/101.4 mmHg 
Method for BP measurement: BP was measured with a standard Mercury sphygmomanometer. 
The mean of 3 readings taken 1 minute apart was calculated. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 to 5 weeks; wash-out period: no 
Intervention: ACEI – enalapril: 10 to 20 mg OD or ARB – irbesartan: 57 to 150 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy, safety, and tolerability 
 
Mounier-Vehier 1998(345) 
Multicentre, randomised controlled, open-label study 
Mean duration of follow-up: 3 months 
Participants N: 103 
Mean baseline BP: seated 166.1/101.9 mmHg 
Method for BP measurement: BP was measured using a conventional mercury 
sphygmomanometer. Two readings were taken and the higher of the 2 was recorded. The first 
reading was taken after 10 minutes of rest, and Korotkoff phase I and phase V sounds were used 
to determine the values of SBP and DBP, respectively. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: no; wash-out period: 2 weeks 
Intervention: CCB – amlodipine: 5 to 10 mg OD or CCB – nifedipine: 20 mg BID 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug compliance and efficacy 
 
Mroczek 1996(346;346)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 200 
Mean baseline BP: seated 153.6/101.5 mmHg 
Method for BP measurement: Korotkoff sounds I and V, using a calibrated Mercury 
sphygmomanometer, were recorded as the SBP and DBP, respectively. Three readings were taken 
1 minute apart after the patient had been seated for a minimum of 5 minutes. 
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Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: no 
Intervention: ACEI – moexipril: 7.5 or 15 mg OD, DI – hydrochlorothiazide: 25 mg OD, or  
P - Placebo 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
 
Narkiewicz 2007(347) 
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 327 
Mean baseline BP: seated 158/98.9 mmHg 
Method for BP measurement: BP readings were taken after 10 minutes of rest in a supine 
position. BP readings were obtained by standard mercury sphygmomanometry. The SBP 
corresponded to Korotkoff phase I and the DBP corresponded at Korotkoff phase V. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no  
Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: ACEI – zofenopril: 30 to 60 mg OD or ARB – losartan: 50 to 100 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and office BP 
 
NICE-EH 1999(348); National Intervention Cooperative Study in Elderly Hypertensives  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 60 months 
Participants N: 429 
Mean baseline BP: seated 172.3/93.8 mmHg 
Method for BP measurement: BP was measured in a standard way on at least 2 occasions with 
the patient resting for at least 1 minute. 
Hypertensive patients (%): >70% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: 2 weeks 
Intervention: CCB – nicardipine: 20 mg SR OD or DI – trichlormethiazide: 2 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: CV complications 
 
Nilsson 2007(349)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 304 
Mean baseline BP: seated 155.2/100.4 mmHg 
Method for BP measurement: BP readings were taken using a standard mercury 
sphygmomanometer with the patient resting for at least 1 minute. The SBP corresponded to 
Korotkoff phase I and the DBP corresponded at Korotkoff phase V. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: ACEI – zofenopril: 30 to 60 mg OD or BB – atenolol: 50 to 100 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy 
 
NORDIL 2000(163;164) 
Multicentre, randomised controlled, open blinded endpoint study 
Mean duration of follow-up: 53 months 
Participants N: 10,881 
Mean baseline BP: supine 173.4/105.7 mmHg 
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Method for BP measurement: BP was measured in a standard way on at least 2 occasions with 
the patient resting for at least 1 minute. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: no; wash-out period: 1 week 
Intervention: CCB – diltiazem: 180 to 360 mg OD or conventional BP-lowering agents (DI or BB) or 
both 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added 
Primary outcomes: stroke, MI, and other CV death 
Secondary endpoints: total mortality and development or deterioration of CHD, CHF, AF, TIA, 
T2DM and RF. 
 
Oparil 1998(350)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 432 
Mean baseline BP: seated 155/101 mmHg 
Method for BP measurement: BP was measured with a mercury sphygmomanometer after the 
patient had rested for 10 minutes. 3 measurements were taken at least 1 minute apart. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 3 weeks; wash-out period: no 
Intervention: ARB - losartan: 50 to 100 mg OD or ARB - irbesartan: 150 to 300 mg OD  
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added 
(hydrochlorothiazide) 
Primary outcomes: drug efficacy, safety, and tolerability 
 
Os 1997(351)  
Multicentre, randomised controlled, triple-blind study 
Mean duration of follow-up: 3 months 
Participants N: 374  
Mean baseline BP: seated 159.5/102.6 mmHg 
Method for BP measurement: BP (Korotkoff phase V) was measured using a standard mercury 
sphygmomanometer after the patient rested in a sitting position for 5 minutes in triplicate with 1 
minute between the measurements 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: no 
Intervention: ACEI + DI - enalapril + hydrochlorothiazide: 20 mg OD + 6 mg OD or BB – atenolol: 50 
mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and tolerability 
 
Papademetriou 1997(352)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 6 months 
Participants N: 159 
Mean baseline BP: seated 159.5/101 mmHg 
Method for BP measurement: according to AHA guidelines 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: LVH 
Pre-intervention: placebo run-in period: 2 weeks; wash-out period: no 
Intervention: CCB – isradipine: 2.5 to 10 mg BID or DI – hydrochlorothiazide: 25 to 50 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: LVM and wall thickness 
 
Pareek 2010(353)  
Multicentre, randomised controlled, double-blind study 
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Mean duration of follow-up: 3 months 
Participants N: 148 
Mean baseline BP: seated 160.2/99.4 mmHg 
Method for BP measurement: BP measurements were taken after 10 minutes of rest in duplicate 
separated by 2 minutes, with the average measurement being taken 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no  
Pre-intervention: Placebo run-in period: 1 week; wash-out period: no 
Intervention: ARB + CCB - losartan + amlodipine: 25 to 50 mg OD + 2.5 to 5 mg OD or BB + CCB - 
metoprolol + amlodipine: 25 to 50 mg OD + 2.5 to 5 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and tolerability 
 
PATS 1995(354); Post-stroke Antihypertensive Treatment Study   
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 36 months 
Participants N: 5,665 
Mean baseline BP: seated 154/93 mmHg 
Method for BP measurement: BP (phase V DBP) was measured and repeated after a 5-minute rest 
in a sitting position. The mean of the 4 readings of sitting BP was taken as the baseline BP. 
Hypertensive patients (%): 84% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: history of CVE 
Pre-intervention: Placebo run-in period: 2 weeks; wash-out period: no 
Intervention: DI – indapamide: 2.5 mg OD or P - placebo 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: mortality, stroke, CHD, and BP 
 
PRESERVE 2001(355); Prospective Randomized Enalapril Study Evaluating Regression of 
Ventricular Enlargement  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 12 months 
Participants N: 303 
Mean baseline BP: seated 171.5/97.9 mmHg 
Method for BP measurement: BP was measured in a standard way on at least 2 occasions with 
the patient resting for at least 1 minute. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: ≥1 weeks; wash-out period: no 
Intervention: ACEI – enalapril: 10 to 20 mg OD or CCB – nifedipine: 30 to 60 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added 
(Hydrochlorothiazide and Atenolol) 
Primary outcomes: LVH and diastolic filling in HTN 
 
RACE 1995(356); Ramipril Cardioprotective Evaluation  
Multicentre, randomised controlled, open blinded endpoint study 
Mean duration of follow-up: 6 months 
Participants N: 193 
Mean baseline BP: seated 163.7/103.2 mmHg 
Method for BP measurement: 3 BP measurements (Korotkoff phase V for DBP) were taken using a 
mercury sphygmomanometer after 10 minutes of sitting, and the average value was recorded 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: LVH 
Pre-intervention: placebo run-in period: 2 weeks; wash-out period: 4 weeks 
Intervention: ACEI – ramipril: 2.5 to 5 mg OD or BB – atenolol: 50 to 100 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added (furosemide 
or hydrochlorothiazide) 
Primary outcomes: LVM 
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Radauceanu 2004(357)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 246 
Mean baseline BP: seated 156.3/99 mmHg 
Method for BP measurement: according to WHO guidelines 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: no 
Intervention: ARB – valsartan: 40 to 80 mg OD or CCB – amlodipine: 5 to 10 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
 
REGAAL 2002(358); Losartan Left Ventricular Hypertrophy Regression 
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 9 months 
Participants N: 225 
Mean baseline BP: seated 148.5/98.5 mmHg 
Method for BP measurement: SBP and DBP were measured using a standard mercury 
sphygmomanometer after 5 minutes of rest. The means of 3 consecutive measurements at 2 to 3-
minute intervals were used. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: LVH 
Pre-intervention: placebo run-in period: 2 to 4 weeks; wash-out period: no 
Intervention: ARB – losartan: 50 to 100 mg OD or BB – atenolol: 50 to 100 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added 
(hydrochlorothiazide) 
 Primary outcomes: changes in LVM index and sitting BP after treatment  
 
REZALT 2009(359)   
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 867 
Mean baseline BP: seated 154.2/97.3 mmHg 
Method for BP measurement: BP was measured using a mercury sphygmomanometer. BP was 
measured 3 times at 1 or 2-min intervals; the mean value of these 3 measurements was used. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: no 
Intervention: ARB – olmesartan: 20 mg OD or CCB – azelnidipine: 16 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
 
Ruilope 2001(360)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 334 
Mean baseline BP: seated 175.5/74.5 mmHg 
Method for BP measurement: BP was measured using a mercury sphygmomanometer after the 
patient had been sitting for at least 5 minutes. BP was measured 3 times at intervals of 
approximately 2 minutes, and the readings were averaged. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 3 to 4 weeks; wash-out period: no 
Intervention: ACEI – enalapril: 5 to 20 mg OD or ARB – eprosartan: 600 to 800 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
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SHELL 2003(361); Systolic Hypertension in the Elderly Long-term Lacidipine  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 60 months 
Participants N: 1,882 
Mean baseline BP: seated 178.1/86.8 mmHg 
Method for BP measurement: BP values were based on the average of 3 sphygmomanometric 
measurements obtained after 5 minutes of rest. The SBP corresponded to Korotkoff phase I and 
the DBP corresponded at Korotkoff phase V. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: no; wash-out period: 15 days 
Intervention: CCB – lacidipine: 4 mg OD or DI – chlorthalidone: 12.5 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added (fosinopril or 
any ACEIs) 
Primary outcomes: composite of CV and CVE including stroke, sudden death, MI, and CHF 
 
Stimpel 1997(362)   
Single-centre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 140 
Mean baseline BP: seated 161.2/101.6 mmHg 
Method for BP measurement: the mean of 3 sitting readings taken 1 minute apart was used 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: no 
Intervention: ACEI + DI - moexipril + hydrochlorothiazide: 7.5 mg OD + 12.5 mg OD or BB + DI - 
metoprolol + hydrochlorothiazide: 100 mg OD + 12.5 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
 
Syst-Eur 1997(363;364); Systolic Hypertension in Europe  
Multicentre, randomised controlled, triple-blind study 
Mean duration of follow-up: 29 months 
Participants N: 4,695 
Mean baseline BP: seated 173.8/85.5 mmHg 
Method for BP measurement: according to BHS guidelines 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 12 weeks; wash-out period: no 
Intervention: CCB – nitrendipine: 10 mg OD or BID, 20 mg BID, or P - placebo 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added (enalapril 
and hydrochlorothiazide) 
Primary outcomes: mortality, stroke, CHD, CHF, and BP 
 
UKPDS 1998(365;366); United Kingdom Prospective Diabetes Study 
Multicentre, randomised controlled, open-label study 
Mean duration of follow-up: 100 months 
Participants N: 1,148 
Mean baseline BP: seated 159/93 mmHg 
Method for BP measurement: BP was measured in a standard way at least 2 times with the 
patient resting for at least 5 minutes 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: smoking 
Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: ACEI – captopril: 25 to 50 mg BID or BB – atenolol: 50 to 100 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added (frusemide, 
nifedipine, methyldopa, or prazosin); if possible, ACEIs and BBs were avoided 
Primary outcomes: mortality, stroke, CHD and CHF, SBP and DBP 
  100 
 
 
Value 2004(367;368); Valsartan Antihypertensive Long-term Use Evaluation  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 50 months 
Participants N: 15,245 
Mean baseline BP: seated 154.6/87.5 mmHg 
Method for BP measurement: BP was recorded in a standard way at least 2 times after patients 
had been seated for 5 minutes 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: smoking, hyperlipidaemia, T2DM, LVH, mild to moderate CKD 
Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: ARB – valsartan: 80 -160 mg OD or CCB – amlodipine: 5-10 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added (excluding 
ARBs) 
Primary outcomes: time to first CV event; incidence of MI, HF and stroke; all-cause mortality; 
and new-onset diabetes  
 
VHAS 1998(47;369)   
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 48 months 
Participants N: 1,414 
Mean baseline BP: seated 167.6/102.3 mmHg 
Method for BP measurement: BP measurements were obtained at each visit from the same arm 
using Korotkoff phases I and V for the SBP and DBP, respectively. Before the assessment the 
patient was asked to rest seated for a minimum of 10 minutes. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 3 weeks; wash-out period: no 
Intervention: CCB – verapamil: 240 mg SR OD or DI – chlorthalidone: 25 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added (including 
captopril) 
Primary outcomes: BP reduction, heart rate, clinical safety, CV events, deaths, and IMT 
 
Volpe 2003(370)  
Multicentre, randomised controlled, open blinded endpoint study 
Mean duration of follow-up: 4.2 months 
Participants N: 857 
Mean baseline BP: seated 171.7/82.5 mmHg 
Method for BP measurement: according to AHA guidelines 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 4 weeks; wash-out period: no 
Intervention: ARB – losartan: 50 to 100 mg OD or CCB – amlodipine: 5 to 10 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added 
(hydrochlorothiazide) 
Primary outcomes: drug efficacy and tolerability 
 
Waeber 1999(371)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 3 months 
Participants N: 946 
Mean baseline BP: seated 157.6/101 mmHg 
Method for BP measurement; measurements were taken using a mercury sphygmomanometer in 
duplicate, with at least a 1-minute interval in between, to the nearest 2 mmHg. The mean of the 
2 readings was then calculated. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
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Pre-intervention: placebo run-in period: 4 weeks; wash-out period: no 
Intervention: ACEI – enalapril: 10 to 20 mg OD or CCB + BB - felodipine + metoprolol: 5 to 10 mg 
OD + 50 to 100 mg OD or P - placebo 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and tolerability 
 
Wu 2004(372)   
Multicentre, randomised controlled, open-label study 
Mean duration of follow-up: 3 months 
Participants N: 121 
Mean baseline BP: seated 153.2/99.2 mmHg 
Method for BP measurement: BP was measured using a mercury sphygmomanometer twice, 5 
minutes apart, and then the average was recorded 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: no; wash-out period: 2 weeks 
Intervention: ARB – losartan: 50 to 100 mg OD or CCB – amlodipine: 5 to 10 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and tolerability 
 
Yang 2015(373) 
Single-centre, randomised controlled, open-label study 
Mean duration of follow-up: 3 months 
Participants N: 180 
Mean baseline BP: seated 170/101.5 mmHg 
Method for BP measurement: BP measurements were taken 3 times using a mercury 
sphygmomanometer after the patient had rested for at least 5 minutes 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: no; wash-out period: no 
Intervention: ACEI – perindopril: 4 mg OD or CCB – lercanidipine: 10 mg OD 
Co-intervention: no other BP-lowering agents were added 
Primary outcomes: drug efficacy and safety 
 
Zanchetti 2001(374)  
Multicentre, randomised controlled, double-blind study 
Mean duration of follow-up: 12 months 
Participants N: 489 
Mean baseline BP: seated 158.1/101.3 mmHg 
Method for BP measurement: 3 measurements were taken using a standard sphygmomanometer 
at 2-minute intervals after 5 minutes of rest. SBP and DBP values corresponded to the phase I and 
phase V Korotkoff sounds, respectively. 
Hypertensive patients (%): 100% 
Type of hypertensive patients: previously treated and untreated 
Other co-morbid conditions: no 
Pre-intervention: placebo run-in period: 3 weeks; wash-out period: no 
Intervention: CCB – amlodipine: 5 to 10 mg OD or CCB – manidipine: 10 to 20 mg OD 
Co-intervention: if BP goal was not achieved, another BP-lowering agent was added (enalapril) 
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3.1.3 Discussion  
This chapter described the protocol for identifying the studies that would be 
useful for a systematic review of antihypertensive BP response. Most of the 
included studies were non-intentional BP-lowering studies; therefore, not all the 
desired BP data were available from each study. The baseline BP represented in 
the pooled population covered a wide range, from mild to moderate HTN, with 
the mean BP ranging from 145.3/80 mmHg (ACCOMPLISH 2004) to 181.5/99.6 mm 
Hg (HYVET pilot 2003), patients with a severe HTN (SBP 180 mmHg or higher or DBP 
110 mmHg or higher) were not included in the present analysis. Monotherapy was 
used as the first line of approach in the majority of studies, though most large key 
studies, such as ACCOMPLISH 2008; ASCOT-BPLA 2005; CONVINCE2003; INSIGHT 2000; 
NORDIL 2000, used combination therapy as the first line of approach. Despite the 
fact that 82 studies with a large number of participants comparing several classes 
of first-line BP-lowering agents were included, the number of studies for each of 
the sub-classes was limited. Therefore, data were insufficient for some 
comparisons. This was particularly the case for the dicarboxylate-containing ACEIs 
included, rendering the evidence for the sulfhydryl and phosphonate-containing 
ACEIs inadequate. The CCBs included were DHPs, rendering the evidence for non-
DHPs inadequate, while the DIs included were thiazide-like, rendering the 
evidence for thiazide and potassium sparing inadequate. 
Randomisation results can be challenging in relatively small sample size clinical 
studies (N < 100), resulting in an unequal number of participants among groups 
(375). Although RCTs that randomised at least 100 participants were included, 
sample size was another apparent difference between older and more recent 
RCTs. Most 1990s studies recruited a smaller numbers of participants, such as 
Alcocer 1995; Hegner 1997; Mimran 1998; Mroczek 1996, compared to more recent 
studies, which for the most part recruited larger numbers of participants, such as 
ALLHAT 2002; ASCOT-BPLA 2005; INVEST 2003; NORDIL 2000. 
 
Hypertensive patients usually attended the clinic every two to three months for 
follow-up and were seen by family medicine residents or senior family physicians 
(376). Therefore, in this review, BP response was measured for at least three 
months of active treatment and all subsequent BP measurements. 
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In general, imputation techniques include the formation of assumptions about 
unidentified statistics, and it is better to avoid using them as much as 
possible. However, SD imputation helps us to include more available studies and 
it could potentially improve the generalizeability of results. The simplest 
imputation is of a specific value borrowed from one or more other studies (such 
as Cushman 1998 imputed from MIDAS 1996 and Stimpel 1997 imputed from BLACK 2001). 
Imputing SDs either from other studies in the same meta-analysis, or from studies 
in another meta-analysis, produced almost correct results in two case studies 
(377). In addition, if more than a few candidate SDs are available, review authors 
would have to decide which one to use.  
3.1.3.1 HTN definition, measurement and co-morbidity 
The review included RCTs in which BP-lowering agents were studied in cohorts of 
hypertensive patients, and, in a wider approach, in cohorts in which at least a 
consistent proportion of hypertensive patients were present (defined as > 70 %), 
regardless of other comorbidities. Overall, only five studies (CONVINCE 2003 (80%); 
DETAIL 2004 (81%); IDNT 2001 (76%); NICS-EH 1999 (> 70 %); PATS 1995 (84%)) included 
non-hypertensive patients, so the analysis mainly focused on hypertensive 
patients.  
 
Accurate measurement of BP is essential to classify individuals, to determine BP –
related risk and to guide management. The auscultatory or oscillometric 
techniques, with a trained observer and sphygmomanometer, continue to be the 
method of choice for measurement in the clinic, using the I and V phases of the 
Korotkoff sounds (378). Following standard protocols, including multiple 
measurements, relaxed environment and positioning of the patient, is a ground 
rule when it comes to measuring BP. One of the strengths of this review was that 
methods of measuring BP were reviewed in as much detail as possible in order to 
make certain that they adhered to standard practice.  
BP measurement is most commonly made in either the sitting or the supine 
position, both of which yield different results. Almost all studies reviewed used 
the sitting position; the supine position appeared in only a few studies (Alcocer 
1995; Benetos 2000; Chanudet 2008; Freytag 2001; James 2002; Mallion 2000; NORDIL 2000), 
while JMIC-B 2004 alone made use of both postures. It is generally accepted that 
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DBP measured while sitting is higher than when measured supine (by ≈ 5 mm Hg), 
though there is less agreement about SBP. When the arm position is exactly 
adjusted so that the cuff is at the level of the right atrium in both positions, the 
SBP has been reported to be 8 mm Hg 95% CI [ 4,11] higher in the supine than in 
the upright position (379). 
In the present review, the patients who enrolled included those with HTN and 
T2DM, CHD, CKD or other conditions. It was not possible to investigate the effect 
of these subgroup populations on the effect size due to the small number of 
studies in each subgroup. 
Worldwide, an estimated 422 million adults are living with T2DM, according to the 
latest 2016 data from the WHO (380). T2DM and HTN are known to coexist in 
patients, as there is a strong correlation between exacerbation of both conditions 
and changing lifestyle factors. HTN affects about 70% of patients with T2DM and 
is about twice as common in persons with diabetes as in those without (381). 
 In the current review, T2DM was the most commonly recorded comorbidity, as it 
was identified in 12 studies (ACCOMPLISH 2008; ASCOT-BPLA 2005; CASE-J 2008; 
CONVINCE 2003; DETAIL 2004; ELSA 2002; FACET 1998; Holsgreve 2003; IDNT 2001; Luque 
2005; Mancia2000; VALUE 2004). HTN, in patients with T2DM, causes a major increase 
in the risk of vascular complications in kidneys (382), and together both conditions 
are predisposed to heightening the chance of contracting CKD. Worldwide, an 
estimated 200 million people have CKD and the burden of CKD continues to 
increase(383). CKD was identified in six studies (AASK 2002; ACCOMPLISH 2008; 
ASCOT-BPLA 2005; CASE-J 2008; INSIGHT 2000; VALUE 2004).  
T2DM is an independent risk factor for CHD, and the risk is markedly increased 
when HTN is present (384). Worldwide, an estimated 7.4 million people died from 
CHD and the overlap between HTN and T2DM also considerably enhances the risk 
of suffering from CHD (385). CHD was identified in nine studies  (ACCOMPLISH 2008; 
ALLHAT 2002; ASCOT-BPLA 2005; CASE-J 2008; CONVINCE 2003; ELSA 2002; INSIGHT 2000; 
INVEST 2003; JMIC-B 2004).  
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3.1.3.2 Treatment status, strategy and agents 
In general, due to increased population awareness and the availability of effective 
treatment options provided by general practitioners, for instance, individuals have 
become more conscious of their health status and once diagnosed, they have 
received treatments. Accordingly, only five studies (Derosa 2014; ELVERA 2004; 
Freytag 2001; Holsgreve 2003; Mallion 2007) stated that untreated hypertensives were 
their study population, while the majority of studies included either previously 
treated patients or both treated and untreated participants. However, the levels 
of awareness of HTN remain low, with rates of adequate BP-lowering treatment 
and control lower still, as only 46.5% of participants with HTN were aware of the 
diagnosis and BP was controlled in 32.5% of those being treated (386). 
The right choice of initial BP–lowering agents can quickly establish the benefits of 
BP control and increase drug adherence. In clinical practice, many factors 
contribute to inadequate BP control, the most important of which include: failure 
to prescribe lifestyle modifications, patient non-compliance, inadequate BP-
lowering drug doses or inappropriate drug combinations; in addition, it is difficult 
to achieve adequate BP control with monotherapy in most patients, even when 
the dose is optimised (16).Physicians are often hesitant to increase the prescribed 
dosages or add another group of agents to the management plan. They rely 
excessively on the monotherapy approach, which usually leads to inadequate 
control of BP and failure to find the ideal dosage regimen for their patients. 
International guidelines provide a number of consistent recommendations on the 
choice of agent; for example, RAAS inhibitors and CCBs, which are used in both 
monotherapy and combination therapy, are emphasised favourably in the NICE 
(14), ESH/ESC (15), JNC (16) as well as Chinese Hypertension League (CHL) (387) 
guidelines. 
 
Nevertheless, monotherapy was used as the first line of approach in the majority 
of studies in the current review; it is still the case that choosing an effective 
monotherapy, which can be continued as part of a preferred combination regimen, 
may be beneficial. For instance, the VALUE 2004 study demonstrated that a CCB 
(amlodipine)-based regimen yielded a more concrete BP reduction, especially in 
the early stages of treatment (SBP/DBP in the amlodipine group was 4.0/2.1 mm 
Hg lower than in the ARB (valsartan)-based regimens at 1 month and 3.6 /2.2 mm 
  106 
 
Hg lower at 2 months), and was associated with a lower incidence of MI and stroke 
over the course of the study (mean follow-up of 50 months). However, both 
regimes were similar in terms of the primary outcome of composite cardiac 
mortality and morbidity (367). 
 
In contrast, studies have shown that combination therapy provokes a superior BP 
response in comparison to the up titration of monotherapy. ESH/ESC guidelines 
reinforce the significance of initiating combination therapy in high-risk patients 
and those with markedly high baseline BP, with SBP/DBP > 15–20/> 10 mmHg above 
the target (15). Combination therapy was used in a number of studies 
(ACCOMPLISH 2008; ASCOT-BPLA 2005; Benetos 2000; Chanudet 2001; CONVINCE 2003; 
Cremonesi 2002; Holsgreve 2003; INSIGHT 2000; Mallion 2000; McInnes 2000; NORDIL 2000; 
Os 1997; Pareek 2010; Stimpel 1997; Waeber 1999) as the first line of approach. For 
example, ACCOMPLISH 2008 was the only large study to directly compare RAAS 
blockade in combination with either a CCB or DI, and demonstrated the benefit of 
an amlodipine-benazepril combination over hydrochlorothiazide-benazepril 
regimen in reducing BP (mean difference between the two groups was 0.9 mm Hg 
systolic and 1.1 mm Hg diastolic (P<0.001 for both SBP and DBP) and CV events in 
high-risk patients with HTN (282).  
 
ACEIs and ARBs, which were used in this review 23.2% and 21.2% of studies 
respectively, have been used in many clinical studies. ARBs were introduced after 
ACEs with the expected profile of having the benefits of ACEI but without causing 
a cough (388). A number of meta-analyses have been done to compare the clinical 
benefits of these two agents in blocking the RAAS system. These meta-analyses 
have created some arguments regarding the possible superiority of ACEIs over ARBs 
in reducing total CV mortality and on the effect of ARBs on the incidence of MI 
(389;390). However, in a more recent meta-analysis, RAAS blockade was 
associated with a significant reduction in total CV mortality over control 
treatments, whereas a significant decrease in all-cause mortality was only found 
in patients receiving an ACEI and not in those being administered an ARB; the 
difference between ARBs and ACEIs was statistically significant (P=0.03) (391).  
In addition, the study ONTARGET2008, which compared ACEI-ramipril to ARB-
telmisartan in high CV risk patients of whom a large proportion were hypertensive, 
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found that there was no significant difference between the ACEI and the ARB in 
terms of total or CV mortality (254). However, the tolerability profile of ACEI 
therapy was an important determinant of the discontinuation rate in treated 
hypertensive patients. In spite of the above, data from recently published studies 
that have used ACEI as a first-line treatment, or included it in combination 
therapy, have shown the beneficial effect of ACEI therapy on the development 
and progression of macro- and microvascular complications in T2DM. A number of 
the studies went further in suggesting that ACEI-based BP-lowering regimens may 
be superior to non-ACEI-based treatments in decreasing the risk of macrovascular 
disease, such as the Appropriate Blood Pressure Control in Diabetes study, ABCD 
1998 (392), the CAPPP 1999 (193) and FACET 1998 (309), or both micro- and 
macrovascular complications in T2DM, such HOPE 2000 (230). 
Enalapril, which was used 31.10% in the review, was developed partly to overcome 
limitations of captopril ( e.g. rash, taste disturbance and proteinuria)  (393). 
However, when hypertensive patients were allocated at random to treatment with 
the ACEI-enalapril or the ARB-losartan, both approaches led to similar clinical BP 
reductions, although enalapril appeared to be more effective at peak (394). It 
significantly reduced BP, as it “normalised < 90 mm Hg' BP” in 88%, 50% and 25% 
of patients with mild DBP (90-104 mmHg), moderate DBP (105-120 mmHg) and 
severe DBP (> 120 mmHg) and HTN respectively. Comparison with BB-atenolol 
revealed an almost parallel efficacy of the two drugs, although enalapril produced 
a significantly greater reduction in SBP in patients with mild and moderate HTN 
(for all, P < 0.01) (395). Both treatments with the ARB-irbesartan and the ACEI-
enalapril significantly lowered BP (P < 0.05), though there was no significant 
difference in efficacy between treatment groups. The incidence of cough in the 
enalapril and Irbesartan groups was 17% and 10% respectively (for all, P > 0.05) 
(344). 
 
Losartan, which was used 30.8% of studies in the review, was the first selective 
ARB agent to be introduced (396).It has been shown to decrease SBP in patients 
with less severe ISH (SBP range 140-200 mmHg), compared with placebos, and in 
patients with more severe ISH (SBP range 160-205 mmHg), compared with 
Atenolol. In addition, losartan was highly effective and well tolerated in both 
studies (397;398).  
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CCBs, which were used 27.30% of studies in the review, constitute a class of 
structurally heterogeneous drugs (DHPs and non-DHPs). Although they share a 
common feature of inhibiting the cellular entry of calcium through voltage-
dependent L- and T-type calcium channels, significant differences exist between 
various CCBs with regard to their binding sites and chemical structure. DHP-CCBs 
are the most frequently prescribed CCBs for HTN and the only class of BP-lowering 
agents with no compelling contraindications. However, they may not be preferred 
in patients with peripheral oedema or heart conditions (rapid heart rate, low 
ejection fraction) (15). Whereas non-DHPs (verapamil and diltiazem) may be used 
when patients suffer unacceptable side effects with DHP-CCBs, their evidence for 
use in HTN is almost nonexistent, so hereafter, only DHPs will be considered. 
DHP-CCBs may well be the preferred drug class in many BP-lowering combination 
strategies in large RCTs (with ACEIs, ARBs and DIs) (15). For example, ASCOT-BPLA 
2005 showed that a CCB–ACEI combination (amlodipine-based) lowered BP by an 
average of 2.7/1.9 mm Hg more than a BB–DI combination (atenolol-based) 
throughout the follow-up period. Significant reductions in a number of outcomes 
(all-cause mortality, nonfatal MI and new-onset T2DM) were noted with CCB–ACEI, 
compared to BB–DI. In addition, by the end of the study, only 15% and 9% of 
participants were taking amlodipine or atenolol monotherapy respectively, 
providing additional evidence for the inadequacy of monotherapy in BP control. In 
addition, there was a lower visit-to-visit BP variability with the CCB-ACEI 
combination as opposed to the BB-DI combination (399). 
Amlodipine, which was used 38.5% of studies in the review, has been commonly 
used in many large clinical studies such as ALLHAT 2002, ASCOT-BPLA 2005 or VALUE 
2004, and it was at least as effective, if not slightly superior, in lowering BP. 
Amlodipine was, at times, more effective in preventing target organ damage than 
BP-lowering strategies that were based on the use of DI, BB and RAAS inhibitors 
(48;51;367).  
Since one of the main clinical side effects of the first and second generation DHP 
CCBs (including amlodipine) is the peripheral oedema, a number of studies have 
demonstrated a reduced incidence of peripheral oedema with the use of these 
new CCBs. For example, such occurrences can be reduced by almost 50% in 
patients who developed oedema with the CCB-amlodipine and were switched to 
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the CCB-lercanidipine (400). In the same way, peripheral oedema occurred in 19% 
of patients treated with amlodipine but only in 9% and 4% of patients receiving, 
respectively, lercanidipine and lacidipine (401). The incidence of leg oedema can 
be significantly decreased through combining the CCB with RAAS inhibitors. This 
strategy has recently led to the development of several fixed-dose combinations 
of amlodipine and RAAS inhibitors (402).  
The argument on whether DIs are the first-choice drug, as recommended by the 
JNC-7 Report, or are just one of the first-choice agents, as recommended by the 
ESH-ESC guidelines, is mainly based on different analyses of RCTs and drug cost 
considerations(15;16). Clinical studies have clearly highlighted the advantage of 
DIs, either as a monotherapy or in combination with BB, in reducing CV morbidity 
and mortality; a benefit comparable to that accomplished with other BP-lowering 
agents, such as ACEIs and CCBs (403).  
DIs, which were used 8.10% of studies in the review, can be subdivided into three 
subclasses: thiazide (e.g., hydrochlorothiazide), thiazide-like (chlorthalidone) and 
potassium sparing (e.g., spironolactone)6. DIs are an essential part of BP therapy, 
and their effectiveness remains unquestioned; however, they have negative 
effects on patients’ metabolic profiles.  
For instance, the data obtained with the DI-chlorthalidone to date indicates that 
the plateau of the dose-response BP-lowering curve is reached with a daily dose 
of 25 mg and that increasing the dosage does not improve the BP-lowering effect; 
however, it does increase the incidence of negative metabolic effects, mainly 
hypokalaemia (404). In addition, the DI- hydrochlorothiazide was associated with 
increased insulin resistance and the risk of gout. Hydrochlorothiazide also 
increases the hepatic triglycerides level (405;406).  
ALPINE 2003 showed that treatment with hydrochlorothiazide is often associated 
with BB-atenolol-impaired glucose metabolism, while treatment with ARB-
candesartan is often linked to CCB-felodipine and is neutral (286). In the same 
way, VALUE 2004, which showed a greater incidence of new onset T2DM in the CCB-
                                         
6
  Potassium-sparing DIs such as (spironolactone and triamterene) were not used in this review. 
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amlodipine arm, can be tentatively explained by the greater occurrence of 
hypokalaemia induced by the association of hydrochlorothiazide (367). 
However, a meta-analysis of randomised studies, in which one arm was based on 
either hydrochlorothiazide or chlorthalidone, reported that the latter was more 
effective than the former in preventing CV events in hypertensive patients (407). 
In most countries, thiazide and thiazide-like DIs are the cheapest BP-lowering 
agents available and the backbone of BP-lowering pharmacotherapy. 
Consequently, DIs such as chlorthalidone, which was used 30% in the review, are 
less expensive than newer types of BP-lowering agents and are preferred in terms 
of cost minimisation (408).  
 
BBs had been used for the management of HTN for several decades. Along with 
DIs, they were the mainstay of antihypertensive management for many years. BBs, 
which were used 13.60% in the review, has been questioned as a first-line therapy 
in the management of hypertensive patients in some guidelines, due to their lower 
ability to prevent stroke and other CV events, in addition to their adverse impacts 
on glucose metabolism(14;16).They have been subjected to comprehensive 
research and their performance was frequently compared with other BP-lowering 
agents .The review of the evidence provided confirms that there are convincing 
reasons to question the usefulness of certain BBs in treating HTN. However, 
evidence suggests that there are essential differences among BB classes (409). 
Overall, the answer to the question of BBs’ effectiveness lies not in worldwide 
generalisations, but in assessing individual patients and specific BB agents.  
Atenolol, which was used 64% of studies in the review, has been studied as a 
monotherapy or in comination with other agent in many clinical studies. For 
instance, a meta-analysis of clinical studies comparing the main BP-lowering 
agents (AECIs, ARBs, CCBs, DIs and BBs (mainly atenolol) showed that ARBs were 
superior to BBs in reducing all-cause mortality, HF and T2DM incidence; in 
addition, DIs were better than BBs in reducing all-cause mortality, MI, stroke and 
HF. BBs were also inferior to ACEIs and CCBs for all-cause mortality, MI and stroke 
(410). Another meta-analysis of RCTs that evaluated BBs, mainly atenolol, for 
HTN, showed that BB-associated reduction in heart rate increased the risk of CV 
events and death for hypertensive patients (P < 0.0001) (411). However, BB studies 
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included in these two meta-analyses were carried out mainly on atenolol, which 
may not be representative of all BBs.  
Only 13 studies used a placebo in one of their treatment arms (Black 1997; BLACK 
2001; Cushman 1998; Giles 2007; Grethouse 2010; Guthrie 1998; Hanefeld 2001; HYVET 2008; 
IDNT 2001; Mroczek 1996; PATS 1995; SYST-EUR 1997; Waeber 1999). This could be 
explained by the fact that the use of placebos is nowadays considered unethical, 
due to the possibility of exposing participants to harm by receiving a placebo 
instead of an active treatment, since not receiving an active treatment can 
aggravate their conditions or even pose the risk of death (412). 
In recent times, traditional placebo-controlled designs can be modified so as to 
study both the placebo response and the response to the active treatment, in 
order to avoid the event of some in-study patients being left untreated. This kind 
of study is called a crossover study, since patients in the study cross over, at 
predetermined time points, from the placebo to the treatment arm and vice versa. 
An alternative option is the ‘add on’ design, in which both groups receive the 
standard treatment as well as either the studied treatment or the placebo (413).
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3.2 Risk of bias in included studies  
While studies with a small sample were excluded from the review, the majority 
of those included were large and multicentre studies with standardised protocols. 
All these studies were stated to be RCTs, (see ‘Methodological quality of included 
studies’, Section 3.2.1)   
As shown in Figure 3.2, all included studies reported randomisation, although 
most did not mention the sequence generation process or method of allocation 




Figure 3.2 Risk of bias graph: review authors' judgements about each risk of bias item, 





Random sequence generation was adequate in 30 studies (AASK 2002; ACCOMPLISH 
2008; Alcocer 1995; ALLHAT 2002; ASCOT-BPLA 2005; CASE-J 2008; CONVINCE 2003; 
Derosa 2013; Derosa 2014; ELSA 2002; FACET 1998; Fogari 2008; Holsgreve 2003; HYVET 
2008; HYVET–P 2003; IDNT 2001; INVEST 2003; James 2002 ; JMIC-B 2004; LAARS 2002; LIFE 
2002; McInnes 2000; MIDAS 1996 ; Mounier-Vehier 1998; PATS 1995; RACE 1995; SHELL 2003; 
SYST-EUR 1997; UKPDS 1998; VALUE 2004) and unclear in the remaining 52 studies. 
Allocation concealment was adequate in 18 studies (ACCOMPLISH 2008; ALLHAT 
2002; ASCOT-BPLA 2005; CONVINCE 2003; Derosa 2013; Derosa 2014; Fogari 2008; HYVET 
2008; IDNT 2001; INVEST 2003; JMIC-B 2004; LAARS 2002; McInnes 2000; Mounier-Vehier 
1998; PATS 1995; RACE 1995; SYST-EUR 1997; UKPDS 1998), whereas in the other 64 
studies the information provided was insufficient to assess this aspect of bias 
risk and was considered unclear. 
A computer-generated code for randomisation was used in 24 studies 
(ACCOMPLISH 2008; ALLHAT 2002; ASCOT-BPLA 2005; CASE-J 2008; Derosa 2013; Derosa 
2014; ELSA 2002; FACET 1998; Fogari 2008; Holsgreve 2003; HYVET–P 2003; IDNT 2001; 
INVEST 2003; James 2002; JMIC-B 2004; LAARS 2002; LIFE 2002; McInnes 2000; Mounier-
Vehier 1998; PATS 1995; RACE 1995; SYST-EUR 1997; UKPDS 1998; VALUE 2004). In 
addition, 12 studies (ACCOMPLISH 2008; ALLHAT 2002; ASCOT-BPLA 2005; Derosa 2013; 
Fogari 2008; IDNT 2001; INVEST 2003; LAARS 2002; McInnes 2000; Mounier-Vehier 1998; 
RACE 1995; SYST-EUR 1997) stated that their randomisation codes were concealed 
at the clinical studies centre, while two (CONVINCE 2003 and HYVET 2008) used an 
Interactive Voice Response System (IVRS) for randomising, assigning and tracking 
blinded medication. 
 
The majority of studies reported a double-blind design, and blinded active drugs 
were described as of identical appearance in some studies; however, it was still 
impossible to know the extent of blinding. Therefore, they were considered to 
have a low risk of performance bias. The method of blinding was not mentioned 
in six studies (LOTHAR 2006; Pareek 2010; SHELL 2003; VHAS 1998; Wu 2004; Yang 2015) 
and performance bias was considered unclear. There was a high risk of 
performance bias in 13 open-label studies (ASCOT-BPLA 2005; CASE-J 2008; 
CONVINCE 2003; Cremonesi 2002; FACET 1998; Fogari 2008; Holzgreve 2003; HYVET 2008; 
HYVET–P 2003; INVEST 2003; Mounier-Vehier 1998; NORDIL 2000; UKPDS 1998). 
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An adequate blinding of outcome assessment was seen in most of the studies. 
However, it was unclear in eight studies (Bremner 1997; DETAIL 2004; LOTHAR 2006; 
Pareek 2010; SHELL 2003; VHAS 1998; Wu 2004; Yang 2015) whether blinding was broken 
prior to making the final decision to withdraw, as the method of binding was not 
described. In six studies (CASE-J 2008; Cremonesi 2002; FACET 1998; HYVET–P 2003; 
Mounier-Vehier 1998; UKPDS 1998) where drugs were administered as open label 
and outcome was not blindly assessed, a high risk of detection bias was 
considered. A PROBE design was instigated in five studies (ASCOT-BPLA 2005; 
CASE-J 2008; Fogari 2008; INVEST 2003; NORDIL 2000); this differed from the typical 
double-blind method. In a PROBE study, outcomes are evaluated by a blinded 
endpoint committee to avoid detection bias. 
 
In terms of incomplete outcome data, 33 studies (AASK 2002 ; Alcocer 1995; 
Bremner 1997; CASE-J 2008; Cremonesi 2002; Cushman 1998; DETAIL 2004; FACET 1998; 
Farsang 2007; Freytag 2001; Holsgreve 2003; HYVET 2008; HYVET–P 2003; IDNT 2001; 
JMIC-B 2004; LIFE 2002; Luque 2005; Mallion 2000; Mallion 2011; MIDAS 1996 ; Mroczek 
1996; Narkiewicz 2007; Nilsson 2007; NORDIL 2000; PATS 1995; PRESERVE 2001; 
Radauceanu 2004; REGAAL 2002; REZALT 2009; SHELL 2003; SYST-EUR 1997; VHAS 1998; 
Yang 2015) evidently accounted for all participants in each study arm, including 
those whose data was unavailable due to loss in follow-up, and they used ITT 
analysis. In these studies, the rate of discontinuation was generally low and 
equal between study arms. 
 
In total, nine studies and their patients were excluded after randomisation as a 
result of poor documentation of informed consent (ALLHAT 2002), data integrity 
concerns (ASCOT-BPLA 2005; CONVINCE 2003), missing outcome data (INVEST 2003; 
Mounier-Vehier 1998; UKPDS 1998; Volpe 2003) or misconduct (INSIGHT 2000; VALUE 
2004), however, adequate information in reports helped to restore those 
participants to the right groups and ITT analysis was performed.Furthermore, 
17 studies (ALPINE 2003; Benetos 2000; Black 1997; CROSS 2003; Derosa 2013; ELSA 2002; 
ELVERA 2004; Giles 2007; Grethouse 2010; Guthrie 1998; Hegner 1997; MAISH 2007; 
Mallion 2007; McInnes 2000; Ruilope 2001; Stimpel 1997; Zanchetti 2001) evidently did 
not account for participants if they did not receive a specific minimum amount 
of the intended intervention, even though they did use “modified ITT” analysis, 
and therefore considered them to have a low risk of attrition bias. 
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Meanwhile, seven studies (Chanudet 2001; ELLE 2003; Grassi 2003; Hanefeld 2001; 
NICS-EH 1999; Oparil 1998; Pareek 2010) did not evidently account for participants 
lost to follow-up, as they did use PP analysis, and therefore considered them to 
have a high risk of attrition bias. Added to this, 16 studies (ACCOMPLISH 2008; 
BLACK 2001; Derosa 2014; Fogari 2008; Hoegholm 1995; James 2002; LAARS 2002; LOTHAR 
2006; Mancia2000; MAPAVEL 2002; Mimran 1998; Os 1997; Papademetriou 1997; RACE 1995; 
Waeber 1999; Wu 2004) had an unclear risk of attrition bias, because it was 
uncertain whether the decision to withdraw participants for “uncontrolled BP” 
was pre-specified in the study’s protocol, and the BP threshold for such 
withdrawal was also undefined. 
 
For selective reporting, all studies reported all pre-specified outcomes, and 
therefore they have been judged as having a low risk of reporting bias. Other 
potential sources of bias came from the requirement to control high BP; a 
number of BP-lowering agents were added to randomly allocated treatment. 
Therefore, an unclear risk of this type of bias was judged for 13 studies (AASK 
2002; ACCOMPLISH 2008; ALLHAT 2002; CONVINCE 2003; FACET 1998; IDNT 2001; INSIGHT 
2000; INVEST 2003; LIFE 2002; NORDIL 2000; UKPDS 1998; VALUE 2004; VHAS 1998). 
 
Visual inspection of funnel plots for BP response (including delta, single measure 
and repeated measures), showed that almost all outliers were placebo 
controlled studies, as shown in appendix  Figure 6.1, Figure 6.2 and Figure 
6.3. However, other Possible sources of asymmetry in funnel plots were 
identified (see ‘Effect of intervention’, Section 4.3) accordingly sensitivity 
analysis was carried out to exclude biased studies. 
 
In the last part, according to the PRISMA summary assessment of the risk of bias, 
48 of the studies (AASK 2002; ACCOMPLISH 2008; Alcocer 1995; ALLHAT 2002; ALPINE 
2003; ASCOT-BPLA 2005; Benetos 2000; Black 1997; CROSS 2003; Cushman 1998; Derosa 
2013; Derosa 2014; ELSA 2002; ELVERA 2004; Farsang 2007; Freytag 2001; Giles 2007; 
Grethouse 2010; Guthrie 1998; Hegner 1997; HYVET 2008; IDNT 2001; James 2002; JMIC-
B 2004; LAARS 2002; LIFE 2002; Luque 2005; MAISH 2007; Mallion 2000; Mallion 2007; Mallion 
2011; McInnes 2000; MIDAS 1996 ; Mroczek 1996; Narkiewicz 2007; Nilsson 2007; PATS 1995; 
PRESERVE 2001; RACE 1995; Radauceanu 2004; REGAAL2002; REZALT 2009; Ruilope 2001; 
Stimpel 1997; SYST-EUR 1997; VALUE 2004; Volpe 2003 ; Zanchetti 2001) were rated as 
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high quality studies (that is, the majority of criteria were met, there was little 
or no risk of bias and the results were unlikely to be changed by further 
research). 
 
Furthermore, 34 (BLACK 2001; Bremner 1997; CASE-J 2008; Chanudet 2001; CONVINCE 
2003; Cremonesi 2002; DETAIL 2004; ELLE 2003; FACET 1998; Fogari 2008; Grassi 2003; 
Hanefeld 2001; Hoegholm 1995; Holsgreve 2003; HYVET–P 2003; INSIGHT 2000; INVEST 
2003; LOTHAR 2006; Mancia 2000; MAPAVEL 2002; Mimran 1998; Mounier-Vehier 1998; 
NICS-EH 1999; NORDIL 2000; Oparil 1998; Os 1997; Papademetriou 1997; Pareek 2010; 
SHELL 2003; UKPDS 1998; VHAS 1998; Waeber 1999; Wu 2004; Yang 2015) were rated as 
acceptable quality studies (that is, most criteria were met, there were some 
flaws in the study, with an associated risk of bias, and conclusions may change 
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3.2.1 Methodological quality of 
included studies (ordered 





Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
The randomisation was stratified by city 
using randomly permuted blocks 
Allocation concealment  
(selection bias) 
Unclear risk  
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk 
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Unclear risk 
A number of BP-lowering agents were added to 
randomly allocated treatment to control BP. The 
observed effects could equally have resulted 
from the different additional drugs 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Low risk Central randomisation 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Unclear risk 
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Unclear risk 
A number of BP-lowering agents were added to 
randomly allocated treatment to control BP. The 
observed effects could equally have resulted 






Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
The randomisation was stratified by centres using 
randomly permuted blocks 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
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Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk 
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 









Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Low risk 
Concealment scheme was implemented at the 
clinical trials centre and stratified by centre 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk 
Two centres initially reported were excluded, due 
poor documentation of informed consent. ITT 
analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Unclear risk 
A number of BP-lowering agents were added to 
randomly allocated treatment to control BP. The 
observed effects could equally have resulted from 
the different additional drugs 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk 
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including all randomised patients who had 
completed the study and had taken at least one 
dose of study drug 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 






Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Low risk Central randomisation 
Blinding of participants 
and personnel 
(performance bias) 
High risk Study drugs were administered open-label  
Blinding of outcome 
assessment (detection 
bias) 
Low risk A PROBE design was used. 
Incomplete outcome data 
(attrition bias) 
Low risk 
Two centres with 85 patients initially reported 
were excluded, due data integrity concerns. ITT 
analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk 
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including all randomly assigned patients who 
received at least one dose of the study 
medication, had one baseline BP measurement, 
and at least one subsequent BP measurement 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 









Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk 
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including all randomised patients with a baseline 
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measurement and at least one post treatment 
observation 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported. 
Other bias Low risk No other possible bias was found. 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Unclear risk 
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 




It is unclear whether blinding was broken prior to 
making final decision to withdraw 
Incomplete outcome data 
(attrition bias) 
Low risk 
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
High risk Participants and personnel were not blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk A PROBE design was used. 
Incomplete outcome data 
(attrition bias) 
Low risk 
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
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Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk Method of sequence generation was not described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
High risk 
Data of withdrawn patients were not included. PP 
analyses was used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
IVRS, for randomising, assigning, and tracking 
blinded medication was used 
Allocation concealment  
(selection bias) 
Low risk 
IVRS, for randomising, assigning, and tracking 
blinded medication was used 




A number of patients discontinued blinded 
medication (administered open-label) 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk 
Participants from two centres with 126 patients 
were excluded, due to data integrity concerns. 
ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Unclear risk 
A number of BP-lowering agents were added to 
randomly allocated treatment to control BP. The 
observed effects could equally have resulted 
from the different additional drugs 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
High risk Participants and personnel were not blinded 
Blinding of outcome 
assessment (detection 
bias) 
High risk Study drugs were administered open-label 
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Incomplete outcome data 
(attrition bias) 
Low risk 
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk 
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including all patients allocated randomly to 
groups, provided that they had received at least 
one dose of the study medication and had post- 
baseline data 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported. 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk 
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 
Derosa 2013  
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Randomization scheme was generated by 
computer 








Participants and personnel blinded 
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Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including patients who had received at least one 
dose of study medication and had a subsequent 
efficacy observation 
Selective reporting  
(reporting bias) 
Low risk Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 




Allocation concealment was done with 
envelopes containing randomisation codes 
prepared by statisticians 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Unclear risk 
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 




It is unclear whether blinding was broken prior to 
making final decision to withdraw 
Incomplete outcome data 
(attrition bias) 
Low risk 
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
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Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
High risk  
Data of withdrawn patients were not included. 
PP analyses was used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Not mentioned whether reasons for missing 
outcome data were similar between treatment 
groups. Modified ITT analysis was performed 
including all patients randomised to double blind 
medication who had the baseline ultrasound scan 
and at least one follow-up scan, including scans 
performed after withdrawal  
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including patients for whom there were valid 
readings at baseline and at least one valid 
observation after 1 and 2 years 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
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Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
High risk Study drugs were administered open-label 
Blinding of outcome 
assessment (detection 
bias) 
High risk Outcome assessment not blinded 
Incomplete outcome data  
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Unclear risk 
A number of BP-lowering agents were added to 
randomly allocated treatment to control BP. The 
observed effects could equally have resulted 
from the different additional drugs 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Low risk Central randomisation 
Blinding of participants 
and personnel 
(performance bias) 
High risk Study drugs were administered open-label 
Blinding of outcome 
assessment (detection 
bias) 
Low risk A PROBE design was used. 
Incomplete outcome data 
(attrition bias) 
Unclear risk  
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
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Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described. 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described. 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded. 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed. 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported. 
Other bias Low risk No other possible bias was found. 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including patients who received at least 1 dose 
of study drug and had a baseline BP 
measurement and at least one post baseline BP 
assessment 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
High risk  
Data of withdrawn patients were not included. 
PP analyses was used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
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Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including all randomised patients who received at 
least one dose of study medication.  
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including all randomised patients who had a 
baseline evaluation and at least one scheduled 
on-therapy evaluation 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
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Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
High risk  
Data of withdrawn patients were not included. 
PP analyses was used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including all randomised patients who had a 
baseline measurement and at least one post-
randomisation measurement for the variable to 
be analysed. 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Unclear risk  
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Unclear risk 
Allocation concealment was done with sealed 
envelopes containing the treatment was provided 
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to the investigator for each random number: two 
of them were opened during the study  
Blinding of participants 
and personnel 
(performance bias) 
High risk Two of study drugs were administered open-label  
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found. 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
IVRS, for randomising, assigning, and tracking 
blinded medication was used 
Allocation concealment  
(selection bias) 
Low risk 
IVRS, for randomising, assigning, and tracking 
blinded medication was used 




Open follow-up was an option if patients used 
additional BP-lowering agent for more than 12 
weeks 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found. 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
High risk Study drugs were administered open-label 
Blinding of outcome 
assessment (detection 
bias) 
High risk Outcome assessment not blinded 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Low risk Randomization was blocked by centres 
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Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Unclear risk 
A number of BP-lowering agents were added to 
randomly allocated treatment to control BP. The 
observed effects could equally have resulted 
from the different additional drugs 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Analysis excluded 254 patients after 
randomisation from centres withdrawn due 
misconduct. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section 
were all reported 
Other bias Un clear risk 
A number of BP-lowering agents were added to 
randomly allocated treatment to control BP. The 
observed effects could equally have resulted 
from the different additional drugs 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
An Internet-based management system 
automatically randomised each patient to a 
treatment strategy 
Allocation concealment  
(selection bias) 
Low risk Central randomisation 
Blinding of participants 
and personnel 
(performance bias) 
High risk Study drugs were administered open-label 
Blinding of outcome 
assessment (detection 
bias) 
Low risk A PROBE design was used. 
Incomplete outcome data 
(attrition bias) 
Low risk  
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Unclear risk 
A number of BP-lowering agents were added to 
randomly allocated treatment to control BP. The 
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observed effects could equally have resulted 
from the different additional drugs 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Unclear risk  
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 






Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer. 
Allocation concealment  
(selection bias) 
Low risk 
Allocation concealment was done with 
sealed envelope method. 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded. 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed. 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported. 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Low risk Central randomisation 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Unclear risk  
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 







Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Unclear risk 
A number of BP-lowering agents were added to 
randomly allocated treatment to control BP. The 
observed effects could equally have resulted 






Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk Method of blinding was not described 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk Method of blinding was not described 
Incomplete outcome data 
(attrition bias) 
Low risk  
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 






Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
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Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including patients who received at least 1 dose 
of study drug and who had at least one visit 
after baseline 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Not indicated whether reasons for missing 
outcome data were similar across treatment 
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groups. Modified ITT was performed including 
randomised patients who received at least one 
dose of trial medication and with at least one 
post randomisation value for the primary 
efficacy variable 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Unclear risk  
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
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Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Unclear risk  
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Low risk Central randomisation 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT was performed including all 
patients who took at least one dose of double-
blind medication and who had efficacy data 
available after randomisation 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
The randomisation was stratified by clinic using 
randomly permuted blocks 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described. 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described. 
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Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded. 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Unclear risk  
It is unclear whether an ITT or PP analysis was 
used. 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported. 
Other bias Low risk No other possible bias was found. 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer. 
Allocation concealment  
(selection bias) 
Low risk Central randomisation. 
Blinding of participants 
and personnel 
(performance bias) 
High risk Participants and personnel were not blinded. 
Blinding of outcome 
assessment (detection 
bias) 
High risk Study drugs were administered open-label. 
Incomplete outcome data 
(attrition bias) 
Low risk  
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. ITT analysis was performed excluding 
one patient whose DBP exceeded 120 mm Hg at 
the end of the washout period 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported. 
Other bias Low risk No other possible bias was found. 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
  137 
 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
High risk  
Data of withdrawn patients were not included. 
PP analyses was used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section 
were all reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed. 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
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Blinding of participants 
and personnel 
(performance bias) 
High risk Study drugs were administered open-label 
Blinding of outcome 
assessment (detection 
bias) 
Low risk A PROBE design was used. 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed. 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Unclear risk 
A number of BP-lowering agents were added to 
randomly allocated treatment to control BP. The 
observed effects could equally have resulted 
from the different additional drugs 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
High risk  
Data of withdrawn patients were not included. 
PP analyses was used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Unclear risk  
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
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Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Unclear risk  
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 






Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk Method of blinding was not described 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk Method of blinding was not described 
Incomplete outcome data 
(attrition bias) 
High risk  
Data of withdrawn patients were not included. 
PP analyses was used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 






Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Low risk 
Allocation concealment was done with 
sealed envelope supplied by the coordinating 
office 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 






Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
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Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Low risk Central randomisation 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Unclear risk  
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
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Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 
Ruilope 2001  
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) Unclear risk 
Method of sequence generation was not 
described. 
Allocation concealment  
(selection bias) Unclear risk 
Method of allocation concealment was not 
described. 
Blinding of participants and 
personnel (performance 
bias) 
Low risk Participants and personnel blinded. 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment. 
Incomplete outcome data  
(attrition bias) Low risk  
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including all randomised subjects with at least one 
valid on-therapy BP measurement 
Selective reporting  
(reporting bias) Low risk 
Outcomes listed in the methods section were all 
reported. 
Other bias Low risk No other possible bias was found. 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization was made by BETA trial 
centre, using a sequentially based criterion 
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Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk  Method of blinding was not described 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk Method of blinding was not described 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported. 
Other bias Low risk No other potential bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data  
(attrition bias) 
Low risk  
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including all randomised patients who had at 
least one baseline BP reading and one post 
baseline reading 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer. 
Allocation concealment  
(selection bias) 
Low risk 
Concealment scheme was implemented at the 
clinical trials centre and stratified by centre, sex 
and pervious cardiovascular complications 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 
UKPDS 1998  





Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Low risk 
Allocation concealment was done with 
opaque, sealed envelopes with a check 
maintained on numerical sequence, until 
dates of opening and results 
Blinding of participants 
and personnel 
(performance bias) 
High risk Study drugs were administered open-label 
Blinding of outcome 
assessment (detection 
bias) 
High risk Outcome assessment not blinded 
Incomplete outcome data 
(attrition bias) 
Low risk  
Not mentioned whether reasons for missing 
outcome data were similar between treatment 
groups. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Unclear risk 
A number of BP-lowering agents were added to 
randomly allocated treatment to control BP. The 
observed effects could equally have resulted 
from the different additional drugs 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Randomization scheme was generated by 
computer 
Allocation concealment  
(selection bias) 
Unclear risk Method of concealment was not described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
68 patients in 9 centres were excluded after 
randomisation due misconduct. ITT analysis was 
performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section 
were all reported 
Other bias Unclear risk A number of BP-lowering agents were added to 
randomly allocated treatment to control BP. The 
observed effects could equally have resulted 
from the different additional drugs 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk Method of blinding was not described 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk Method of blinding was not described 
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Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Unclear risk A number of BP-lowering agents were added to 
randomly allocated treatment to control BP. The 
observed effects could equally have resulted 






Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded. 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  
Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. ITT analysis was performed including 
population with any missing post-randomisation 
measurements estimated by carrying forward 
previous post- randomisation measurements 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported. 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants and personnel blinded 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blind outcome assessment 
Incomplete outcome data  
(attrition bias) 
Unclear risk  
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 






Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described 
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Blinding of participants 
and personnel 
(performance bias) 
Unclear risk Method of blinding was not described 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk Method of blinding was not described 
Incomplete outcome data 
(attrition bias) 
Unclear risk  
It is unclear whether an ITT or PP analysis was 
used 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported 
Other bias Low risk No other possible bias was found 
 




Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk 
Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk 
Method of allocation concealment was not 
described. 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk Method of blinding was not described 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk Method of blinding was not described 
Incomplete outcome data 
(attrition bias) 
Low risk  
Patients withdrawing from the study were 
accounted. ITT analysis was performed 
Selective reporting  
(reporting bias) 
Low risk 
Outcomes listed in the methods section were all 
reported. 





Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk Method of sequence generation was not 
described 
Allocation concealment  
(selection bias) 
Unclear risk Method of allocation concealment was not 
described 




Participants and personnel blinded 




Blind outcome assessment 
Incomplete outcome data 
(attrition bias) 
Low risk  Not indicated whether reasons for missing 
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including all randomly assigned patients who 
received at least one dose of the treatment drug 
and who had at least one visit after baseline 
Selective reporting  
(reporting bias) 
Low risk Outcomes listed in the methods section were all 
reported. 
Other bias Low risk No other possible bias was found 
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3.2.2 Discussion  
In a systematic review of published studies, there are multiple sources of biases 
that may lead to erroneous results and rigorous efforts required to protect against 
this. All included studies stated that they were RCTs; however, most studies did 
not address how treatment randomization occurred or how allocation of treatment 
was concealed, and, therefore, had an unclear risk of selection bias. All included 
studies also stated that they were double-blinded studies, but again, most did not 
describe how double blinding was ensured throughout the studies. Most of the 
studies were assessed as having a low risk of performance and detection bias. All 
efforts were made to reduce the risk of attrition bias by reporting all randomized 
participants in the analysis (ITT population) as much as possible. All of the studies 
had a low risk for reporting bias. One potential unclear source of bias was present 
in 13 of the 82 studies; mainly because a number of BP-lowering agents were 
added to randomly allocated treatment to control high BP. The overall quality was 
rated to be acceptable to high. Whereas 48 studies were rated to be high quality 
studies (as the majority of criteria were met and there was little or no risk of 
bias), 34 studies were rated as acceptable quality studies (as most criteria were 
met and there were some flaws in the study). 
  
RCTs are considered the gold standard for demonstrating treatment efficacy. The 
main goal of comparative clinical studies is to provide comparisons of treatments 
with maximum precision and validity. This is the critical component of clinical 
studies, since it helps remove the effect of extraneous variables (such as age and 
previous injury) and reduces the bias associated with treatment assignment (414). 
Generally, biases are often assumed and acknowledged in observational studies, 
and the statistical analysis and subsequent interpretation try to take those biases 
into account. However, studies labelled as randomised are frequently assumed to 
be free of bias, and it is common that inadequate reporting masks the deficiencies 
they might have. Therefore, researchers should ensure both adequate sequence 
generation and reliable allocation concealment in randomisation schemes. An 
error in either factor could compromise randomisation, leading to incorrect results 
(415).  
Randomisation is the process of assigning participants to treatment and control 
groups, assuming that each participant has an equal chance of being assigned to 
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any group and it depends mainly on two measures. Firstly, an allocation sequence 
that is appropriate to prevent selection bias must be generated (e.g. using a 
computer algorithm). Secondly, this sequence must be concealed from 
investigators enrolling patients (416). Proper randomisation, also known as 
allocation concealment, ensures no a priori knowledge of group assignment, as 
researchers are unaware of which group patients are allocated to at the time they 
enter the study. Knowledge of group assignment creates a level of possible 
selection bias that may affect the data. However, it is not uncommon for an 
adequate (i.e. randomized) allocation sequence to be inadequately concealed.   
Since all included studies were stated as being RCTs, a high risk of selection bias 
(sequence generation and allocation concealment) was excluded. Adequate (that 
is, described in sufficient detail) random sequencing and allocation concealment 
was conducted in 30 and 18 studies respectively. However, 11 meta-analyses that 
involved 127 RCTs on the efficacy of interventions showed that studies with 
inadequate or unclear randomisation had a tendency to overestimate treatment 
effects by up to 40%, compared with those that used proper randomisation, and 
the outcome of the study can be negatively influenced by this (417). 
Consequently, an unclear risk of selection bias is still possible some studies. 
 
The risk posed by prior knowledge of the allocated interventions on the part of 
participants and personnel in study is referred to as performance bias, which can 
be reduced by blinding of the above parties. However, some review authors 
confuse allocation concealment with blinding of allocated interventions. 
Allocation concealment aims to avoid selection bias in intervention assignment 
through protecting the allocation sequence before and until assignment, and can 
always be effectively implemented in spite of the study subject. On the other 
hand, blinding aims to avoid performance and detection bias through protecting 
the sequence after assignment, and cannot always be implemented (e.g. in studies 
comparing surgical with medical treatments)(416). In general, a patient or 
researcher who expects the effect of a particular intervention could intentionally 
observe or detect an improved treatment effect. The common term “double-
blinded” refers to complete avoidance of performance bias through blinding both 
participants and personnel.  
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When the outcome can possibly be affected by patient or investigator's 
expectations, then blinding is important. Blinding is of three types - single blind: 
when the patient is blind, double blind: when the patient and the investigator are 
blind, and triple blind: when the patient, investigator and data clean-up people 
are blind (39). Bias may as well be introduced at some stage in the statistical 
analysis of the study through the selective use and reporting of statistical tests. 
This may be unintentionally made by investigators keen to observe a positive 
result, however the consequences are weighty (418).  
 
In the current review, the majority of studies had a low risk for bias, as they 
described all measures used, if any, to blind study participants and personnel from 
knowledge of which intervention a participant received and providing any 
information relating to whether the intended blinding was effective. Effective 
blinding can also ensure that the compared groups have a similar amount of care 
and additional treatment, as well as diagnostic investigations. However, blinding 
is not always possible in many situations, for various reasons. For instance, it is 
generally impossible to blind people to whether or not major surgery had been 
undertaken (159)  .  
 
In total, 13 open-label studies (ASCOT-BPLA 2005; CASE-J 2008; CONVINCE 2003; 
Cremonesi 2002; FACET 1998; Fogari 2008; Holsgreve 2003; HYVET 2008; HYVET–P 2003; 
INVEST 2003; Mounier-Vehier 1998; NORDIL 2000; UKPDS 1998) were considered to be at 
high risk of performance bias due to knowledge of the allocated interventions on 
the part of participants and personnel throughout the study. However, open-label 
studies are still few and the PROBE design was used in a number of them, such as 
ASCOT-BPLA 2005; CASE-J 2008; Fogari 2008; INVEST 2003; NORDIL 2000.  The PROBE 
design was compared to the classical double-blind design, and has a lower cost 
and is more similar to standard clinical practice (419). Since the review is on BP 
response and the primary outcome is based on repeat measurements which (in 
this review) followed well-defined protocols and standardised techniques in all 
included studies, there was no difference between the two types of studies in this 
regard.  
Regardless of careful concern of methods to blind individuals in clinical studies, 
situations will always happen when some or all groups of individuals cannot 
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ethically be blinded. Researchers have to understand this reality and consider 
other approaches to reduce bias when blinding is not possible. For instance, when 
patients or clinicians cannot be blinded, researchers should ensure that the two 
(or more) allocation groups are, apart from the intervention, treated as equally 
as possible. This might involve providing a standard care for patients (e.g., co-
interventions, follow-up frequency and complications management) (418). On the 
other hand, researchers may decide to use an expertise-based study design, in 
which patients are randomly assigned to different clinicians that each performs 
one intervention. 
Detection bias refers to the risk of how the evaluation of the outcome may impose 
a bias on effects. If bias is introduced during a study because of differential 
treatment of groups or biased assessment of outcomes, no analytical techniques 
can correct for this limitation. Therefore, researchers must interpret the results 
from un-blinded studies with caution as blinding of outcome assessors reduces 
detection bias (159) . Outcome assessors or investigators, who are aware of the 
real treatment, could intentionally change their assessment. An adequate blinding 
of outcome assessment was applied in most of the studies in this review by means 
of describing all measures used, if any, to blind outcome assessors from knowledge 
of which intervention a participant received and providing any information 
relating to whether the intended blinding was effective.  
Nonetheless, it was unclear in eight studies (Bremner 1997; DETAIL 2004; LOTHAR 
2006; Pareek 2010; SHELL 2003; VHAS 1998; Wu 2004; Yang 2015) whether blinding was 
broken prior to making the final decision to withdraw, as the method of binding 
was not described in sufficient detail. Detection bias was seen in a number of 
studies (CASE-J 2008; Cremonesi 2002; FACET 1998; HYVET–P 2003; Mounier-Vehier 1998; 
UKPDS 1998) where drugs were administered under an open label and outcome was 
not blindly assessed. Although open-label studies are still relatively rare, 
detection bias, due to outcome assessors’ knowledge of the allocated 
interventions, may be present in these studies. 
According Cochrane recommendations for systematic reviews of interventions, an 
acceptable overall drop-out rate is considered to be 20% or less of participants 
who were randomised or allocated into each group (159). While it is easier to 
assess whether a drop-out rate goes above 20%, there is no guarantee that results 
  150 
 
from a study with a drop-out rate of less than 20% are at low risk of bias (420). 
Low total drop-out rates are often expected in shorter studies ,however high total 
drop-out rates might be acceptable for studies of longer duration (159).  
Missing outcome data, due to attrition (drop-out) during the study or exclusions 
from the analysis, increase the risk that the observed effect estimate is biased. In 
most cases, attrition can happen if participants are withdrawn from the study, 
lost to follow-up, non-compliers or unavailable for other reasons. Some 
participants may be excluded from analysis when they were later found to be 
ineligible or PP analysis is performed (included only if they received the intended 
intervention in accordance with the protocol). The intention to exclude such 
participants should be specified before the outcome data are seen, although, 
some exclusions of participants may be justified and not be considered as leading 
to missing outcome data (421;422). Although omitting some participants from 
reports of analyses, in spite of outcome data being available, is justified in some 
cases, it is usually still advised to avoid it as much as possible. Ideally, 
investigators would have no exclusions after randomisation and use an ITT 
analysis, as all participants enrolled should be analysed as part of the original 
group they were assigned to.  
 
An ITT analysis is often recommended as the least biased way to measure 
intervention effects in randomized studies. It includes keeping participants in the 
intervention groups to which they were randomized, in spite of the intervention 
they actually received, measure outcome data on all participants, and include all 
randomized participants in the analysis. The first principle can often be applied. 
Though, the second is often impossible due to attrition beyond the control of the 
researchers. In consequence, the third principle of including all participants can 
only be followed by making assumptions about the missing values (imputations) 
(423). Consequently, a small number of studies can perform a true ITT analysis 
without making imputations, mainly when there is extended follow-up. Therefore, 
in this systematic review, the risk of attrition bias was avoided by performing an 
ITT analysis including a description of the completeness of outcome data for each 
main outcome, incorporating attrition and exclusions from the analysis. 
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In practice, researchers can describe an analysis as ITT even when some outcome 
data are missing.The term “ITT” does not have a clear and consistent definition, 
and it is used inconsistently in study reports. For instance, review authors might 
also encounter analyses described as “modified ITT” such as ALPINE 2003; Benetos 
2000; Black 1997; CROSS 2003; Derosa 2013; ELSA 2002; ELVERA 2004; Giles 2007; Grethouse 
2010; Guthrie 1998; Hegner 1997; MAISH 2007; Mallion 2007; McInnes 2000; Ruilope 2001; 
Stimpel 1997; Zanchetti 2001), which usually means that participants were excluded 
if they did not receive a specific minimum amount of the intended intervention 
(e.g. who did not receive at least one dose of study medication and from whom 
at least one post-baseline BP measurement) .This term is as well used in a variety 
of ways so review authors should always look for information about exactly who 
was included (424). 
As a general observation, analyses with statistically significant differences 
between intervention groups are more likely to be reported than non-significant 
differences. However, all studies in this systematic review reported pre-specified 
outcomes listed in the methods section, therefore the reporting bias (defined as 
systematic differences between reported and unreported findings) was avoided.  
Many patients require more than one BP-lowering agent to achieve their BP goal 
(AASK 2002; ACCOMPLISH 2008; ALLHAT 2002; CONVINCE 2003; FACET 1998; IDNT 2001; 
INSIGHT 2000; INVEST 2003; LIFE 2002; NORDIL 2000; UKPDS 1998; VALUE 2004; VHAS 1998). 
The observed effects could equally have resulted from the different additional 
drugs. If this was not balanced between groups, it would lead to a risk of 
performance bias and the results may have been confounded; however, they were 
assumed to reflect the effect of the first drug. In addition, the results of this 
review are less likely to be affected, given that only 13 studies used additional 
BP-lowering agents. 
In most cases, smaller numbers of participants was the problem with older studies, 
and the researchers tried to overcome this problem with new and larger studies, 
since a study with low statistical power has a smaller chance of detecting a true 
effect, based on the likelihood that a statistically significant result reflects a true 
effect. Consequently, the effect size will be overestimated, the results will be 
less reproducible and there is also an ethical dimension, as unreliable researches 
are ineffective and wasteful (425). 
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Funnel plot of the studies effect estimates against sample size, can be used assess 
the validity of meta-analyses. It is based on the theory that the precision in 
estimating the underlying treatment effect will increase as the sample size of 
included studies increases. Funnel plots have been interpreted in different ways 
by different observers and the value of them has not been systematically 
examined, and symmetry (or asymmetry) has generally been defined informally, 
through visual inspection (426;427).  
Funnel plot asymmetry was found in (38%) journal meta-analyses and (13%) 
Cochrane reviews (426). Therefore, critical examination for the presence of 
publication and related biases has to become an important part of meta-analytic 
studies as well as systematic reviews. However, when there is evidence of small-
study effects, publication bias should be considered as only one of a number of 
possible explanations such as data irregularities ( such as poor methodological 
quality or inadequate analysis), true heterogeneity ( such as intensity of 
intervention or differences in underlying risk) or chance (426). In the review, 
almost all the outlier were placebo controlled studies where the intensity of 
intervention might differ considerably. In most cases, funnel plot and tests for 
funnel plot asymmetry, might alert review authors to a problem which needs 
considering, although they do not provide a solution to this problem.
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3.3 Effect of intervention 
3.3.1 Delta-BP response  
For the delta -BP response, 56 studies were included in the analysis (ordered by 
study ID):  
AASK 2002 ELSA 2002 JMIC-B 2004 Oparil 1998 
Alcocer 1995 FACET 1998 LAARS 2002 Os 1997 
ALLHAT 2002 Farsang 2007 LIFE 2002 Papademetriou 1997 
ALPINE 2003 Freytag 2001 MAISH 2007 Pareek 2010 
ASCOT-BPLA 2005 Giles 2007 Mallion 2000 PRESERVE 2001 
Benetos 2000 Grassi 2003 Mallion 2007 REZALT 2009 
Black 1997 Greathouse 2010 Mallion 2011 Ruilope 2001 
Black 2001 Guthrie 1998 Mancia 2000 Stimpel 1997 
Bremner 1997 Hanefeld 2001 MAPAVEL 2002 Syst-Eur 1997 
Chanudet 2001 Hegner 1997 Mimran 1998 UKPDS 1998 
CONVINCE 2003 Hoegholm 1995 Mroczek 1996 Value 2004 
Cremonesi 2002 HYVET 2008 NICE-EH 1999 Volpe 2003 
DETAIL 2004 HYVET pilot 2003 Nilsson 2007 Waeber 1999 
ELLE 2003 INVEST 2003 NORDIL 2000 Wu 2004 
 
3.3.1.1 BP response for ACEI-delta  
During a total of 56,431 person-years of follow-up, using the WMD method and FE 
model, the mean SBP reduction of ACEI was 1.98 mmHg, 95% CI 1 [1.81, 2.15] less 
than ARB, 1.43 mmHg, 95% CI [1.00, 1.85] less than CCB, 0.50 mmHg, 95% CI [0.15, 
0.85] less than DI. SBP reduction was -0.99 mmHg, 95% CI [-1.50, -0.48] more than 
BB and -6.27 mmHg, 95% CI - [-8.06, -4.49] more than the placebo. However, there 
was no significant difference between ACEIs (P = 0.18), as shown in Figure 3.3. 
For DBP, as shown in Figure 3.4, the mean DBP reduction of ACEI was 0.76 mm 
Hg, 95% CI [0.52, 1.01]. DBP reduction of ACEI was -0.52 mmHg, 95% CI [-0.67, -
0.36] more than ARB, -0.83 mmHg 95% CI [-1.03, -0.63] more than DI, -0.95 mm 
Hg 95% CI [-1.21, -0.69] more than BB and -3.55 mmHg 95% CI [-4.09, -3.00] more 
than the placebo. However, there was no significant difference between ACEIs (P 
= 0.14). 
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Figure 3.3 Forest plot of comparison of ACEI vs other agents: BP-delta, outcome [FE 
model]: SBP reduction.Net change in clinic/office SBP for ACEI versus other agents, both 
in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect represents the 
pooled estimate of mean net change in SBP response. 
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Figure 3.4 Forest plot of comparison of ACEI vs other agents: BP-delta, outcome [FE 
model]: DBP reduction. Net change in clinic/office DBP for ACEI versus other agents, both 
in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect represents the 
pooled estimate of mean net change in DBP response. 
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Heterogeneity was seen of an I2 value of 74% for the nine studies comparing SBP 
reduction respectively, with ACEIs vs CCBs. Using the RE model, mean differences 
were shown for both SBP and DBP of 2.06, 95% CI [0.66, 3.47] and 0.87, 95% CI 
[0.49, 1.25] respectively, as shown in Figure 3.5 and Figure 3.6.The observed 
statistical heterogeneity was most likely due to the methodological diversity of 
the FACET 1998 study, drugs were administered under open labels. Sensitivity 
analyses, without the FACET 1998 study, resulted in homogeneously mean 
differences for both SBP and DBP of 1.20, 95% CI [0.76, 1.63] and 0.76, 95% CI 
[0.51, 1.00] respectively, as shown in Figure 3.7 and Figure 3.8. 
Heterogeneity was observed at an I2 value of 97% and 96% for the four studies 
comparing ACEIs vs DIs. Using the RE model, mean differences were shown for 
both SBP and DBP of -0.29, 95% CI [-2.91, 2.33] and -0.50, 95% CI [-1.87, 0.87] 
respectively. The observed statistical heterogeneity was most likely due the 
methodological diversity of the ASCOT-BPLA 2005 and HYVET–P 2003 studies, as drugs 
were administered under open labels in both the studies, might have contributed 
the observed heterogeneity. Sensitivity analyses, without these studies, resulted 
in resulted in homogeneous mean differences for both SBP and DBP of 1.79, 95% 
CI [1.35, 2.23] and -0.09, 95% CI [-0.36, 0.18], respectively. 
Heterogeneity was noticed to the tune of an I2 value of 80 % and 95% for the eight 
studies comparing SBP and DBP reduction respectively, with ACEIs vs BBs. Using 
the RE model, mean differences were observed for both SBP and DBP of 0.43, 95% 
CI [-1.13, 1.98] and 0.32, 95% CI [-1.16, 1.80] respectively. The observed 
statistical heterogeneity was most likely due to the methodological diversity of 
the ASCOT-BPLA 2005 and UKPDS 1998 studies, as drugs were given under open labels. 
Sensitivity analyses, without these studies, resulted in homogeneous mean 
differences for both SBP and DBP of 0.79, 95% CI [-0.24, 1.83] and 0.82, 95% CI 
[0.34, 0.31] respectively. 
Heterogeneity was also flagged up with an I2 value of 74% and 96% for the three 
studies comparing SBP and DBP reduction respectively, with ACEIs vs placebo. 
Using the RE model, mean differences were highlighted for both SBP and DBP of -
7.06, 95% CI [-10.96, -3.16] and -4.10, 95% CI [-7.23, -0.98] respectively. The 
observed statistical heterogeneity was most likely due the clinical diversity of the 
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Waeber 1999 study, as one of its intervention arms was a combination treatment. 
Sensitivity analyses, without this study, resulted in homogeneous mean 
differences for both SBP and DBP of -9.06, 95% CI [-11.73, -6.40] and -5.85, 95% 
CI [-6.72, -4.99] respectively. 
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Figure 3.5 Forest plot of comparison of ACEI vs other agents: BP-delta, outcome [RE 
model]: SBP reduction. Net change in clinic/office SBP for ACEI versus other agents, both 
in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect represents the 
pooled estimate of mean net change in SBP response. 
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Figure 3.6 Forest plot of comparison of ACEI vs other agents: BP-delta, outcome [RE 
model]: DBP reduction. Net change in clinic/office DBP for ACEI versus other agents, both 
in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect represents the 
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Figure 3.7 Forest plot of comparison of ACEI vs other agents: BP-delta, outcome 
[sensitivity analysis]: SBP reduction. Net change in clinic/office SBP for ACEI versus other 
agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 
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Figure 3.8 Forest plot of comparison of ACEI vs other agents: BP-delta, outcome 
[sensitivity analysis]: DBP reduction. Net change in clinic/office DBP for ACEI versus 
other agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall 







3.3.1.2 BP response to ARBs-delta 
During a total of 27,900 person-years of follow-up, using the WMD method and FE 
model, the mean SBP reduction with ARBs was 1.92 mmHg, 95% CI [1.57, 2.26] less 
than that of CCBs. SBP reduction was -1.98 mmHg, 95% CI [-2.15, -1.81] more than 
ACEIs, -1.16 mmHg, 95% CI [-1.88, -0.44] more than BBs, -9.60 mmHg, 95% CI [-
11.24, -7.96] more than the placebo and -2.12 mmHg, 95% CI [-3.88, -0.35] more 
than another ARB. However, there was no significant difference between ARBs 
and DIs (P = 0.05), as shown in Figure 3.9. 
For DBP, as shown in Figure 3.10, the mean DBP reduction with ARBs was 0.52 
mmHg, 95% CI [0.36, 0.67] less than ACEIs and 1.53 mmHg, 95% CI [1.34, 1.73] less 
than CCBs. For DBP, the mean reduction with ARBs was -6.13 mmHg, 95% CI [-
6.62, -5.65] more than the placebo and -1.57 mmHg, 95% CI [-2.07, -1.07] more 
than another ARB. However, there was no significant difference between ARBs 
and DIs (P = 0.70) or between ARBs and BBs (P = 0.46).  
Heterogeneity was also observed at an I2 value of 69% and 85% for the five  studies 
comparing SBP and DBP reduction respectively, with ARBs vs CCBs. Using the RE 
model, mean differences were shown for both SBP and DBP of 0.82, 95% CI [-0.58, 
2.21] and 0.55, 95% CI [-0.48, 1.59] respectively, as shown in Figure 3.11.The 
observed statistical heterogeneity was most likely due to the methodological 
diversity of the VALUE 2004 study, as a number of BP-lowering agents were added 
to randomly allocated treatment to control BP. Sensitivity analyses, without this 
study, resulted in homogeneous mean differences for both SBP and DBP of 0.16, 
95% CI [-0.96, 1.28] and 0.25, 95% CI 0.25 [-0.33, 0.83] respectively, as shown in 
Figure 3.12. 
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Figure 3.9 Forest plot of comparison of ARBs vs other agents: BP-delta, outcome [FE 
model]: SBP reduction. Net change in clinic/office SBP for ARBs versus other agents, 
both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 
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Figure 3.10 Forest plot of comparison of ARBs vs other agents: BP-delta, outcome [FE 
model]: DBP reduction. Net change in clinic/office DBP for ARBs versus other agents, 
both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 










Figure 3.11 Forest plot of comparison of ARBs vs other agents: BP-delta, outcome [RE 
model]: BP reduction. Net change in clinic/office BP for ARBs versus other agents, both 
in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect represents the 












Figure 3.12 Forest plot of comparison of ARBs vs other agents: BP-delta, outcome 
[sensitivity analysis]: BP reduction. Net change in clinic/office BP for ARBs versus other 
agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 





3.3.1.3 BP response to CCBs-delta 
During a total of 207,289 person-years of follow-up, using the WMD method and 
FE model, the mean SBP reduction from CCBs was 0.48 mmHg, 95% CI [0.24, 0.73] 
less than DI. SBP reduction was -1.43 mmHg, 95% CI [-1.85, -1.00] more than ACEIs, 
-1.92 mmHg, 95% CI [-2.26, -1.57] more than ARBs and -9.88 mmHg, 95% CI [-
10.56, -9.20] more than the placebo. However, there was no significant difference 
between CCBs and BBs (P = 0.13) or between CCBs (P = 0.23), as shown in Figure 
3.13. 
For DBP, as shown in Figure 3.14, the mean DBP reduction under CCBs was -0.76 
mmHg, 95% CI [-1.01, -0.52] more than ACEIs, -1.53 mmHg, 95% CI [-1.73, -1.34] 
more than ARBs, -0.76 mmHg, 95%CI [-0.90, -0.62] more than DIs, -0.50 mmHg, 
95% CI [-0.64, -0.36] more than BBs and -4.64 mmHg, 95% CI [-4.96, -4.31] more 
than the placebo. However, there was no significant difference between CCBs (P 
= 0.64).  
Heterogeneity was seen at an I2 value of 95% and 93% for the seven studies 
comparing SBP and DBP reduction respectively, with CCBs vs DIs. Using the RE 
model, mean differences were shown for both SBP and DBP of 0.82, 95% CI [-0.62, 
2.27] and -0.49, 95% CI [-1.18, 0.21] respectively, as shown in Figure 3.15. The 
observed statistical heterogeneity was most likely due to the methodological 
diversity of the ASCOT-BPLA 2005, CONVINCE 2003 and NORDIL 2000 studies, as drugs 
were administered under open labels. Sensitivity analyses, without these studies, 
resulted in homogeneously mean differences for both SBP and DBP of 0.82, 95% CI 
[0.44, 1.21] and -0.63, 95% CI [-0.89, -0.38] respectively, as shown in Figure 3.16. 
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Figure 3.13 Forest plot of comparison of CCB vs other agents: BP-delta, outcome [FE 
model]: SBP reduction. Net change in clinic/office SBP for CCBs versus other agents, 
both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 
represents the pooled estimate of mean net change in SBP response. 
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Figure 3.14 Forest plot of comparison of CCB vs other agents: BP-delta, outcome [FE 
model]: DBP reduction. Net change in clinic/office DBP for CCBs versus other agents, 
both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 
represents the pooled estimate of mean net change in DBP response. 
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Heterogeneity was also observed of an I2 value of 95% and 95% for the seven studies 
comparing SBP and DBP reduction respectively, with CCBs vs BBs. Using the RE 
model, mean differences were shown for both SBP and DBP of 0.09, 95% CI [-1.31, 
1.49] and -0.36, 95% CI [-1.11, 0.39] respectively. The observed statistical 
heterogeneity was most likely due the methodological diversity of ASCOT-BPLA 
2005, INVEST 2003, CONVINCE 2003 and NORDIL 2000 studies, as drugs were administered 
under open labels. Sensitivity analyses, without these studies, resulted in 
homogeneously mean differences for both SBP and DBP of-0.27, 95% CI [-1.22, 
0.68] and 0.12, 95% CI [-0.28, 0.52] respectively. 
Heterogeneity was also noticed at an I2 value of 84% for the four studies comparing 
SBP reduction respectively, with CCBs vs the placebo. Using the RE model, mean 
differences were shown for both SBP and DBP of -9.58, 95% CI [-11.65, -7.51] and 
-4.64, 95% CI [-5.12, -4.15] respectively. The observed statistical heterogeneity 
was most likely due the methodological diversity of the HYVET 2008 study, as drugs 
were administered under open labels. Sensitivity analyses, without this study, 
resulted in homogeneously mean differences for both SBP and DBP of-8.76, 95% CI 
[-9.62, -7.90] and -4.46, 95% CI [-4.84, -4.08] respectively. 
 




Figure 3.15 Forest plot of comparison of CCBs vs other agents: BP-delta, outcome [RE 
model]: BP reduction. Net change in clinic/office BP for CCBs versus other agents, both 
in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect represents the 
pooled estimate of mean net change in BP response. 




Figure 3.16 Forest plot of comparison of CCBs vs other agents: BP-delta, outcome 
[sensitivity analysis]: BP reduction. Net change in clinic/office BP for CCBs versus other 
agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 
represents the pooled estimate of mean net change in BP response. 
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3.3.1.4 BP response to DIs-delta  
During a total of 108,399 person-years of follow-up, using the WMD method and 
FE model, the mean SBP reduction with DIs was -0.50 mmHg, 95% CI [-0.85, -0.15] 
more than ACEIs, -0.48 mmHg, 95% CI [-0.73, -0.24] more than CCBs and -10.00 
mmHg, 95% CI [-15.78, -4.22] more than the placebo. However, there was no 
significant difference between DIs and ARBs (P = 0.05), between DIs and BBs (P = 
0.14) or between DIs (P = 0.25), as shown in Figure 3.17. 
For DBP, as shown in Figure 3.18, the mean DBP reduction under DIs was 0.83 
mmHg, 95% CI [0.63, 1.03] less than ACEIs and 0.76 mmHg, 95% CI [0.62, 0.90] less 
than CCBs. For DBP, the mean reduction with DIs was -5.40 mmHg, 95% CI [-8.19, 
-2.61] more than the placebo. However, there was no significant difference 
between DIs and ARBs (P = 0.70), between DIs and BBs (P = 0.90) or between DIs 
(P = 0.22). 
Heterogeneity was also in evidence to an I2 value of 79% for the two studies 
comparing SBP reduction respectively, with DIs vs BBs. Using the RE model, mean 
differences were shown for both SBP and DBP of 1.72, 95% CI [-2.39, 5.83] and -
0.08, 95% CI [-1.65, 1.48] respectively, as shown in Figure 3.19. The observed 
statistical heterogeneity was most likely due the clinical diversity of the Mallion 
2000 study, as BP was measured in the supine position.  
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Figure 3.17 Forest plot of comparison of DIs vs other agents: BP-delta, outcome [FE model]: 
SBP reduction. Net change in clinic/office SBP for DIs versus other agents, both in 
diagrammatic and numerical format (mmHg, 95% CI) .The overall effect represents the 
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Figure 3.18 Forest plot of comparison of DIs vs other agents: BP-delta, outcome [FE model]: 
DBP reduction. Net change in clinic/office DBP for DIs versus other agents, both in 
diagrammatic and numerical format (mmHg, 95% CI) .The overall effect represents the 









Figure 3.19 Forest plot of comparison of DIs vs other agents: BP-delta, outcome [RE 
model]: BP reduction. Net change in clinic/office BP for DIs versus other agents, both in 
diagrammatic and numerical format (mmHg, 95% CI) .The overall effect represents the 




3.3.1.5 BP response to BBs-delta 
During a total of 109,415 person-years of follow-up, using the WMD method and 
FE model, the mean SBP reduction under BBs was 0.99 mmHg CI [0.48, 1.50] less 
than ACEIs and 1.16 mmHg CI [0.44, 1.88] less than ARBs. SBP reduction was -7.24 
mmHg, 95% CI [-9.22, -5.27] more than the placebo. However, there was no 
significant difference between BBs and CCBs (P = 0.13), between BBs and DIs (P = 
0.14) or between BBs (P = 0.63), as shown in Figure 3.20. 
For DBP, as shown in Figure 3.21, the mean DBP reduction under BBs was 0.95 
mmHg, 95% CI [0.69, 1.21] less than ACEIs and 0.50 mmHg, 95% CI [0.36, 0.64] less 
than CCBs. For DBP, the mean reduction under BBs was -4.53 mmHg, 95%CI [-5.18, 
-3.88] more than the placebo. However, there was no significant difference 
between BBs and ARBs (P = 0.46), between BBs and DIs (P = 0.90) or between BBs 
(P = 0.85).  
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Figure 3.20 Forest plot of comparison of BBs vs other agents: BP-delta, outcome [FE 
model]: SBP reduction. Net change in clinic/office SBP for BBs versus other agents, both 
in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect represents the 
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Figure 3.21 Forest plot of comparison of BBs vs other agents: BP-delta, outcome [FE 
model]: DBP reduction. Net change in clinic/office DBP for BBs versus other agents, both 
in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect represents the 





3.3.2 Single measure-BP 
response  
For single measure-BP response, 37 studies were included in the analysis (ordered 
by study ID):  
AASK 2002 Farsang 2007 Luque 2005 Radauceanu 2004 
Benetos 2000 Fogari 2008 McInnes 2000 REGAAL 2002 
CASE-J 2008 Grassi 2003 MIDAS 1996 Value 2004 
Chanudet 2001 Hegner 1997 Mounier-Vehier 1998 VHAS 1998 
CROSS 2003 Hoegholm 1995 Narkiewicz 2007 Volpe 2003 
Cushman 1998 Holzgreve 2003 NICE-EH 1999 Wu 2004 
Derosa 2013 James 2002 Nilsson 2007 Yang 2015 
Derosa 2014 JMIC-B 2004 Os 1997   
ELLE 2003 LIFE 2002 PATS 1995   
ELVERA 2004 LOTHAR 2006 RACE 1995   
 
 
3.3.2.1 BP response to ACEIs-single measure 
During a total of 8974 person-years of follow-up, using the WMD method and FE 
model, the mean SBP reduction under ACEIs was 1.17 mmHg, 95% CI [0.20, 2.14] 
less than CCBs and 5.20 mmHg, 95% CI [2.08, 8.32] less than DIs. SBP reduction 
with ACEIs was -7.10 mmHg, 95% CI [-10.99, -3.21] more than the placebo. 
However, there was no significant difference between ACEIs and ARBs (P = 0.19) 
or between ACEIs and BBs (P = 0.87), as shown in Figure 3.22. 
For DBP, as shown in Figure 3.23, the mean DBP reduction under ACEIs was 1.29 
mmHg, 95% CI [0.74, 1.84] less than CCBs and 2.20 mmHg, 95% CI [0.56, 3.84] less 
than DIs. DBP reduction with ACEIs was -1.83 mmHg, 95% CI [-2.78, -0.89] more 
than ARBs and -2.40 mmHg, 95% CI [-3.54, -1.26] more than the placebo. However, 
there was no significant difference between ACEIs and BBs (P = 0.12). 
Heterogeneity was seen to an I2 value of 76% and 80% for the five studies 
comparing SBP and DBP reduction respectively, with ACEIs vs BBs. Using the RE 
model, mean differences were shown for both SBP and DBP of -0.11, 95% CI [-2.94, 
2.71] and -0.23, 95% CI [-1.76, 1.30] respectively, as shown in Figure 3.24.The 
observed statistical heterogeneity was most likely due to the methodological 
diversity of the Holzgreve 2003 study, as drugs were administered under open 
labels. Sensitivity analyses, without this study, resulted in homogeneous mean 
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differences for both SBP and DBP of of -1.40, 95% CI [-2.93, 0.14] and -1.09, 95% 
CI [-1.84, -0.35] respectively, as shown in Figure 3.25. 
 
 
Figure 3.22 Forest plot of comparison of ACEIs vs other agents: BP-single measure, 
outcome [FE model]: SBP reduction. Net change in clinic/office SBP for ACEIs versus 
other agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall 








Figure 3.23 Forest plot of comparison of ACEIs vs other agents: BP-single measure, 
outcome [FE model]: DBP reduction. Net change in clinic/office DBP for ACEIs versus 
other agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall 











Figure 3.24 Forest plot of comparison of ACEIs vs other agents: BP-single measure, 
outcome [RE model]: BP reduction. Net change in clinic/office BP for ACEIs versus other 
agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 












Figure 3.25 Forest plot of comparison of ACEIs vs other agents: BP-single measure, 
outcome [sensitivity analysis]: BP reduction. Net change in clinic/office BP for ACEIs 
versus other agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The 





3.3.2.2 BP response to ARBs-single measure  
During a total of 29,927 person-years of follow-up, using the WMD method and FE 
model, the mean SBP reduction under ARBs was 1.67 mmHg, 95% CI [1.30, 2.04] 
less than CCBs. SBP reduction was -1.26 mmHg, 95% CI [-2.02, -0.51] more than 
BBs and -5.20 mmHg, 95% CI [-7.38, -3.02] more than another ARB. However, there 
was no significant difference between ARBs and ACEIs (P = 0.19) or between ARBs 
and DIs (P = 0.06), as shown in Figure 3.26. 
For DBP, as shown in Figure 3.27, the mean DBP reduction with ARBs was 1.83 
mmHg, 95% CI [0.89, 2.78] less than ACEIs, 1.10 mmHg, 95% CI [0.87, 1.33] less 
than CCBs, 1.37 mmHg, 95% CI [0.48, 2.27] less than DIs and 0.44 mmHg, 95% CI 
[0.03, 0.85] less than BBs. For DBP, the mean reduction under ARBs was -3.20 mm 
Hg, 95% CI [-4.95, -1.45] more than another ARB.  
Heterogeneity was seen at an I2 value of 74% for the eight studies comparing SBP 
reduction respectively, with ARBs vs CCBs. Using the RE model, mean differences 
were shown for both SBP and DBP of 1.40, 95% CI [0.34, 2.45] and 1.10, 95% CI 
[0.61, 1.60] respectively, as shown in Figure 3.28. The observed statistical 
heterogeneity was most likely due to the clinical diversity of the James 2002 study, 
as BP was measured in the supine position). Sensitivity analyses, without this 
study, resulted in homogeneously mean differences for both SBP and DBP of 1.77, 
95% CI [1.40, 2.14] and 1.12, 95% CI [0.88, 1.35] respectively, as shown in Figure 
3.29. 
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Figure 3.26 Forest plot of comparison of ARBs vs other agents: BP-single measure, 
outcome [FE model]: SBP reduction. Net change in clinic/office SBP for ARBs versus other 
agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 
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Figure 3.27 Forest plot of comparison of ARBs vs other agents: BP-single measure, 
outcome [FE model]: DBP reduction. Net change in clinic/office DBP for ARBs versus 
other agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall 










Figure 3.28 Forest plot of comparison of ARBs vs other agents: BP-single measure, 
outcome [RE model]: BP reduction. Net change in clinic/office BP for ARBs versus other 
agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 












Figure 3.29 Forest plot of comparison of ARBs vs other agents: BP-single measure, 
outcome [sensitivity analysis]: BP reduction. Net change in clinic/office BP for ARBs 
versus other agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The 






3.3.2.3 BP response to CCBs-single measure 
During a total of 48,795 person-years of follow-up, using the WMD method and FE 
model, the mean SBP reduction with CCBs was 2.69 mmHg, 95% CI [1.35, 4.02] less 
than DIs. SBP reduction was -1.17 mmHg, 95% CI [-2.14, -0.20] more than ACEIs, -
1.67 mmHg, 95% CI [-2.04, -1.30] more than ARBs and -4.50 mmHg, 95% CI [-8.33, 
-0.67] more than the placebo. However, there was no significant difference 
between CCB and BB (P=0.81) or between CCBs (P = 0.95), as shown in Figure 
3.30. 
For DBP, as shown in Figure 3.31, the mean DBP reduction under CCBs was 0.94 
mmHg, 95% CI [0.10, 1.78] less than DIs and 1.27 mmHg, 95% CI [0.11, 2.44] less 
than BBs. For DBP, the mean reduction with CCBs was -1.29 mmHg, 95% CI [-1.84, 
-0.74] more than ACEIs, -1.10 mmHg, 95% CI [-1.33, -0.87] more than ARBs and -
2.30 mmHg, 95% CI [-3.43, -1.17] more than the placebo. However, there was no 
significant difference between CCBs (P = 0.73). 
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Figure 3.30 Forest plot of comparison of CCBs vs other agents: BP-single measure, 
outcome [FE model]: SBP reduction. Net change in clinic/office SBP for CCBs versus other 
agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 










Figure 3.31 Forest plot of comparison of CCBs vs other agents: BP-single measure, 
outcome [FE model]: DBP reduction. Net change in clinic/office DBP for CCBs versus 
other agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall 






3.3.2.4 BP response to DIs-single measure 
During a total of 16,833 person-years of follow-up, using the WMD method and FE 
model, the mean SBP reduction with DIs was -5.20 mmHg, 95% CI [-8.32, -2.08] 
more than ACEIs, -2.41 mmHg, 95% CI [-3.63, -1.19] more than CCBs, -3.00 mmHg, 
95% CI [-5.93, -0.07] more than BBs and -6.20 mmHg, 95% CI [-7.14, -5.26] more 
than the placebo. However, there was no significant difference between DIs and 
ARBs (P = 0.06), as shown in Figure 3.32. 
For DBP, as shown by Figure 3.33,the mean DBP reduction under DIs was –2.20 
mmHg, 95% CI [-3.84, -0.56] more than ACEIs, –1.37 mmHg, 95% CI [-2.27, -0.48] 
more than ARBs, -0.94 mmHg, 95% CI [-1.78, -0.10] more than CCBs and -2.90 mm 
Hg, 95% CI [-3.39, -2.41] more than the placebo and -2.42 mmHg. However, there 
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Figure 3.32 Forest plot of comparison of DIs vs other agents: BP-single measure, outcome 
[FE model]: SBP reduction. Net change in clinic/office SBP for DIs versus other agents, 
both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 
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Figure 3.33 Forest plot of comparison of DIs vs other agents: BP-single measure, outcome 
[FE model]: DBP reduction. Net change in clinic/office DBP for DIs versus other agents, 
both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 









3.3.2.5 BP response to BBs-single measure 
During a total of 19,422 person-years of follow-up, using the WMD method and FE 
model, the mean SBP reduction with BBs was 1.26 mmHg, 95% CI [0.51, 2.02] less 
than ARBs and 3.00 mmHg, 95% CI [0.07, 5.93] less than DIs. SBP reduction was -
2.73 mmHg, 95% CI [-4.91, -0.56] more than CCBs. However, there was no 
significant difference between BBs and ACEIs (P = 0.87) or between BBs (P = 0.52), 
as shown in Figure 3.34. 
For DBP, as shown by Figure 3.35, the mean reduction under BBs was -0.44 mmHg, 
95% CI [-0.85, -0.03] more than ARBs and -1.27 mmHg, 95% CI [-2.44, -0.11] more 
than CCBs. However, there was no significant difference between BBs and ACEIs 
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Figure 3.34 Forest plot of comparison of BBs vs other agents: BP-single measure, outcome 
[FE model]: SBP reduction. Net change in clinic/office SBP for BBs versus other agents, 
both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 







Figure 3.35 Forest plot of comparison of BBs vs other agents: BP-single measure, outcome 
[FE model]: DBP reduction. Net change in clinic/office DBP for BBs versus other agents, 
both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 






3.3.3 Repeated measures-BP 
response  
For repeated measures –BP response, 20 studies were included in the analysis 
(ordered by study ID):  
ACCOMPLISH 2004 HYVET 2008 LIFE 2002 SHELL 2003 
ALLHAT 2002 IDNT 2001 NICE-EH 1999 Syst-Eur 1997 
CASE-J 2008 INSIGHT 2000 NORDIL 2000 UKPDS 1998 
Derosa 2014 INVEST 2003 PATS 1995 Value 2004 
DETAIL 2004 JMIC-B 2004 REGAAL 2002 Zanchetti 2001 
 
3.3.3.1 BP response to ACEIs-repeated measures 
During a total of 35,188 person-years of follow-up, using the WMD method and FE 
model, the mean SBP reduction with ACEIs was 1.09 mmHg, 95% CI [0.64, 1.54] 
less than CCBs and 2.00 mmHg, 95% CI [1.56, 2.44] less than DIs. However, there 
was no significant difference between ACEIs and ARBs (P = 0.53) or between ACEIs 
and BBs (P = 0.12), as shown in Figure 3.36. 
For DBP, the mean reduction under ACEIs was 1.01 mmHg, 95% CI [0.73, 1.30] less 
than CCBs. However, there was no significant difference between ACEIs and ARBs 
(P = 0.45), between ACEIs and DIs (P = 0.15) or between ACEIs and BBs (P = 0.71). 
Heterogeneity was observed to an I2 value of 90% for the three studies comparing 
DBP reduction with ACEIs vs CCBs. Using the RE model, mean differences for both 
SBP and DBP were shown of1.09, 95% CI [0.64, 1.54] and 2.19, 95% CI [0.42, 3.96] 
respectively, as shown in Figure 3.37. The observed statistical heterogeneity was 
most likely due the methodological diversity of the ALLHAT 2002 study, as a number 
of BP-lowering agents were added to randomly allocated treatment to control BP. 
Sensitivity analyses, without this study, resulted in homogeneously mean 
differences for both SBP and DBP of 1.81, 95% CI [0.44, 3.17] and 2.99, 95% CI 






Figure 3.36 Forest plot of comparison of ACEIs vs other agents: BP-repeated measures, 
outcome [FE model]: BP reduction. Net change in clinic/office BP for ACEIs versus other 
agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 













Figure 3.37 Forest plot of comparison of ACEIs vs other agents: BP-repeated measures, 
outcome [RE model]: BP reduction. Net change in clinic/office BP for ACEIs versus other 
agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 


























Figure 3.38 Forest plot of comparison of ACEIs vs other agents: BP-repeated measures, 
outcome [sensitivity analysis]: BP reduction. Net change in clinic/office BP for ACEIs 
versus other agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The 






3.3.3.2 BP response to ARBs-repeated measures 
During a total of 27,222 person-years of follow-up, using the WMD method and FE 
model, the mean SBP reduction with ARBs was 1.43 mmHg, 95% CI [1.04, 1.82] less 
than CCBs. SBP reduction was -0.99 mmHg, 95% CI [-1.75, -0.23] more than ACEIs. 
However, there was no significant difference between ARBs and ACEIs (P = 0.53) 
or between ARBs and the placebo (P = 0.15), as shown in Figure 3.39. 
For DBP, the mean reduction with ARBs was 0.88 mm Hg, 95% CI [0.63, 1.13] less 
than CCBs and 0.90 mmHg, 95% CI [0.49, 1.31] less than BBs. However, there was 
no significant difference between ARBs and ACEIs (P = 0.45) or between ARBs and 
the placebo (P = 0.05).  
 
 






Figure 3.39 Forest plot of comparison of ARBs vs other agents: BP-repeated measures, 
outcome [FE model]: BP reduction. Net change in clinic/office BP for ARBs versus other 
agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 






3.3.3.3 BP response to CCBs-repeated measures  
During a total of 117,259  person-years of follow-up, using the WMD method and 
FE model, the mean SBP reduction under CCBs was 0.97 mmHg, 95% CI [0.71, 1.24] 
less than DIs and 1.43 mmHg, 95% CI [1.00, 1.85] less than BBs. SBP reduction was 
-1.09 mmHg, 95% CI [-1.54, -0.64] more than ACEIs, -1.43 mm Hg, 95% CI [-1.82, -
1.04] more than ARBs and -8.04 mmHg, 95% CI [-8.73, -7.35] more than the 
placebo. However, there was no significant difference between CCBs (P = 0.80), 
as shown in Figure 3.40. 
For DBP, as shown in Figure 3.41, the mean DBP reduction with CCBs was -1.01 
mmHg, 95% CI [-1.30, -0.73] more than ACEIs, -0.88 mmHg, 95% CI [-1.13, -0.63] 
more than ARBs, -0.37 mmHg, 95% CI [-0.52, -0.21] more than DIs and -4.66 mmHg, 
95% CI [-5.03, -4.30] more than the placebo. However, there was no significant 
difference between CCBs and BBs (P = 0.13) or between CCBs (P = 1.00). 
Heterogeneity was also observed to an I2 value of 93% and 77% for the six studies 
comparing SBP and DBP reduction respectively, with CBBs vs DIs. Using the RE 
model, mean differences were shown for both SBP and DBP of 0.84, 95% CI [-0.31, 
1.98] and -0.35, 95% CI [-0.71, 0.00] respectively, as shown in Figure 3.42 .The 
observed statistical heterogeneity was most likely due the clinical diversity of the 
ACCOMPLISH 2004 and NORDIL 2000 studies, as randomisation started with two 
interventional BP-lowering agents in either one or both treatment arms. 
Sensitivity analyses, without these studies, resulted in homogeneously mean 
differences for both SBP and DBP of 0.84, 95% CI [0.51, 1.16] and -0.46, 95% CI [-
0.66, -0.25] respectively, as shown in Figure 3.43. 
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Figure 3.40 Forest plot of comparison of CCBs vs other agents: BP-repeated measures, 
outcome [FE model]: SBP reduction. Net change in clinic/office SBP for CCBs versus other 
agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 
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Figure 3.41 Forest plot of comparison of CCBs vs other agents: BP-repeated measures, 
outcome [FE model]: DBP reduction. Net change in clinic/office DBP for CCBs versus 
other agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall 











Heterogeneity was seen at an I2 value of 98% and 86% for the two studies 
comparing SBP and DBP reduction respectively, with CBBs vs BBs. Using the RE 
model, mean differences were shown for both SBP and DBP of 1.55, 95% CI [-1.49, 
4.59] and -0.20, 95% CI [-0.78, 0.39] respectively. The observed statistical 
heterogeneity was most likely due to the the clinical diversity of the NORDIL 2000 
study, as BP was measured in the supine position.  
 
Heterogeneity was also observed to an I2 value of 95% and 90% for the three studies 
comparing SBP and DBP reduction respectively, with CBBs vs the placebo. Using 
the RE model, mean differences were shown for both SBP and DBP of -6.42, 95% 
CI [-9.91, -2.93] and -4.02, 95% CI [-5.35, -2.69] respectively. The observed 
statistical heterogeneity was most likely due to the methodological diversity of 
the IDNT 2001 study, as a number of BP-lowering agents were added to randomly 
allocated treatment to control BP. Sensitivity analyses, without this study, 
resulted in homogeneously mean differences for both SBP and DBP of -8.76, 95% 
CI [-9.48, -8.03] and -4.90, 95% CI [-5.28, -4.53] respectively. 




Figure 3.42 Forest plot of comparison of CCBs vs other agents: BP-repeated measures, 
outcome [RE model]: BP reduction. Net change in clinic/office BP for CCBs versus other 
agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 









Figure 3.43 Forest plot of comparison of CCBs vs other agents: BP-repeated measures, 
outcome [sensitivity analysis]: BP reduction. Net change in clinic/office BP for CCBs 
versus other agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The 












3.3.3.4 BP response to DIs-repeated measures  
During a total of 85,624 person-years of follow-up, using the WMD method and FE 
model, the mean SBP reduction with DIs was -2.00 mmHg, 95% CI [-2.44, -1.56] 
more than ACEIs, -0.97 mmHg, 95% CI [-1.24, -0.71] more than CCBs and -4.40 
mmHg, 95% CI [-5.34, -3.46] more than the placebo, as shown in Figure 3.44. 
For DBP, the mean reduction under DIs was 0.37 mm Hg, 95% CI [0.21, 0.52] less 
than CCBs and -2.00 mmHg, 95% CI [-2.49, -1.51] more than the placebo. However, 
there was no significant difference between DIs and ACEIs (p = 0.15). 
 




Figure 3.44 Forest plot of comparison of DIs vs other agents: BP-repeated measures, 
outcome [FE model]: BP reduction. Net change in clinic/office BP for DIs versus other 
agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 







3.3.3.5 BP response to BBs-repeated measures 
During a total of 38,847 person-years of follow-up, using the WMD method and FE 
model, the mean SBP reduction with BBs was 0.99 mmHg, 95% CI [0.23, 1.75] less 
than ARBs and -1.43 mmHg, 95% CI [-1.85, -1.00] more than CCBs. However, there 
was no significant difference between BBs and ACEIs (P = 0.12), as shown in Figure 
3.45. 
For DBP, the mean reduction under BBs was -0.90 mmHg, 95% CI [-1.31, -0.49] 
more than ARBs. However, there was no significant difference between BBs and 
ACEIs (P = 0.71) or between BBs and CCBs (P = 0.13).  
 




Figure 3.45 Forest plot of comparison of BBs vs other agents: BP-repeated measures, 
outcome [FE model]: BP reduction. Net change in clinic/office BP for BBs versus other 
agents, both in diagrammatic and numerical format (mmHg, 95% CI) .The overall effect 
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3.3.1 Summary for BP 
responses  
Table 3.2 Summary of ACEI-BP responses.  
The table shows delta, single and repeated measures - BP response. Considering the level 
of statistical significance (P < 0.05) [White highlights] indicate significant statistical effect 
and [Grey highlights] indicate insignificant statistical effect. 
ACEI Studies N  Subjects N SBP I2 Studies N Subjects N DBP I2 
Delta-BP response [FE model] 
ACEI vs. ARB 9 2605 1.98 60% 9 2605 -0.52 53% 
ACEI vs. CCB 9 22215 1.43 74% 9 22215 0.76 24% 
ACEI vs. DI 4 44447 0.5 97% 4 44447 -0.83 96% 
ACEI vs. BB 8 22798 -0.99 80% 8 22798 -0.95 95% 
ACEI vs. Placebo 3 1093 -6.27 74% 3 1093 -3.55 96% 
ACEI vs. ACEI 2 332 -2 0% 2 332 -1 0% 
Delta-BP response [RE model] 
ACEI vs. CCB 9 22215 2.06 74% 9 22215 0.87 24% 
ACEI vs. DI 4 44447 -0.29 97% 4 44447 -0.5 96% 
ACEI vs. BB 8 22798 0.43 80% 8 22798 0.32 95% 
ACEI vs. Placebo 3 1093 -7.06 74% 3 1093 -4.1 96% 
Delta-BP response [sensitivity analysis] 
ACEI vs. CCB 8 21835 1.2 46% 8 21835 0.76 33% 
ACEI vs. DI 2 24407 1.79 0% 2 24407 -0.09 0% 
ACEI vs. BB 6 2783 0.79 60% 6 2783 0.82 58% 
ACEI vs. Placebo 2 468 -9.06 0% 2 468 -5.85 9% 
     
Single measure-BP response [FE model] 
ACEI vs. ARB 4 1038 -1.11 0% 4 1038 -1.83 10% 
ACEI vs. CCB 9 3610 1.17 21% 9 3610 1.29 59% 
ACEI vs. DI 1 463 5.2 - 1 463 2.2 - 
ACEI vs. BB 5 2211 -0.11 76% 5 2211 -0.54 80% 
ACEI vs. Placebo 1 290 -7.1 - 1 290 -2.4 - 
Single measure-BP response [RE model] 
ACEI vs. BB 5 2211 -0.11 76% 5 2211 -0.23 80% 
Single measure-BP response [sensitivity analysis] 
ACEI vs. BB 4 1748 -1.4 0% 4 1748 -1.09 56% 
     
Repeated measures-BP response [FE model] 
ACEI vs. ARB 1 250 1.3 - 1 250 -0.8 - 
ACEI vs. CCB 3 19982 1.09 0% 3 19982 1.01 90% 
ACEI vs. DI 1 24309 2 - 1 24309 0.2 - 
ACEI vs. BB 1 758 1.6 - 1 758 0.2 - 
Repeated measures-BP response [RE model] 
ACEI vs. CCB 3 19982 1.09 0% 3 19982 2.19 90% 
Repeated measures-BP response [sensitivity analysis] 
ACEI vs. CCB 2   1880 1.81 0% 2 1880 2.99 0% 
 
As shown in Table 3.2 : 
ACEIs were superior to ARBs in lowering DBP (delta: -0.51 mmHg (P < 0.00001)), 
single measure: -1.83 mmHg (P = 0.0001) and repeated measures: -0.8 mmHg (P = 
0.45).  
 
ACEIs were “significantly” superior to the placebo in lowering both SBP and DBP: 
for SBP (delta: -9.06 mmHg (P < 0.00001) and single measure: -7.1 mmHg (P = 
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0.0003)) and for DBP (delta: -5.85 mmHg (P < 0.00001) and single measure: -2.4 
mmHg (P < 0.0001)).  
 
There was no significant BP variance between different agents within the same 




Table 3.3 Summary of ARB-BP responses.  
The table shows delta, single and repeated measures - BP response .Considering the level 
of statistical significance (P < 0.05), [White highlights] indicate significant statistical effect, 
[Grey highlights] indicate insignificant statistical effect and [Red highlights] indicate 
significant statistical effect in all BP measures. 
ARB Studies N  Subjects N SBP I2 Studies N Subjects N DBP I2 
Delta-BP response [FE model] 
ARB vs. ACEI 9 2605 -1.98 60% 9 2605 0.52 53% 
ARB vs. CCB 5 16991 1.92 69% 5 16991 1.53 85% 
ARB vs. DI 3 836 1.97 0% 3 836 0.2 57% 
ARB vs. BB 4 10154 -1.16 53% 4 10154 0.14 3% 
ARB vs. Placebo 4 995 -9.6 0% 4 995 -6.13 57% 
ARB vs. ARB 2 829 -2.12 18% 2 829 -1.57 10% 
Delta-BP response [RE model] 
ARB vs. CCB 5 16991 0.82 69% 5 16991 0.55 85% 
Delta-BP response [sensitivity analysis] 
ARB vs. CCB 4 1746 0.16 0% 4 1746 0.25 48% 
     
Single measure-BP response [FE model] 
ARB vs. ACEI 4 1038 1.11 0% 4 1038 1.83 10% 
ARB vs. CCB 8 21909 1.67 74% 8 21909 1.1 52% 
ARB vs. DI 3 571 1.97 48% 3 571 1.37 60% 
ARB vs. BB 2 9418 -1.26 0% 2 9418 0.44 16% 
ARB vs. ARB  1 126 -5.2 - 1 126 -3.2 - 
Single measure-BP response [RE model] 
ARB vs. CCB 8 21909 1.40 74% 8 21909 1.10 52% 
Single measure-BP response [sensitivity analysis] 
ARB vs. CCB 7 21444 1.77 40% 7 21444 1.12 56% 
     
Repeated measures-BP response [FE model] 
ARB vs. ACEI 1 250 -1.3 - 1 250 0.8 - 
ARB vs. CCB 3 21094 1.43 43% 3 21094 0.88 28% 
ARB vs. BB 2 9418 -0.99 0% 2 9418 0.9 0% 
ARB vs. Placebo 1 1148 -1.7 - 1 1148 -1.3 - 
 
As shown in Table 3.3 : 
ARBs were “significantly” superior to BBs in lowering SBP (delta: -1.16 mmHg (P = 
0.002), single measure: -1.26 mmHg (P = 0.001), repeated measures: -0.99 mmHg 
(P = 0.01).  
 
ARBs were superior to the placebo in lowering BP, both SBP and DBP. For SBP 
(delta: -9.6 mmHg (P < 0.00001) and repeated measures: -1.7 mmHg (P = 0.15)). 
For DBP (delta: -6.13 mmHg (P < 0.00001) and repeated measures: -1.3 mmHg (P 
= 0.05)). 
 
There was a “significant” BP variance between different agents within same the 
ARB classes in BP response. For SBP (delta: -2.12 mmHg (P = 0.02) and single 
measure: -5.2 mmHg (P < 0.00001)). For DBP (delta: -1.57 mmHg (P < 0.00001) 
and single measure: -3.2 mmHg (P = 0.0003).
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Table 3.4 Summary of CCB-BP responses.  
The table shows delta, single and repeated measures - BP response .Considering the level 
of statistical significance (P < 0.05), [White highlights] indicate significant statistical effect, 
[Grey highlights] indicate insignificant statistical effect and [Red highlights] indicate 
significant statistical effect in all BP measures. 
CCB Studies N  Subjects N SBP I2 Studies N Subjects N DBP I2 
Delta-BP response [FE model] 
CCB vs. ACEI 9 22215 -1.43 74% 9 22215 -0.76 24% 
CCB vs. ARB 5 16991 -1.92 69% 5 16991 -1.53 85% 
CCB vs. DI 7 71766 0.48 95% 7 71766 -0.76 93% 
CCB vs. BB 7 72468 0.21 95% 7 72468 -0.5 95% 
CCB vs. Placebo 4 9336 -9.88 84% 4 9336 -4.64 43% 
CCB vs. CCB 3 529 -1.34 0% 3 529 -0.27 0% 
Delta-BP response [RE model] 
CCB vs. ACEI 9 22215 -2.06 74% 9 22215 -0.87 24% 
CCB vs. ARB 5 16991 -0.82 69% 5 16991 -0.55 85% 
CCB vs. DI 7 71766 0.82 95% 7 71766 -0.49 93% 
CCB vs. BB 7 72468 0.09 95% 7 72468 -0.36 95% 
CCB vs. Placebo 4 9336 -9.58 84% 4 9336 -4.64 43% 
Delta-BP response [sensitivity analysis] 
CCB vs. ACEI 8 21835 -1.2 46% 8 21835 -0.76 33% 
CCB vs. ARB 4 1746 -0.16 0% 4 1746 -0.25 48% 
CCB vs. DI 4 25026 0.82 42% 4 25026 -0.63 58% 
CCB vs. BB 3 3152 -0.27 0% 3 3152 0.12 42% 
CCB vs. Placebo 3 5491 -8.76 0% 3 5491 -4.46 0% 
     
Single measure-BP response [FE model] 
CCB vs. ACEI 9 3610 -1.17 21% 9 3610 -1.29 59% 
CCB vs. ARB 8 21909 -1.67 74% 8 21909 -1.1 52% 
CCB vs. DI 4 1810 2.69 0% 4 1810 0.94 45% 
CCB vs. BB 3 818 2.73 58% 3 818 1.27 24% 
CCB vs. Placebo 1 302 -4.5 - 1 302 -2.3 - 
CCB vs. CCB  3 437 0.07 0% 3 437 -0.25 0% 
Single measure-BP response [RE model] 
CCB vs. ARB 8 21909 -1.40 74% 8 21909 -1.10 52% 
Single measure-BP response [sensitivity analysis] 
CCB vs. ARB 7 21444 -1.77 40% 7 21444 -1.12 56% 
     
Repeated measures-BP response [FE model] 
CCB vs. ACEI 3 19982 -1.09 0% 3 19982 -1.01 90% 
CCB vs. ARB 3 21094 -1.43 43% 3 21094 -0.88 28% 
CCB vs. DI 6 55313 0.97 93% 6 55313 -0.37 77% 
CCB vs. BB 2 33457 1.43 96% 2 33457 -0.16 86% 
CCB vs. Placebo 3 9676 -8.04 95% 3 9676 -4.66 90% 
CCB vs. CCB  1 489 -0.3 - 1 489 0 - 
Repeated measures-BP response [RE model] 
CCB vs. ACEI 3 19982 -1.09 0% 3 19982 -2.19 90% 
CCB vs. DI 6 55313 0.84 93% 6 55313 -0.35 77% 
CCB vs. BB 2 33457 1.55 98% 2 33457 -0.20 86% 
CCB vs. Placebo 3 9676 -6.42 95% 3 9676 -4.02 90% 
Repeated measures-BP response [sensitivity analysis] 
CCB vs. ACEI 2 1880 -1.81 0% 2 1880 -2.99 0% 
CCB vs. DI 4 32935 0.84 0% 4 32935 -0.46 18% 
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As shown in Table 3.4 : 
CCBs were “significantly” superior to ACEIs in lowering BP, both SBP and DBP. For 
SBP (delta: -1.2 mmHg (P < 0.00001), single measure: -1.17 mmHg (P = 0.02), 
repeated measures: -1.81 mmHg (P = 0.010)). For DBP (delta: -0.76 mmHg (P < 
0.00001), single measure: -1.29 mmHg (P < 0.00001), repeated measures: -2.99 
mmHg (P < 0.00001)). 
 
CCBs were also superior to ARBs in lowering BP, both SBP and DBP. For SBP (delta: 
-0.16 mmHg (P = 0.78), single measure: -1.77 mmHg (P < 0.00001), repeated 
measures: -1.43 mmHg (P < 0.00001)). For DBP (delta: -0.25 mmHg (P = 0.39), 
single measure: -1.12 mmHg (P < 0.00001), repeated measures: -0.88 mmHg (P < 
0.00001)). 
 
CCBs were “significantly” superior to the placebo in lowering BP, both SBP and 
DBP. For SBP (delta: -8.76 mmHg (P < 0.00001), single measure: -4.5 mmHg (P = 
0.02), repeated measures: -8.76 mmHg (P < 0.00001)). For DBP (delta: -4.46 mmHg 
(P < 0.00001), single measure: -2.3 mmHg (P < 0.0001), repeated measures: -4.9 
mmHg (P < 0.00001)). 
 
There was no significant BP variance between different agents within the same 
CCB classes in BP response. For SBP (delta: -1.34 mmHg (P = 0.23), single measure: 
0.07 mmHg (P = 0.95) and repeated measures: -0.3 mmHg (P = 0.80)). For DBP 
(delta: -0.27 mmHg (P = 0.64), single measure: -0.25 mmHg (P = 0.73) and 
repeated measures: 0 mmHg (P = 1.00).
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Table 3.5 Summary of DI-BP responses.  
The table shows delta, single and repeated measures - BP response .Considering the level 
of statistical significance (P < 0.05), [White highlights] indicate significant statistical effect, 
[Grey highlights] indicate insignificant statistical effect and [Red highlights] indicate 
significant statistical effect in all BP measures. 
DI Studies N  Subjects N SBP I2 Studies N Subjects N DBP I2 
Delta-BP response [FE model] 
DI vs. ACEI 4 44447 -0.5 97% 4 44447 0.83 96% 
DI vs. ARB 3 836 -1.97 0% 3 836 -0.2 57% 
DI vs. CCB 7 71766 -0.48 95% 7 71766 0.76 93% 
DI vs. BB 2 820 1.42 79% 2 820 -0.07 54% 
DI vs. Placebo 1 102 -10 - 1 102 -5.4 - 
DI vs. DI 1 171 -2 - 1 171 -1 - 
Delta-BP response [RE model] 
DI vs. ACEI 4 44447 0.29 97% 4 44447 0.5 96% 
DI vs. CCB 7 71766 -0.82 0% 7 71766 0.49 0% 
DI vs. BB 2 820 1.72 79% 2 820 -0.08 54% 
Delta-BP response [sensitivity analysis] 
DI vs. ACEI 2 24407 -1.79 0% 2 24407 0.09 0% 
DI vs. CCB 4 25026 -0.82 42% 4 25026 0.63 58% 
     
Single measure-BP response [FE model] 
DI vs. ACEI 1 463 -5.2 - 1 463 -2.2 - 
DI vs. ARB 3 571 -1.97 48% 3 571 -1.37 60% 
DI vs. CCB 4 1810 -2.41 0% 4 1810 -0.94 45% 
DI vs. BB 1 374 -3 - 1 374 -1 - 
DI vs. Placebo 1 5665 -6.2 - 1 5665 -2.9 - 
     
Repeated measures-BP response [FE model] 
DI vs. ACEI 1 24309 -2 - 1 24309 -0.2 - 
DI vs. CCB 6 55313 -0.97 93% 6 55313 0.37 77% 
DI vs. Placebo 1 5665 -4.4 - 1 5665 -2 - 
Repeated measures-BP response [RE model] 
DI vs. CCB 6 55313 -0.84 93% 6 55313 0.35 77% 
Repeated measures-BP response [sensitivity analysis] 
DI vs. CCB 4 32935 -0.84 0% 4 32935 0.46 18% 
 
As shown in Table 3.5 : 
DIs were “significantly” superior to ACEIs in lowering SBP (delta: -1.79 mmHg (P < 
0.00001), single measure: -5.2 mmHg (P = 0.001) and repeated measures: -2 mmHg 
(P < 0.00001)).  
 
DIs were superior to ARBs in lowering BP, both SBP and DBP. For SBP (delta: -1.97 
mm Hg (P = 0.05) and single measure: -1.97 mmHg (P = 0.06)). For DBP (delta: -
0.2 mmHg (P = 0.70) and single measure: -1.37 mmHg (P = 0.003)).  
 
DIs were “significantly” superior to CCBs in lowering SBP (delta: -0.82 mmHg (P < 
0.0001), single measure: -2.41 mmHg (P < 0.0001) and repeated measures: -0.84 
mmHg (P < 0.00001)). 
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DIs were “significantly” superior to the placebo in lowering BP, both SBP and DBP. 
For SBP (delta: -10 mmHg (P = 0.0007), single measure: -6.2 mmHg (P < 0.00001) 
and repeated measures: -4.4 mmHg (P < 0.00001)). For DBP (delta: -5.4 mmHg (P 
= 0.0002), single measure: -2.9 mmHg (P < 0.00001) and repeated measures: -2 
mmHg (P < 0.00001)). 
 
There was no significant BP variance between different agents within the same DI 




Table 3.6 Summary of BB-BP responses.  
The table shows Delta, single and repeated measures - BP response. Considering the level 
of statistical significance (P < 0.05), [White highlights] indicate significant statistical effect 
and [Grey highlights] indicate insignificant statistical effect. 
BB Studies N  Subjects N SBP I2 Studies N Subjects N DBP I2 
Delta-BP response [FE model] 
BB vs. ACEI 8 22798 0.99 80% 8 22798 0.95 95% 
BB vs. ARB 4 10154 1.16 53% 4 10154 -0.14 3% 
BB vs. CCB 7 72468 -0.21 95% 7 72468 0.5 95% 
BB vs. DI 2 820 -1.42 79% 2 820 0.07 54% 
BB vs. Placebo 2 944 -7.24 0% 2 944 -4.53 0% 
BB vs. BB 1 205 0.9 - 1 205 0.2 - 
Delta-BP response [RE model] 
BB vs. ACEI 8 22798 -0.43 80% 8 22798 -0.32 95% 
BB vs. CCB 7 72468 -0.09 95% 7 72468 0.36 95% 
Delta-BP response [sensitivity analysis] 
BB vs. ACEI 6 2783 -0.79 60% 6 2783 -0.82 58% 
BB vs. CCB 3 3152 0.27 0% 3 3152 -0.12 42% 
     
Single measure-BP response [FE model] 
BB vs. ACEI 5 2211 0.11 76% 5 2211 0.54 80% 
BB vs. ARB 2 9418 1.26 0% 2 9418 -0.44 16% 
BB vs. CCB 3 818 -2.73 58% 3 818 -1.27 24% 
BB vs. DI 1 374 3 - 1 374 1 - 
BB vs. BB  1 205 -1.2 - 1 205 0.3 - 
Single measure-BP response [RE model] 
BB vs. ACEI 5 2211 0.11 76% 5 2211 0.23 80% 
Single measure-BP response [sensitivity analysis] 
BB vs. ACEI 4 1748 1.4 0% 4 1748 1.09 56% 
     
Repeated measures-BP response [FE model] 
BB vs. ACEI 1 758 -1.6 - 1 758 -0.2 - 
BB vs. ARB 2 9418 0.99 0% 2 9418 -0.9 0% 
BB vs. CCB 2 33457 -1.43 98% 2 33457 0.16 86% 
Repeated measures-BP response [RE model] 
BB vs. CCB 2 33457 -1.55 98% 2 33457 0.20 86% 
 
As shown in Table 3.6 : 
BBs were superior to ARBs in lowering DBP (delta: -0.14 mmHg (P = 0.46), single 
measure: -0.44 mmHg (P = 0.04), repeated measures: -0.9 mmHg (P < 0.0001)).  
 
BBs were “significantly” superior to the placebo in lowering BP, both SBP and DBP 
(delta: -7.24 (P < 0.00001)/-4.53 mmHg (P < 0.00001)). 
 
There was no significant BP variance between different agents within the same BB 
classes in BP response. For SBP (delta: 0.9 mmHg (P = 0.63) and single measure: -
1.2 mmHg (P = 0.52)). For DBP (delta: 0.2 mmHg (P = 0.85) and single measure: 
0.3 mmHg (P = 0.78)). 
  223 
 
3.3.2 Discussion 
After a systematic search and selection process according to the PRISMA protocol 
that included 82 RCTs assessing BP response (including delta, single and repeated 
measures) with 197,684 hypertensive patients, 56 studies were included in the 
analysis of delta BP response, 37 studies were included in the analysis of single-
measure BP response and 20 studies were included in the analysis of repeated 
measures. The majority of the included studies, as mentioned before, were non-
intentional BP-lowering studies; so, not all the desired BP response data were 
available from each study.The review found that CCBs were significantly superior 
to ACEIs in lowering both SBP and DBP (Chen 2010 (143)). DIs were significantly 
superior to ACEIs (Baguet2007(123)) and CCBs (Chen2010 (143), Baguet2007(123) and 
Psaty2003 (141)) in lowering SBP. ARBs were significantly superior to BBs in 
lowering SBP (BP response as an outcome; no reviews included or compared ARBs 
to BBs to our knowledge). CCBs (Wright2009 (138)) and DIs (Wright2009 (138) and 
Psaty2003 (141)) were significantly superior to placebos in lowering both SBP and 
DBP. 
 
In the majority of patients, reducing SBP has been much more difficult than 
lowering DBP. Whereas effective BP control can be achieved in most patients who 
are hypertensive, the majority of patients require two or more BP-lowering 
agents. In recent years, there has been a global improvement in BP control rates 
that has been largely attributed to the increased use of BP-lowering agents, such 
as monotherapy or combination therapy(33).  
 
RAAS inhibitors play an important role in regulating BP. Both ACEIs and ARBs have 
been found to inhibit RAAS and effectively treat HTN. They have been found to 
have additional beneficial effects that may be independent of their BP-lowering 
properties (such as reducing the progression of nephropathy in T2DM and RF) 
(428;429). Furthermore, RAAS inhibitors are considered the class of choice for the 
treatment of HTN in obese patients due to their wide range of CV benefits (430). 
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In the review, ACEIs were superior to ARBs in lowering DBP7. Similarly, the 
candesartan and lisinopril microalbuminuria (CALM 2000) study showed that for 
hypertensive patients with T2DM, ACEI-lisinopril is superior to ARB–candesartan 
in lowering BP; the mean SBP reductions were -15.7 mmHg and -12.4 mmHg, 
respectively, and the mean DBP reductions were -9.7 mmHg and -9.5 mmHg, 
respectively. However, there was no significant difference between the two 
treatments for SBP (P = 0.18) and DBP (P > 0.20) (431). Though, a large 
randomised study in hypertensive women to compare the BP-lowering efficacy 
and effects of ARB-candesartan and ACEI- enalapril showed that candesartan 
lowered seated BP by -17/-11 and -19/-11 mmHg after 6 and 12 weeks of 
treatment, respectively. This reduction was greater than with enalapril (-12/-8 
and -13/-9 mmHg) (P < 0.01) (432). 
 
ACEIs were significantly superior to the placebo in lowering BP, including both SBP 
and DBP. Similarly, the HOPE 2000 study showed that the mean BP was 135/76 
mmHg in the ACEI-ramipril group and 138/78 mmHg in the placebo group after 
two years, and 136/76 mmHg and 139/77 mmHg respectively at the end of the 
study. In addition, treatment with ACEI-ramipril significantly reduced the rates of 
death from CV causes, MI, stroke, HF (P < 0.001) and complications related to 
T2DM (P = 0.03) compared to the placebo (230). Furthermore, ACEI-trandolapril 
significantly reduced 24-hour BP compared to the placebo; this reduction involved 
both daytime SBP/DBP (-9/-7.6 mmHg (P < 0.01)) and nighttime SBP/DBP (-5.3/-
4.3 (P < 0.01)) (433). 
There was no significant difference in BP response between different agents 
within the same ACEI class. ACEI-enalapril and lisinopril significantly lowered 24-
hour BP (SBP/DBP: 127/81 and 124/78 mmHg respectively; P < 0.001). Whereas 
both daytime and nighttime BP were significantly reduced by both drugs, ACEI-
lisinopril was more effective in lowering BP (P < 0.05) (434). 
ARBs were significantly superior to BBs in lowering SBP. Similarly, LIFE 2002 showed 
that SBP at the last visit decreased by 30.2 and 29.1 mmHg in the ARB-losartan 
and BB-atenolol groups, respectively (treatment difference P = 0.017).  DBP was 
                                         
7
  No significant difference in repeated measures -BP response. This comparison included only one 
study (DETAIL2004).  
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reduced by 16.6 and 16.8 mmHg, respectively (P = 0.37). The LIFE 2002 results 
showed that ARB-losartan was superior to BB-atenolol in reducing the primary 
composite endpoints of CV morbidity and mortality, which were both significant 
(14·6%, P = 0.009) (435).  
 
ARBs were superior to the placebo in lowering BP, including both SBP and DBP8. 
Similarly, RENAAL 2001 showed that ARB-losartan was superior to the placebo in 
lowering SBP/DBP by -2.0/-0.0 mmHg, but BP reduction was not significant (P = 
0.59). Though CV morbidity and mortality was similar between the two 
interventions, the rate of first hospitalisation for HF was significantly lower with 
ARB-losartan (P = 0.005), and the level of proteinuria dropped by 35% with the 
same drug in comparison with the placebo (P < 0.001) (265). Furthermore, 
TRANSCEND 2008 showed that the mean BP was lower with ARB-telmisartan than it 
was with the placebo by -3.2/-1.3 mmHg at the end of the study. Of the secondary 
outcomes, a composite of CVS death, MI and/or stroke occurred in 384 (13.0%) 
patients on ARB-telmisartan compared to 440 (14.8%) on the placebo (P = 0.048) 
(276).  
There was a significant difference in BP response between different agents within 
the same ARB class. Similarly, a meta-analysis of randomised studies of ARB 
therapy for BP reduction showed that telmisartan therapy was associated with a 
statistically significant difference in BP reduction relative to valsartan therapy in 
both the monotherapy and combination therapy groups (SBP/DBP: –2.04/–
1.08 mmHg (P < 0.00001)) (436). 
Among the drugs currently available as first-line treatments of HTN, DHP-CCBs 
continue to receive significant attention for their renowned BP-lowering efficacy 
and clear benefits in preventing CV complications and reducing associated 
mortality. Therefore, in the past few years, numerous large clinical studies, such 
as ALLHAT 2002 (48), VALUE 2004 (367), ASCOT-BPLA 2005 (51) and ACCOMPLISH 2004 
(282), have confirmed clinical interest in a CCB-based therapy for the 
management of normal and high CV risk hypertensive patients. Meanwhile, a 
                                         
8
 There was no significant difference in repeated measures -BP responses. This comparison 
included only one study (IDNT 2001).  
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meta-analysis found that compared to ACEIs, BBs and DIs, CCBs were associated 
with a significantly higher risk of MI (OR = 1.26; P = 0.0003), HF (OR = 1.25; P = 
0.005) and CV events (OR = 1.10; P = 0.02) (437). However, a larger meta-analysis 
including more subclasses of CCBs has cleared doubts regarding the increasing 
incidence of coronary events, and CCBs have been reported to show the lowest 
interindividual variation in SBP as opposed to other BP-lowering agents, which may 
be linked to a reduced risk of stroke (438).  
CCBs were significantly superior to ACEIs in lowering BP, both SBP and DBP.  
Similarly, AASK 2002 showed that CCB–amlodipine was superior to ACEI-ramipril in 
lowering SBP/DBP by -2/-1 mmHg (48;50).On the other hand, Agabiti 2005 showed 
that ACEI-enalapril was superior to CCB-nifedipine in lowering SBP by -16.3 and -
15.3 mmHg (P = 0.30) and DBP by -12.4 and -11.8 mmHg (P = 0.36), respectively 
(439). 
Despite a similar BP reduction, ABCD 1998 showed a lower incidence of fatal and 
non-fatal MI in the ACEI-enalapril group (P = 0.001). Compared to CCB-nisoldipine, 
significantly more patients in the ACEI-enalapril group received a combination of 
drugs, including BBs (P = 0.03) and DIs (P = 0.02) (392). Furthermore, the ABCD 
1998 (392), FACET 1998 (309) and MIDAS 1996 (343) studies showed the positive effects 
of ACEIs over CCBs on the development and progression of macro- and 
microvascular complications in T2DM and together may raise concern regarding 
the use of CCB in hypertensive patients with T2DM. 
CCBs were superior to ARBs in lowering BP, including both SBP and DBP9. Similarly, 
the Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine 
for Secondary Prevention (MOSES 2005) study, which was the first to compare ARB-
eprosartan with CCB-nitrendipine in secondary-stroke prevention. The study 
showed that an early normotensive and superior BP reduction was achieved in 
CCB-nitrendipine of 132.7/80.2 mmHg over ARB-eprosartan (133.2/80.4 mmHg) 
but without any significant difference in BP values. However, cerebrovascular and 
CV events and non-CV deaths were significantly lower in the ARB-eprosartan group 
(P = 0.014) (440). In the VALUE 2004 study, there was no difference in fatal and 
                                         
9
 There was no significant difference in delta BP responses. This comparison included only four 
studies with a relatively smaller N of participants.  
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nonfatal cardiac events at 4.2 years among patients randomised to CCB amlodipine 
or ARB valsartan. However, the amlodipine-based regimen was associated with 
more rapid control of HTN and fewer CV events during the first year of the study 
(367). 
CCBs were significantly superior to the placebo in lowering BP, including both SBP 
and DBP, similar to the results of the ACTION 2004 study showing that CCB-
nifedipine significantly reduced BP compared to the placebo by -14.6/-7.6 mmHg 
as opposed to -9.1/-4.5 mmHg (P < 0.001). CCB-nifedipine therapy showed a 
significant 13% reduction (P < 0.05) in the combined incidence of all-cause 
mortality: MI, angina, HF, stroke and peripheral revascularisation (179). However, 
BENEDICT 2004 showed that the average SBP/DBP was 141/82 mmHg in the CCB-
verapamil group, 139/81 mmHg in the ACEI-trandolapril group and 142/83 mmHg 
in the placebo group. Compared to the placebo, BP reduction was significant (P ≤ 
0.002) for ACEI-trandolapril though not for CCB-verapamil (187).  
There was no significant variance in BP response between different agents within 
the same CCB class. Similarly, a meta-analysis reporting comparative efficacy 
(changes in SBP and DBP), showed that CCB-manidipine and CCB-amlodipine were 
statistically equivalent: the effect size for DBP was -0.08 (P = 0.22) and for SBP 
was -0.01 (P = 0.83) (441). In addition, there were no statistically significant 
differences between CCB-nifedipine and CCB-amlodipine in their effects on SBP 
and DBP. The patients treated with nifedipine had a mean decrease in SBP of -
18.8 mmHg and in DBP of -15.5 mmHg compared to amlodipine (-19.7 and -15.7 
mmHg, respectively; P = 0.55) (442). 
 
Multiple HTN treatment guidelines from various regions of the world recommend 
thiazide or thiazide-like DIs as a first-line treatment for patients with essential 
HTN (15;16;387). However, an analysis of clinical studies suggests that DI is less 
effective in lowering BP than RAAS blockers or CCBs and thus offers less CV 
protection than the latter options. In general, when a DI is used for the treatment 
of HTN, thiazide or thiazide-like DIs are mainly prescribed; however, the majority 
of large RCTs, such as ALLHAT 2002 or HYVET 2008, which demonstrate the CV benefit 
of DIs, have used thiazide-like DIs, such as chlorthalidone or indapamide, but not 
thiazide DI-hydrochlorothiazide (48;322). 
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DIs were significantly superior to ACEIs in lowering SBP. Similarly, the study 
Identification of the Determinants of the Efficacy of Arterial Blood Pressure 
Lowering drugs (IDEAL2005) showed that in middle-aged women, SBP reduction was 
superior with DI-indapamide at -11.5 mmHg compared to ACEI-perindopril at -
8.3 mmHg (P = 0.001). However, the response in men was significantly smaller: -
4.8 mmHg for DI-indapamide and -4.3 mmHg for ACEI-perindopril (P = 0.015). 
Although the SBP response to ACEI-perindopril reduced by 2 mmHg every 10 years 
in both sexes (P = 0.01), the response to DI-indapamide increased by 3 mmHg every 
10 years of age in women (P = 0.02) (443).  
The Treatment of Mild Hypertension Study (TOMHS 1993) indicated the superiority 
of DI-chlorthalidone over ACEI-enalapril in lowering SBP (a change based on all 
follow-up BP measurements): -17.7 mmHg and -14.7 mmHg, respectively (P < 0.01) 
(444). Furthermore, ANBP2 2003 showed the superiority of DI- hydrochlorothiazide 
compared to ACEI-enalapril in SBP reduction by -22/-9 mmHg with DIs and -20/-9 
mmHg with ACEIs at year 1 and by -24/-10 mmHg with DIs and -23/-10 mmHg ACEIs 
at year 2 but with no significant difference. There was a borderline superiority of 
ACEI-enalapril compared to hydrochlorothiazide-based therapy in terms of CV 
event MI (P = 0.04) (445).  
DIs were superior to ARBs in lowering BP, including both SBP and DBP10. BP 
decreased by -16.3/-12.0 mmHg in patients treated with ARB-candesartan and by 
-18.8/-11.4 mmHg in patients treated with DI- hydrochlorothiazide. However, the 
difference between treatments in favour of ARB-candesartan was not statistically 
significant (P > 0.20). Although the profile of adverse events was generally similar 
in both treatment groups, hypokalaemia and hyperuricemia were not found in 
patients treated with ARB-candesartan but occurred in 8.1% and 6.5%, 
respectively, of patients treated with DI- hydrochlorothiazide (249). 
DIs were significantly superior to CCBs in lowering SBP. Similarly, ALLHAT 2002 
showed that after 5 years, SBP was significantly higher with CCB-amlodipine (P = 
0.03) compared to DI-chlorthalidone, whereas DBP was significantly lower with 
                                         
10
 There was no significant difference (apart from DBP single measures). This comparison included 
only four studies with a relatively smaller N of participants.  
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CCB-amlodipine (0.8 mmHg, P < 0.001). However, stroke, combined CHD and CVD 
and all-cause mortality were similar for CCB-amlodipine and DI-chlorthalidone, 
with the exception that the CCB-amlodipine group had a 38% higher risk of HF and 
a 35% higher risk of hospitalisation/fatal HF (all, P < 0.001), compared to the DI-
chlorthalidone group (48).Therefore, DI-chlorthalidone has been effectively 
incomparable in preventing the CV complications of HTN and can be useful in 
achieving BP control, along with enhancing the BP-lowering efficacy of multidrug 
regimens.  
Furthermore, CONVINCE2003 showed that CCB-verapamil was also associated with 
an increased risk of HF when compared to BB-atenolol or DI-hydrochlorothiazide 
(1.5% vs. 1.2%, P = 0.05) (446). Despite a similar BP reduction, INSIGHT 2000 showed 
that CCB therapy decreased the risk of all-cause mortality in patients from 
vascular and nonvascular causes, with T2DM compared to those without T2DM (P 
= 0.03); it also decreased the incidence of new cases of T2DM compared to DI 
therapy (P = 0.02) (447). CCB-nifedipine monotherapy decreased DBP by -4.3 
mmHg (P = 0.005) in comparison to DI-HCTZ, and a progressive decrease in the 
LVM index was observed with CCB-nifedipine monotherapy (P = 0.03) (448). 
DIs were significantly superior to the placebo in lowering BP, including both SBP 
and DBP. Similarly, the Medical Research Council trial of treatment of mild 
hypertension in older adults (MRCO 1992) (449) and Oslo 1980(45) showed the 
superiority of DI-HCTZ over the placebo in lowering SBP and DBP: -16/-6 mmHg (P 
< 0.05) and -17/-10 mmHg (P < 0.01), respectively. 
 
There was no significant variation in BP response between different agents within 
the same DI class11. SBP and DBP decreased similarly in patients with mild-to-
moderate HTN and T2DM by 15% and 9%, respectively, with indapamide and by 
17% and 10%, respectively, with hydrochlorothiazide (450). The data indicated a 
greater reduction of 24-hour mean SBP with chlorthalidone compared to 
hydrochlorothiazide (-12.4 mmHg versus -7.4 mmHg) and a reduction of 24-hour 
mean DBP with chlorthalidone compared to hydrochlorothiazide (-7.1 mmHg 
                                         
11
  There was no significant difference in the delta BP response. This comparison included only one 
study (Cremonesi 2002).  
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versus -5.1 mmHg). However, there was no statistical significance ((P = 0.05) and 
(P = 0.29), respectively). BP reduction was also not statistically significant for 
both: clinic SBP was -17.1 mmHg for hydrochlorothiazide and -10.8 mmHg for 
chlorthalidone (P= 0.84) and clinic DBP was -6.9 mmHg for hydrochlorothiazide 
versus -8.1 mmHg for chlorthalidone (P = 0.89) (451).  
A number of international guidelines, including ESH/ESC (15) and CHL(387), still 
consider BB in their recommendations for HTN management. BBs are still 
preferred in hypertensive patients who have suffered from MI or other forms of 
CHDs and HF due to systolic dysfunction (452). The NICE guidelines recommend 
not using BBs as a first line of treatment for HTN, which has brought the BB group 
to the forefront of academic research (14), and JNC-7 found that BB-atenolol was 
lacking in protection against stroke (16).  
An ASCOT-BPLA 2005 sub-study showed that BBs effectively lower brachial (arm) 
BP; however, they may be less effective in reducing central aortic pressure 
compared to other BP-lowering classes (for example, central aortic SBP was 
decreased by 4.3 mmHg with CCB-amlodipine compared to BB-atenolol (P < 
0.0001))(453). Increased central aortic pressure has been associated with an 
increased risk of vascular events, particularly stroke (454). These results may at 
least explain the stroke risk associated with traditional BBs.  
 
Another subgroup analysis of INVEST 2003 showed that the incidence of new-onset 
T2DM in the CCB-verapamil arm was significantly lower than in the BB-atenolol 
arm (6.2% vs. 7.3%, P < 0.05), as was the composite of death (12.0% vs. 13.4%, P < 
0.05) (455). Consequently, BBs’ clinical utility could still be in question due to 
their limited effectiveness in decreasing BP.  
 
BBs were superior to ARBs in lowering DBP12. The study Swedish Irbesartan Left 
Ventricular Hypertrophy Investigation versus atenolol (SILVHIA 2001) showed similar 
results, favouring BB-atenolol over ARB-irbesartan in reducing DBP; they attained 
-2.1 mmHg and –1.1 mmHg reductions at 12 and 24 weeks, respectively. However, 
there was no significant difference (for all, P > 0.001). LVM was reduced more 
                                         
12
 There was no significant difference in the delta BP response. This comparison included only four 
studies with a relatively smaller N of participants.  
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extensively in the irbesartan group than in the BB-atenolol group (P = 0.024) (456). 
Furthermore, CVIP 2004 results showed that even though BBs were slightly superior 
to ARBs in reducing DBP toward the end of the study by -1.1 mmHg, there was no 
significant difference (P > 0.05) (202). 
BBs were significantly superior to the placebo in lowering BP, including both SBP 
and DBP. Similarly, the Medical Research Council Trial of Treatment of Mild 
Hypertension (MRC 1985) (449;457) and MRCO 1992 (449;457) showed the superiority 
of BBs over the placebo: propranolol by -9.5/-5.0 mmHg and atenolol by -13.0/-
7.0 mmHg, respectively (for all, P < 0.05).  
There was no significant discrepancy in BP response between different agents 
within the same BB class. Similarly, GEMINI2004 showed that both carvedilol and 
metoprolol reduced BP; however, there was no significant difference between the 
two agents for SBP (P = 0.21) and DBP (P = 0.53). However, BB-carvedilol showed 
better metabolic effects in all races and both genders (221). Another study showed 
that both the BB atenolol and bisoprolol drugs significantly lowered BP compared 
to baseline (all, P < 0.5); however, SBP and DBP changes were not different 
between the two drugs (SBP (P = 0.55) and DBP (P = 0.37)) (458). 
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4 Genome-wide Study  
This chapter summarises the results of NORDIL 2000 – GWAS subjects (including, 
demographics, quality control, GWAS and specificity of BP response , survival 
analysis, and replication studies) in order to identify SNPs associated with the 
BP-lowering responses of CCBs and BBs. 
4.1.1 Demographics  
The demographics of the NORDIL2000 population on CCBs and BBs are presented in 
the Table 4.1. 
Table 4.1 Demographics of the NORDIL2000 population. 
 CCB Arm BB Arm 
N 2018 2021 
Male :Female  % 50.1:49.9 49.6:50.4 
Mean (SD) 
Age 60.2 (6.6) 60 (6.6) 
BMI 28 (4.4) 28.3 (4.4) 
SBP-baseline 173.8 (16.7) 173.3 (16.7) 
DBP-baseline 104.3 (5.3) 104.2 (5.4) 
% delta SBP -9.6 (8.7) -10.9 (9.2) 
% delta DBP -13.9 (7.5) -13.7 (7.9) 
 
4.1.2 Quality control 
The NORDIL2000 data contains 4,039 samples and 500,915 SNPs. Following quality 
check for low MAF, HWE, and/or high rate of missingness: no SNPs had missingness 
rate of <0.95, no SNPs had MAF <0.01 and only 10 SNPs fail HWE at significant 
threshold of (P< 5×1-6) and were therefore removed. The IBS pairwise distance 
matrix was calculated. MDS was performed on this matrix as a data reduction 
measure. The first two MDS components were plotted against each other, as shown 
in Figure 4.1. 
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Figure 4.1 MDS plot of first two components for HapMap samples and NORDIL2000 
samples. The plot confirmed the NORDIL2000samples as being of European descent 
and did not reveal any outlier individuals .CEU= Utah residents with Northern and 
Western European ancestry. CHB= Chinese in Beijing.JPT= Japanese in Tokyo. 
NORDIL= European in Norway and Sweden. YOR=Yoruba in Nigeria. 
 
4.1.1 GWAS of BP response 
Association analysis using linear regression (under an additive genetic model) was 
performed on the change from baseline of SBP and DBP at six months post-
randomisation. Analysis was performed in the BB arm (N=2021) and CCB arm 
(N=2018) and in the subset who were on monotherapy at 6 months- CCB (N= 1,639) 
or BB (N= 1,070). As shown in Table 4.2, 51 SNPs reached a significant threshold 
of (P<1X10-5). However, no SNP achieved a genome wide significant threshold of 
(P<5x10-8). 
Figure 4.2 shows the manhattan plot for BP response to BB monotherapy in the 
NORDIL2000 cohort. There was no evidence for genomic inflation (λ=1) and no SNP 
achieved a genome wide significant threshold of p<5x10-8. The top signals are 
indicated by arrows and the underlying genes presented in the table below.  
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Figure 4.3 shows the manhattan plot for BP response to CCB monotherapy in the 
NORDIL2000 cohort. The top signals are indicated by arrows and the underlying 




Table 4.2 Top GWAS-NORDIL2000 SNPs considering level of statistical significance 1X10-5. 
[Red highlights] indicate SNPs presented in the manhattan plot below. 
CHR SNP POS A1 BETA SE P 
13 rs12866529 75835110 A -4.50 0.87 3.36E-07 
2 rs7583409 25344560 G -2.40 0.54 4.01E-07 
6 rs12663184 30409579 T 5.08 1.05 1.40E-06 
11 rs1502447 29206734 C -1.30 0.27 2.33E-06 
11 rs1502448 29207021 A -1.30 0.27 2.33E-06 
17 rs216195 2149917 C 2.55 0.54 2.71E-06 
1 rs7548027 38864643 C 3.19 0.65 2.94E-06 
5 rs1664786 53317468 T 1.76 0.38 3.24E-06 
11 rs575929 78565913 G -1.36 0.29 3.80E-06 
16 rs8061566 26704144 A -2.25 0.49 3.96E-06 
5 rs1664789 53318406 C 1.75 0.38 3.98E-06 
3 rs9830122 16102226 C -1.76 0.38 4.07E-06 
10 rs1914525 125535626 A -2.50 0.54 4.17E-06 
5 rs2062400 154574494 C -1.87 0.40 3.93E-06 
2 rs4907206 96924640 T -1.65 0.36 4.47E-06 
7 rs1406603 147570218 T 2.55 0.55 4.70E-06 
1 rs4970609 38865036 G 2.44 0.54 5.85E-06 
1 rs4970610 38865078 T 2.44 0.54 5.85E-06 
1 rs594856 38880584 C 2.44 0.54 5.85E-06 
2 rs4907203 96920270 T -1.61 0.35 6.12E-06 
18 rs605902 46699496 T 3.88 0.85 6.21E-06 
18 rs625566 46668924 T 3.88 0.85 6.21E-06 
19 rs8104633 56937927 T -2.67 0.59 6.21E-06 
12 rs2363877 6162722 G 1.27 0.28 6.84E-06 
11 rs7480026 11945018 A 3.38 0.75 7.08E-06 
14 rs2144067 101022159 T -2.23 0.50 7.72E-06 
13 rs17066095 75801978 C -7.60 1.69 2.56E-06 
8 rs17072101 4877059 G 0.52 0.96 4.61E-06 
8 rs1810195 23537855 C 2.98 0.73 6.20E-06 
3 rs10865738 16108387 C -1.77 0.38 8.54E-06 
6 rs7752482 148633692 G 2.32 0.52 9.27E-06 
17 rs216182 2119813 G 2.42 0.54 9.51E-06 
14 rs7147183 45528446 G 1.22 0.28 1.06E-05 
14 rs8017812 84165788 A 1.83 0.41 1.07E-05 
13 rs9585548 100368236 A -1.23 0.28 1.09E-05 
14 rs7141196 84175762 G 1.82 0.41 1.20E-05 
9 rs1778982 137303859 T 2.23 0.51 1.26E-05 
12 rs2363880 6172270 A 1.23 0.28 1.27E-05 
14 rs8017871 45495969 G 1.21 0.28 1.30E-05 
13 rs9565263 75842776 A -3.61 0.82 1.30E-05 
9 rs1981047 22163499 G 4.33 0.99 1.31E-05 
2 rs749581 86301742 A -1.86 0.43 1.36E-05 
12 rs2363878 6163236 A 1.23 0.28 1.42E-05 
1 rs6421774 204153436 C 2.76 0.63 1.43E-05 
6 rs9403095 139985440 A -1.68 0.39 1.54E-05 
14 rs10148201 101029334 C -2.14 0.49 1.55E-05 
14 rs4411445 83929459 T 3.16 0.73 1.69E-05 
4 rs2321559 141954857 G -1.85 0.43 1.76E-05 
7 rs1534702 147567736 T 2.48 0.58 1.82E-05 
6 rs7766818 46825413 C -2.10 0.49 1.87E-05 
10 rs666595 6268232 T -3.12 0.73 1.90E-05 
CHR= chromosome. SNP= single nucleotide polymorphism. POS= chromosomal position. 




Figure 4.2 Manhattan plot of –log10 transformed P values against genomic position for 
BP response to BB monotherapy in the NORDIL2000. 
Red line indicates P=5x10-8 and blue line indicates P=5x10-7.GALNT2= polypeptide N-
acetylgalactosaminyltransferase 2 (possibly influence triglyceride levels, and involved in 
T2DM). SNTG1= syntrophin gamma 1 (involved in idiopathic scoliosis). FAM110B= 
family with sequence similarity 110 member B (possibly involved in tumor progression). 
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Figure 4.3 Manhattan plot of –log10 transformed P values against genomic position for 
BP response to CCBmonotherapy in the NORDIL2000.   
Red line indicates P=5x10-8 and blue line indicates P=5x10-7 .DNMT3A =DNA (Cytosine-
5- )-methyltransferase 3 Alpha (possibly involved in cerebellar ataxia, deafness, and 
narcolepsy). PTCD3= pentatricopeptide repeat domain 3 (involved in mitochondrial 
translation). CTNND2=catenin delta 2 (involved in brain and eye development and 
cancer formation).  
 
4.1.2 Specificity of BP response 
by studying discordant 
effect of SNPs to BB and 
CCB 
The differential effects of SNP genoptype on BP response was studied in order to 
identify SNPS with directionally opposite BP responses to BB and CCB, as shown in 
Table 4.3 and Table 4.4. The top discordant signals included five SNPs for SBP on 
BB arm, seven SNPs for DBP on BB arm, 12 SNPs for SBP on CCB arm and nine SNPs 
for DBP on CCB arm. The reason for conducting this analysis was to determine 
SNPs that show specific response to either BB or CCB and as they reflect different 
BP regulatory pathways. The Figure 4.4 below depicts the top discordant signals 
identified in this study.
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Table 4.3 Top discordant SNPs considering level of statistical significance 1X10-5 [SBP]. 
 [Red highlights] indicate SNPs presented in the figure of top discordant signals below.  
  BB CCB 
CHR SNP POS A1 N BETA SE P N BETA SE P 
13 rs12866529 75835110 A 970 -4.50 0.87 3.36E-07 1500 0.14 0.62 0.8269 
6 rs12663184 30409579 T 971 5.08 1.05 1.40E-06 1500 -0.35 0.79 0.6611 
13 rs17066095 75801978 C 971 -7.60 1.69 2.56E-06 1498 1.24 1.18 0.2924 
8 rs17072101 4877059 G 971 0.52 0.96 4.61E-06 1499 -1.64 0.70 0.01936 
13 rs9565263 75842776 A 971 -3.61 0.82 1.30E-05 1500 0.25 0.57 0.6629 
2 rs7583409 25344560 G 971 0.82 0.73 0.2634 1500 -2.40 0.54 4.01E-07 
17 rs216195 2149917 C 963 -1.48 0.72 0.04124 1489 2.55 0.54 2.71E-06 
1 rs7548027 38864643 C 971 -0.77 0.88 0.3773 1500 3.19 0.65 2.94E-06 
16 rs8061566 26704144 A 968 1.11 0.71 0.1199 1499 -2.25 0.49 3.96E-06 
1 rs594856 38880584 C 971 -1.08 0.75 0.1476 1500 2.44 0.54 5.85E-06 
1 rs4970609 38865036 G 971 -1.05 0.75 0.1587 1500 2.44 0.54 5.85E-06 
1 rs4970610 38865078 T 971 -1.05 0.75 0.1587 1500 2.44 0.54 5.85E-06 
19 rs8104633 56937927 T 968 1.39 0.80 0.08277 1498 -2.67 0.59 6.21E-06 
17 rs216182 2119813 G 971 -1.34 0.74 0.06782 1499 2.42 0.54 9.51E-06 
9 rs1981047 22163499 G 971 -0.82 1.36 0.5487 1500 4.33 0.99 1.31E-05 
1 rs6421774 204153436 C 971 -0.57 0.81 0.4864 1499 2.76 0.63 1.43E-05 
7 rs1534702 147567736 T 970 -0.09 0.77 0.9031 1495 2.48 0.58 1.82E-05 
CHR= chromosome. SNP= single nucleotide polymorphism. POS= chromosomal position. A1= major allele. SE =standard error. P= P value. 
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Table 4.4 Top discordant SNPs considering level of statistical significance 1X10-5 [DBP]. 
 [Red highlights] indicate SNPs presented in the figure of top discordant signals below.  
  BB CCB 
CHR SNP POS A1 N  BETA SE P  N BETA SE P 
10 rs1914525 125535626 A 970 -2.50 0.54 4.17E-06 1500 0.32 0.40 0.4236 
8 rs1810195 23537855 C 971 2.98 0.73 6.20E-06 1500 -0.90 0.54 0.09667 
3 rs10865738 16108387 C 971 -1.77 0.38 8.54E-06 1499 0.02 0.29 0.9382 
6 rs7752482 148633692 G 971 2.32 0.52 9.27E-06 1500 -0.25 0.40 0.5435 
14 rs8017812 84165788 A 971 1.83 0.41 1.07E-05 1500 -0.26 0.30 0.3922 
14 rs7141196 84175762 G 971 1.82 0.41 1.20E-05 1500 -0.26 0.30 0.3816 
14 rs4411445 83929459 T 971 3.16 0.73 1.69E-05 1499 -0.50 0.55 0.3681 
5 rs2062400 154574494 C 970 -1.10 0.52 0.0344 1499 -1.87 0.40 3.93E-06 
2 rs4907206 96924640 T 971 0.57 0.47 0.2219 1499 -1.65 0.36 4.47E-06 
2 rs4907203 96920270 T 971 0.61 0.46 0.182 1500 -1.61 0.35 6.12E-06 
12 rs2363877 6162722 G 971 -0.46 0.37 0.2162 1497 1.27 0.28 6.84E-06 
11 rs7480026 11945018 A 971 -0.66 0.98 0.4969 1500 3.38 0.75 7.08E-06 
12 rs2363880 6172270 A 970 -0.57 0.37 0.1285 1499 1.23 0.28 1.27E-05 
2 rs749581 86301742 A 971 0.22 0.61 0.7234 1500 -1.86 0.43 1.36E-05 
12 rs2363878 6163236 A 970 -0.44 0.37 0.2344 1500 1.23 0.28 1.42E-05 






Figure 4.4 Top discordant signals identified in NORDIL2000. 
Y-axis represents BP response (delta BP changes before and after drug randomisation). X-
axis represents drug groups. Red stars represent top discordant SNPs considering level of 
statistical significance 1X10
-5.mBB= beta blocker monotherapy. mDi= diuretic monotherapy. 
mCC= calcium channel blocker monotherapy. 
 
 
4.1.3 Survival Analysis  
The 32 SNPs showing specific effects on BP response were taken forward for 
survival analysis. The results are presented in                 Table 4.5. 
As shown in Figure 4.5, taking into consideration the SNP treatment and 
genotype, rs12866529, rs7548027, rs1914525 and rs4907206 in CHR 13, 1, 10 and 
2 respectively, showed that CCB-0 has a greater subject survival rate than BBD-1, 
and it took longer for CCB-0 subjects to experience death compared to BBD-1. 




                Table 4.5 Survival analysis for top SNP showing specific effects on BP response13. 
 
SNP= single nucleotide polymorphism. CHR= chromosome. POS= chromosomal position. A1= major allele. P= P value. SE =standard 
error. BBD= Beta-blocker + Diuretic. BBD-0= major homozygous subjects (AA) on BB. REF= reference. BBD-1= heterozygous (AB) and 
minor homozygous (BB) subjects on CCB. CCB-0= major homozygous subjects (AA) on CCB. CCB-1= Heterozygous (AB) and minor 
homozygous (BB) subjects on CCB.      
 
                                         
13











Figure 4.5 Examples for KM survival curves. 
Y – Axis represents the cumulative incidence (probability of CV mortality).X- axis represents 
the survival time (follow-up time) .CCB-0 (green line) has a greater subject survival rate 
than BBD-1 (blue line), and it took longer for CCB-0 subjects to experience death compared 
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4.1.4 Replication studies  
In total, 286 replication SNPs have been genotyped as listed below. The Table 
4.6, Table 4.7, Table 4.8 and Table 4.9 show the top 35 SNPs for SBP and DBP 
responses on BB arm and CCB arm. SNPs reached a significant threshold of (P<1X10-
5) include 11 SNPs for SBP on BB arm, 22 SNPs for DBP on BB arm, 23 SNPs for SBP 
on CCB arm, and 18 SNPs for DBP on CCB arm. Still, no SNP achieved a genome 





Table 4.6 Top 35 SNPs in NORDIL2000 and replication studies [BB-SBP]. 
 
 PHENO=phenotype. CHR= chromosome. POS= chromosomal position. SNP= single nucleotide polymorphism. SE =standard error. P= P value. 
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Table 4.7 Top 35 SNPs in NORDIL2000 and replication studies [BB-DBP]. 
 
PHENO=phenotype. CHR= chromosome. POS= chromosomal position. SNP= single nucleotide polymorphism. SE =standard error. P= P value. 
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Table 4.8 Top 35 SNPs in NORDIL2000 and replication studies [CCB-SBP]. 
 
PHENO=phenotype. CHR= chromosome. POS= chromosomal position. SNP= single nucleotide polymorphism. SE =standard error. P= P value. 
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Table 4.9 Top 35 SNPs in NORDIL2000 and replication studies [CCB-DBP]. 
 




PG, may represent a useful tool in the future to select antihypertensive therapy 
with the greatest efficacy, based on individual’s genetic profile. This study 
performed the largest PG genome-wide meta-analysis of BP response to 
monotherapy with BB and CCB. In total, 51 SNPs showed a significant (P<1X10-5) 
association with BP response. However, no SNP achieved a genome-wide 
significance of (P<5x10-8) even after replication. This may just be a reflection of 
lack of statistical power or phenotypic heterogeneity.  In order to prioritise the 
most plausible signals for further study two analytic methods were applied – [1] 
identify directionally discordant signals between SNP and BP response for BB and 
CCB and [2] confirm the validity of a SNP BP response by analysing the SNP effect 
on mortality. This strategy allows selecting the right SNPs for further study, 
because this reflects not just specificity of response, but also indicates a greater 
potential use in personalised therapy, if they were validated and functional. SNPs 
which in contrast show similar response to drugs from multiple classes are of 
limited value in personalisation of therapy. The rationale for studying directionally 
opposite association with BP response stems from the “ABCD” (ACEI/ARB, BB, CCB 
and DI) algorithm that HTN can be broadly classified as “high renin” or “low renin” 
based on the vasoconstriction-volume (renin/sodium) model of HTN(459-461). 
In general, the biggest challenge to successfully carrying out a GWAS is attaining 
good, clean genotype data, given that the practical utility of genetic predictors 
will ultimately depend upon the quality of the original data. The missingness rate 
is a good indicator of marker quality. The missingness threshold should be 
determined based on a goal whereby a balance, which minimises the number of 
samples dropped and maximises genotyping efficiency, is attained (462). 
It is essential to filter SNPs based on MAF, as statistical power is extremely low 
for rare SNPs. However, SNPs with MAF greater than 0.01 might account for a high 
% of the genetic differences between individuals. As a result, these common 
variants might contribute significantly to those common diseases in which 
susceptibility alleles might not be under intense negative selection. Therefore, 
there are likely to be hundreds of common and rare variants contributing to the 
familial clustering of HTN (60). Checking HWE is also an important step in quality 
control markers within GWAS data. Departure from this equilibrium can indicate 
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potential genotyping errors, population stratification or even actual association 
with the trait under study (63).  
IBD and population structure procedures work best under an assumption of no LD 
among SNPs, because quality control steps can take a long time if performed on 
the full dataset. In addition, the relatedness of the pair of individuals within 
families would be overrepresented, and the samples might no longer be a 
reasonable reflection of allele frequencies in the population (as, 3rd degree 
relatives (PI_HAT>0.125) were identified). Population structure was used to 
decrease the dimensionality of the data while retaining most of the variation in 
the dataset. By using few components, each sample can be represented by 
relatively few values instead of thousands of variables (172;462). 
In the main, a significant P value indicates that the evidence is strong enough to 
reject H0, assuming that there is no difference between the NORDIL2000 subjects 
under investigation. The P value depends on the difference that exists between 
the study groups, the sample size and SD, which represents the variability (scatter) 
of the NORDIL2000 data, considering the level of statistical significance (1X10-5); 
the smaller (that is, more significant) the P value, the larger the difference 
between the study groups, the smaller the SD or the larger the sample size. 
Conversely, a non-significant P value does not indicate that H0 is true. Large P 
values could be simply due to small sample sizes or highly scattered data (for 
example, large SD). A non-significant P value merely indicates that the evidence 
is not strong enough to reject H0 (463).  
Survival analysis is concerned with the time from treatment until death; still, it is 
applicable to certain areas other than mortality. In clinical studies, an 
intervention’s effect is assessed by measuring the number of subjects who 
survived following that intervention over a period of time. However, this can be 
affected by a number of subject-related situations, known as censored 
observations, such as subjects who were uncooperative or fell out of contact 
during the study, who did not experience the event before the end of the study 
or who would have experienced the event if the study continued (464). In most 
cases, KM makes suitable allocations for those censored observations and makes 
use of the information about those subjects, up to the point when they are 
censored. Therefore, a KM test is one of the simplest ways to compute survival 
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over time, regardless of all subject- or situation-related difficulties. In addition, 
it applies to both small and larger samples, and time is divided not into periods of 
fixed length, but periods of variable duration (465). Consequently, KM could play 
a significant role in providing evidence-based data on the survival time of 
NORDIL2000 subjects. 
A log-rank test was used to test the probability of an event occurring at any time 
point and was the same for each population; it tests the difference between 
survival times of CCB- and BB-treated groups of NORDIL2000 patients, and does not 
allow other covariates, such as age, sex or BMI, to be taken into account. The Cox 
proportional hazard model was used to study the probability that the event of 
interest occurred at a given time for certain values of the predictor variables; it 
tests the difference between survival times of CCB- and BB-treated groups of 
NORDIL2000 patients, allowing for other covariates to be taken into account 
(464;465).In multiple linear regression analysis, the outcome is continuous. 
Therefore, a positive beta indicates that the outcome value (such as BP response) 
increases when independent variables (such as BP-lowering agents) increase. For 
instance, for discordant SBP-SNPs, rs12866529 showed a negative effect (-4.495 
beta) on BB and a positive effect on CCB (0.1361 beta), whereas rs12663184 
showed a positive effect (5.077 beta) on BB and a negative effect on CCB (-0.3452 
beta).  
Replication across multiple, well-powered, independent samples is the gold 
standard for reliability of genetic associations. In this study, it was possible to 
replicate the top signals in multiple cohorts for BP response but not for outcomes. 
The main reason for the difficulties in finding a genome-wide significant signal is 
likely due to the differences in the study and BP measurement characteristics of 
each replication cohort. Although there are several genes with convincing data for 
both BP response and treatment-related outcomes, further replication and 
functional studies are needed, mainly those identified through GWAS.  
Replication studies, such as ASCOT-BPLA 2005, GenHat 2002, GENRES 2007, INVEST 2003 
and PEAR 2009, are vital to ensuring that a genotype-phenotype association 
observed through NORDIL2000-GWAS represents a convincing association, in order 
to provide a reliable statistical association and rule out a chance finding or an 
artefact due to uncontrolled biases.The purpose of replication is to improve effect 
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estimation, requiring that replication studies use the same phenotype definition 
used in the initial study, which also helps avoid false positives due to data 
dredging. Consequently, testing and validation of statistical hypotheses of 
potentially identifiable SNPs and clinical outcomes linked to these SNPs must be 
carried out to define how these data can be integrated into patient care, in order 
to further clarify their role in HTN PG and their mechanisms of action (466;467). 
The definite data of a replicated association represents only the start of the 
process toward identifying the causal genetic variant and the biologically relevant 
causal pathways. Several recent replicated associations point to genes in 
unpredicted positions of the genome or to regulatory regions between genes. 
Thus, these will lead to a better understanding of the pathological processes in 
disease causation (70).Failure to replicate the association signals in populations 
with different ancestries does not always make the initial findings invalid, as the 
differences in LD, defined as the non-random association of alleles in adjacent 
loci, create patterns across different populations that can be used to shorten the 
region of interest for further functional analysis (69). A marker that is not in strong 
LD with a causal variant might be identified in a study. Testing it within a different 
population can cause false rejection of the association; however, testing other 
markers in the same region can reveal another association signal.  
 
Therefore, in order to search for other variants associated with the phenotype, a 
significant factor to consider in a replication study is the differentiation between 
tests of the same SNPs as in the original study—those in strong LD with the reported 
SNP and others in the reported region. New SNPs should be clearly rationalised by 
separating them from the others (i.e., earlier tested SNPs). If the new SNPs are 
selected on the basis of LD patterns across populations with original SNPs, then 
the different patterns should be empirically confirmed in the two populations 
(i.e., original and replication populations)(70). 
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5 General discussion and prospects  
For the most part, the choice of BP-lowering agents should be based on a number 
of considerations, as follows. First, the efficacy of decreasing BP, besides 
tolerability (including metabolic effects) must be individually evaluated in each 
patient. Second, the presence of related clinical conditions with compelling 
indications; sub-clinical target organ damage and other associated clinical 
conditions (but not related to HTN) can highlight the choice of certain BP-lowering 
agents. Third, a combination of two or more drugs is needed in the majority of 
hypertensive patients in order to achieve their desired BP (16;468). 
5.1 Systematic review 
RCTs gained increasing recognition during the course of the twentieth century as 
the best approach to the assessment of healthcare and prevention alternatives. 
However, the included studies have many differences in terms of designs and 
methods, baseline and goal BP, and study populations and drugs; therefore, trying 
to attain a coherent conclusion from their data may be a challenge. Systematic 
reviews, like other types of research, are certainly based on subjective 
judgements. The assessments were, however, conducted by at least two reviewers 
and the majority of included studies were labelled as high quality, making 
misjudgements less likely, but still possible.  
5.1.1 Strengths of the review 
Other research groups have conducted meta-analyses on BP–lowering agents, a 
number of which have studied BP response as an outcome. The current review has 
the potential to contribute important dimensions to BP response measures. First, 
many reviewers have mainly considered delta BP response (Chen2010 (143), 
Wright2009 (138) and Zanchetti2015(150)), whereas this review classified BP response 
into delta, single and repeated measures. Second, this review was strict in terms 
of BP measurement techniques as it only included studies that followed standard 
protocols for measuring BP response and described these protocols clearly in their 
methodology sections in order to guarantee high-quality BP data. Third, this 
review had no language restrictions, meaning that non-English studies were 
translated, reviewed and included if they fit the inclusion criteria for this review. 
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In total, seven studies in languages other than English were screened and excluded 
after the translation of their abstracts, as they did not fit the inclusion criteria: 
three Chinese studies (one was cross-sectional, and the other two observed 
participants for less than three months of active treatment), two Russian studies 
(one randomised less than 100 participants, and the other enrolled HF 
participants), and two French studies (one observed participants for less than 
three months of active treatment, and the other enrolled participants who self-
measured the mean BP response). 
 
5.1.2 Limitations of the review 
Since, more than one BP-lowering agent is required to achieve BP targets (15;16), 
the sequential administration of additional drugs following the first-line drug may 
have resulted in confounding as BP responses are presumed to reflect the effect 
of the first drug. This is possibly the major weakness of the review, and explains 
why other reviews (Wright 1999;(469)) and (Wright2000;(470)) restricted their 
systematic reviews to studies where confounding supplementary BP-lowering 
agents were administered to less than half of patients. 
 
The limited number of studies providing BP repeated measures data might be 
another limitation, as the majority of studies present mainly a baseline reading 
and mean BP response towards the end of the study (as a delta or single measure). 
Apart from ALLHAT 2002, Derosa 2014, NORDIL 2000 and PATS 1995, all repeated 
measures data were extracted from supplementary graphs or figures. Although the 
extractions from the graphs or figures were confirmed by reviewers, it is still 
preferable to present BP readings numerically. 
 
To maximise inclusiveness, two assumptions were made: [1] the equi-
effectiveness of all approved doses of BP-lowering agents within either class, with 
respect to BP response; and [2] the equi-effectiveness of a background BP-
lowering agent if the same protocol was followed in both arms. However, it is 
unknown whether the same background treatment regimen would unequally 
affect the BP response through the unequal drug. However, the subgroup analyses 
necessary to test these assumptions adequately would have been underpowered. 
Another limitation was in those with HTN and T2DM, CHD, CKD or concomitant 
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conditions as it was not possible to investigate the effect of these subgroup 
populations on the effect size (lacked the performance of subgroup analyses).  
5.1.3 Agreements and 
disagreements with other 
studies or reviews 
We believe this is the first review of its kind.  
5.1.4 Implication for research  
Systematic reviews of RCTs comparing different drugs provide evidence of the 
choices of BP-lowering medication. However, direct comparative studies are 
lacking in relation to many of the competing drug sub-classes. As the current 
review did not focus on comparing different BP-lowering sub-classes and their 
effects on BP response, new RCTs comparing BP-lowering sub-classes would be 
useful to determine whether it is appropriate to combine such sub-classes. As 
some of the included BP-lowering agents are heterogeneous groups of drugs that 
can be sub-classified into classes (such as CCBs, DHPs and non-DHPs), the different 
classes have various binding sites and mechanisms and could therefore evoke 
diverse BP responses. 
 
Because the majority of clinical studies reported the difference in BP response 
towards the end of the study, further RCTs reporting all types of BP measures are 
required, especially for repeated measures. These studies should avoid 
confounding factors as much as possible, such as considering the number of 
background/secondary drugs and drug dosages. 
 
Better-designed RCTs are required to study the BP response to the main BP–
lowering agents, especially for patients with co-morbidities, such as T2DM, CHD 
and CKD. These studies should consider BP control goals and adherence. It is 
important that all relevant outcomes are well defined and reported. Furthermore, 
studies investigating BP response over 24 hours (ABPM) are required and should 
accurately record the time of drug intake. They should also report the BP data 
with zero hour being the time of drug intake, and they should be required to report 
the SD for each hourly measurement. 
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5.1.5 Implication for practice 
This review has two main implications: [1], BP response measurements in clinical 
studies, mainly RCTs, can be used to guide physicians to the expected BP reduction 
for each BP-lowering agent. Consequently, they can set their management plans 
in terms of the likely duration to achieve the target BP and the need for using 
additional BP-lowering agents besides first-line agents. [2], using more than one 
BP-lowering agent (as combination therapy) should be emphasized more than it is 
at present for the initial treatment of hypertensive patients because the classic 
“up titration” of monotherapy titrated at a time to reduce BP is mostly 
inadequate. The review supports JNC 7 and ESH/ESC guidelines in acknowledging 
the value of combination therapy and suggesting that a two-drug combination is 
more likely to achieve target BP in hypertensive patients. Consequently, 
combination therapy makes more sense for high-risk patients such as T2DM and 
CKD who need aggressive BP targets because achieving these targets reduces 
events. 
5.2 Genome-wide Study  
There is major interest in identifying genes that influence the PK and PD 
determinants of BP response, because these mechanisms may play the 
predominant role in determining interindividual variation in BP responses to 
antihypertensive drugs now in common use. However, thre are major challenges 
in using identical phenotype criteria should be used in both GWAS and replication 
studies , as using different phenotype definitions can cause a misinterpretation of 
results, accordingly, replication of a GWAS result should be assumed to be the 
replication of a specific statistical model; a given SNP predicts a specific 
phenotype effect (70). However, there are some situations in which there are 
inadequate participant numbers for replication, such as rare diseases. Therefore, 
meta-analysis of genome-wide datasets provides a strategy that increases power 
over that of individual studies, as well as potentially being more cost-effective 
than replication (471).  
The integration of results in the clinical situation will determine which SNPs/genes 
have adequate evidence to be clinically functional. Nowadays, a single SNP chip 
would be most useful as a means of stratifying patients to the best BP-lowering 
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treatment option; accordingly, only a single test would be ordered (88). However, 
there are many new discoveries every year, and the level of evidence differs 
according to the BP-lowering agent class. There are still many unanswered 
questions in HTN PG, and several regions of the genome have yet to be 
investigated.Further studies will include exhaustive sequencing of the candidate 
interval, genotyping of variants in multiple population samples, testing for 
association, and functional studies and investigation of interactions with other 
genes or environmental factors. Identification of these validated gene variants 
should help us to understand the disease biology; however, their applicability to 
clinical practice and public health will depend on whether they can improve 
diagnosis, prevention or treatment strategies (73). The overall goal is to increase 
the understanding of HTN causation and its consequences, and to apply this 
knowledge to developing better-quality treatments and risk assessment strategies 
that will have a major positive impact on public health. 
5.3 Future work  
The plan is first to publish the results of the systemic review highlighting the fact 
that not all BP–lowering agents are equal in reducing BP. CCBs should be the choice 
for first-line mono-therapy or second-line combination therapy, as in most of the 
existing BP guidelines. Next, the drug-specific effects of BP-lowering agents on BP 
over 24 hours (ABPM) will be identified and compared with the findings of the 
current review. The studies reporting ABPM have already been screened (their 
records are available, so this review only needed to be updated to include studies 
after 2015) and excluded, as this review focuses on office and clinic BP pressure 
taken as delta, single and repeated measurements. 
For the genome-wide study, the plan is first to publish the GWAS results 
highlighting the fact that only a small number of the  GWAS studies on HTN and/or 
BP have been published; the current study is the largest PG genome-wide meta-
analysis of BP response to mono-therapy with BB and CCB. A number of SNPs 
achieved significance (P < 5 × 10-7), but no SNP achieved genome-wide significance 
(P < 5 × 10-8), even after replication. Then, the SNPs associated with BP-lowering 
responses will be identified in subjects using the GWAS approach in a new study 
with higher statistical power and lower phenotypic heterogeneity. 
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6 Appendix 
Table 6.1 Search strategy for MEDLINE (OVID): searched on 3 April 2015. 
“MP” indicates multi-purpose search terms in the title, original title, abstract, subject 
heading, name of substance and registry word fields; “tw” indicates that the term is a text 
word meaning the title and abstract; “Pt” indicates publication types, such as reviews, 
clinical trials, directories and letters; “Ab” indicates all searchable words from the abstract; 
“/” indicates that it is a Medical Subject Heading (MeSH) term; “$” indicates all possible 
suffix variations of the root word; “?” indicates the retrieval of documents with British and 
American word variants; “adj” plus a number between any two terms returns records that 
contain both terms within the specified number of words from each other. 
# Searches 
1 antihypertensive agents.mp. 
2 calcium channel blockers.mp. 
3 (calcium adj2 (inhibit$ or blockader?)).tw. 
4 angiotensin receptor antagonists.mp. 
5 (angiotensin adj2 (inhibit$ or blockader?)).tw. 
6 adrenergic beta-antagonists.mp. 
7 (beta adj2 (inhibit$ or blockader?)).tw. 





13 (blood adj pressure).tw. 
14 or/11-13 
15 10 and 14 
16 randomized controlled trial.pt. 
17 controlled clinical trial.pt. 
18 randomized.ab. 
19 placebo.tw. 




24 animals/ not (humans/ and animals/) 
25 23 not 24 
26 15 and 25 
















Table 6.2 Search strategy for EMBASE (OVID): searched on 15 June 2015. 
“MP” indicates multi-purpose search terms in the title, original title, abstract, subject 
heading, name of substance and registry word fields; “tw” indicates that the term is a text 
word, meaning the title and abstract; “Ab” indicates all searchable words from the abstract; 
“sh” indicates all searchable words in the subject heading field; “hw” indicates all searchable 
words in the heading word field; “/” indicates that it is a Medical Subject Heading (MeSH) 
term; “$” indicates all possible suffix variations of the root word; “?” indicates the retrieval of 
documents with British and American word variants; “adj” plus a number between any two 
terms returns records that contain both terms within the specified number of words from 
each other. 
# Searches 
1 antihypertensive agents.mp. 
2 calcium channel blockers.mp. 
3 (calcium adj2 (inhibit$ or blockader?)).tw. 
4 angiotensin receptor antagonists.mp. 
5 (angiotensin adj2 (inhibit$ or blockader?)).tw. 
6 adrenergic beta-antagonists.mp. 
7 (beta adj2 (inhibit$ or blockader?)).tw. 





13 (blood adj pressure).tw. 
14 or/11-13 
15 randomized controlled trial/ 
16 Clinical Trial/ 
17 crossover procedure/ 
18 double-blind procedure/ 
19 (doubl$ adj blind$).tw. 
20 (clin$ adj25 trial$).tw. 
21 placebo$.tw. 
22 random$.tw. 
23 (meta?analys$ or systematic review$).tw. 
24 (crossover$ or cross-over$).tw. 
25 or/15-24 
26 (animal$ not human$).sh,hw. 
27 25 not 26 
28 10 and 14 and 27 
29 limit 28 to (yr="1996 - 2015" and adult <18 to 64 years>) 
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Table 6.3 Search strategy for CENTRAL: searched on 20 August 2015. 
“MP” indicates multi-purpose search terms in the title, original title, abstract, subject 
heading, name of substance and registry word fields; “tw” indicates that the term is a text 
word, meaning the title and abstract; “$” indicates all possible suffix variations of the root 
word; “?” indicates the retrieval of documents with British and American word variants; “adj” 
plus a number between any two terms returns records that contain both terms within the 
specified number of words from each other. 
# Searches 
1 antihypertensive agents.mp. 
2 calcium channel blockers.mp. 
3 (calcium adj2 (inhibit$ or blockader?)).tw. 
4 angiotensin receptor antagonists.mp. 
5 (angiotensin adj2 (inhibit$ or blockader?)).tw. 
6 adrenergic beta-antagonists.mp. 
7 (beta adj2 (inhibit$ or blockader?)).tw. 





13 (blood adj pressure).tw. 
14 or/11-13 
15 10 and 14 
16 Publication Year from 1995 to 2015, in Cochrane Reviews (Reviews and Protocols), 
with Hypertension Group 
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Table 6.4 Search strategy for Web of Science: searched on 28 September 2015. 
“TS” indicates all searchable words in the topic subject; “TI” indicates all searchable words 
in the title; “*” indicates any group of characters, including no character; “” indicates a search 
for the exact phrase appearing between the quotation marks; “$” indicates all possible suffix 
variations of the root word; “?” indicates the retrieval of documents with British and American 
word variants; “adj” indicates a search for two terms where they appear adjacent to one 
another. 
# Searches 
1 TS=”antihypertensive agents” 
2 TS=”calcium channel blockers” 
3 TS=”calcium inhibit*” 
4 TS=”calcium block*” 
5 TS=”angiotensin receptor antagonists” 
6 TS=”angiotensin inhibit*” 
7 TS=”angiotensin block*” 
8 TS=(adrenergic beta antagonists) 
9 TS=”beta inhibit*” 
10 TS=”beta block*” 
11 TS=”ace inhibitors” 
12 TS=”diuretics” 
13 #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1 
14 TS=”hypertension” 
15 TI=”hypertens*” 
16 TS=(*blood adj pressure*) 
17 #16 OR #15 OR #14 
18 #13 and #17 
19 TI=”randomized controlled trial” 
20 TI=”controlled clinical trial” 
21 TS=”Randomized” 
22 TS=”Placebo” 
23 TI=”drug therapy” 
24 TS=”Randomly” 
25 TI=”Trial” 
26 #25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19 
27 TS=(animals/ not (humans/ and animals/)) 
28 #26 NOT #27 
29 #18 and #28 


























Figure 6.2 Funnel plot of comparison of BP-lowering agents: outcome: single 






Figure 6.3 Funnel plot of comparison of CCB vs other agents: outcome: repeated 
measures - BP response.  
Funnel plot was only used to visually inspect CCB comparison as other comparison 
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